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Zusammenfassung 
Hintergrund 
Bei dem Perkutanen Aortenklappenersatz (auch Transkatheter-Aortenklappen-
implantation/ TAVI oder Transkatheter-Aortenklappenersatz/TAVR) handelt es sich 
um das Einsetzen einer Bioprothese in die Aortenklappe unter Verwendung eines Ka-
theters.  Im Gegensatz zur herkömmlichen Operationsmethode am offenen Herzen, 
dem chirurgischen Aortenklappenersatz (SAVR), ist TAVI minimal-invasiv und kann 
unter leichter Sedierung und ohne den Einsatz einer Herz-Lungen-Maschine durchge-
führt werden. Die defekte Herzklappe wird dabei nicht entfernt und beim Einsetzen der 
neuen Klappe wird keine Naht benötigt. Die Wahl des Zugangswegs bei der Implantati-
on ist abhängig von der Form der Arterien und der Anatomie der PatientInnen. Der 
häufigste und bevorzugte Weg führt transfemoral über den Oberschenkel. Weitere Zu-
gangswege sind transapikal (durch die Herzwand), subklavikulär (unterhalb des 
Schlüsselbeins), transaortal (über eine minimal-invasive chirurgische Inzision in die 
Aorta) und transcaval (durch die Haut in die untere Hohlvene und weiter in die an-
grenzende abdominenelle Aorta). Für PatientInnen mit mittlerem Operationsrisiko 
werden als Vorteile von TAVI, verglichen mit SAVR, verringerte oder vergleichbare 
Mortalitätsraten, verringerte oder vergleichbare Raten für Kurzzeit-Risiken und gestei-
gerte oder vergleichbare funktionelle Vorteile genannt. Weitere genannte Vorteile kön-
nen die Dauer des Spitalsaufenthalts und die Genesungszeit beeinflussen. 
Die ersten TAVI-Systeme erhielten 2007 das Conformité Européene (CE)-Zeichen, bis 
2016 war die Indikation auf die Behandlung von PatientInnen mit schwerer, sympto-
matischer Aortenklappenstenose (auch Aortenstenose), bei denen die Erkrankung 
entweder inoperabel war oder zu einem hohen operativen Mortalitätsrisiko oder Kom-
plikationen durch SAVR geführt hätte, beschränkt. Seit Juni 2017 bieten die beiden 
Hersteller Edwards Lifesciences und Medtronic TAVI-Systeme (Edwards SAPIEN 3 und 
Medtronic Evolut R, gemäß CE-Kennzeichnung) eine Erweiterung der Indikation auf 
PatientInnen mit schwerer Aortenstenose aber nur mittlerem operativem Risiko an.  
Eine Erhebung unter EUnetHTA Partnern, zwischen Oktober und November 2017 
durchgeführt, zeigt, dass die Kosten für TAVI bei PatientInnen mit hohem operativem 
Risiko in allen 20 rückmeldenden Ländern und Regionen übernommen werden. Hinge-
gen sind in einigen Ländern die Erstattungsentscheidungen bei PatientInnen mit mitt-
lerem Risiko noch ausständig. Seit der Einführung von TAVI im Jahr 2007 kam es in al-
len Ländern zu einem raschen, wenngleich variablen Anstieg in der Häufigkeit der An-
wendung: Diese variiert in europäischen Ländern mit jährlichen Raten zwischen 20 
und knapp 200 Eingriffen pro Million EinwohnerInnen. 
Bei den meisten PatientInnen ist SAVR die erste Wahl für die Behandlung der schwe-
ren, symptomatischen Aortenstenose. SAVR wird unter Vollnarkose über eine chirurgi-
sche Öffnung des Brustkorbs (Thorakotomie) durchgeführt.  Der Grad der Invasivität 
dieses Eingriffs variiert je nach Herangehensweise, die Verwendung einer Herz-
Lungen-Maschine ist dafür erforderlich. Kürzlich wurde die nahtlose SAVR als Alterna-
tive zur herkömmlichen SAVR und TAVI vorgestellt. Die nahtlose SAVR ähnelt TAVI in 
der Art des Einsetzens der Prothese, basiert aber – um Zugang zur Aortenklappe zu er-
halten – auf einer offenen Operationsmethode (Sternotomie oder Mini-Sternotomie). 
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Die Aortenstenose, eine Verengung der Aortenklappe, die den Abfluss des Blutes aus 
dem linken Ventrikel in die Aorta beeinträchtigt, ist die häufigste Herzklappenerkran-
kung in Industrieländern. Die Beeinträchtigung der Herzfunktion ist meist progredient 
und kann zu Linksherzhypertrophie und der Entwicklung einer Herzinsuffizienz  füh-
ren, welche unbehandelt eine schlechte Prognose hat. Die Erkrankung schreitet lang-
sam fort und die meisten neu diagnostizierten klinisch signifikanten Aortenstenosen 
treten bei älteren PatientInnen (älter als 70 Jahre) auf. Die häufigste Ursache der Aor-
tenstenose bei älteren PatientInnen ist die degenerative Verkalkung der Taschenklap-
pensegel, während bei jüngeren PatientInnen meist kongenitale Herzfehler, im speziel-
len das Vorhandensein einer bikuspidalen Aortenklappe, ursächlich sind.  
Die Prävalenz schwerer Aortenstenosen bei älteren PatientInnen liegt in Europa bei 
etwa 3,4%, davon ist die Erkrankung bei 75,6% der Betroffenen symptomatisch. Die 
Gesamt-Inzidenzrate liegt bei ca. 0,49% pro Jahr, bei den über 65-Jährigen liegt diese 
bei 2%-7%. Etwa 20% der über 60-jährigen PatientInnen mit Aortenstenose weisen 
eine schwere Form der Erkrankung auf, davon ist die Erkrankung bei 71% der Patien-
tInnen symptomatisch. 
Die ausschließlich medikamentöse Behandlung von PatientInnen mit schwerer und 
symptomatischer Aortenstenose ist nur palliativ und weist einen beschränkten klini-
schen Nutzen auf. Der frühzeitige Klappenersatz wird als wirksame Behandlung erach-
tet. Das Operationsrisiko steigt mit höherem Alter der PatientInnen und dem Vorhan-
densein von Komorbititäten. Die am häufigsten verwendeten Verfahren zur Berech-
nung des operativen Risikos sind STS-PROM (Society of Thoracic Surgeons-Predicted 
Risk of Mortality), EuroSCORE (European System for Cardiac Operative Risk Evaluati-
on) und EuroSCORE II, der seit 2011 verwendet wird.  
 Ein Score von <4% (STS-PROM oder EuroSCORE II) wird als niedriges Risiko 
definiert,  
 ein Risiko-Score von 4-8% als mittleres Risiko und  
 ein Score von >8% als hohes Risiko.  
 
Im aktuellsten Update der ESC/EACTS (European Society of Cardiology/European 
Association for Cardio-Thoracic Surgery) – Guideline (August 2017) wird empfohlen, 
entweder TAVI oder SAVR bei PatientInnen mit erhöhtem Operationsrisiko (definiert 
als STS oder EuroSCORE II ≥4%  oder logistic EuroSCORE I ≥10% oder mit anderen Ri-
sikofaktoren, welche in diesen Scores nicht berücksichtigt sind) in Betracht zu ziehen. 
Jedenfalls sollte ein Team aus HerzspezialistInnen basierend auf einer Einschätzung 
der individuellen Patientin/des Patienten und den assoziierten Risiken die Entschei-
dung zwischen SAVR und TAVI treffen. 
Methode 
Das Assessment basiert auf dem EUnetHTA Core Model für Rapid Relative Effectiveness 
Assessments (REA), Version 4.2. Die systematische Suche wurde in mehreren Daten-
banken durchgeführt (Cochrane Library, Centre for Research and Dissemination [CDR] 
Database, Embase, Medline, Medline Pub Status ahead of print), weitere Informationen 
wurden durch Internetsuche, Informationen des Herstellers, eine Erhebung unter 
EUnetHTA-Partnern (Gebrauch von TAVI und Status der Kostenrückerstattung, Okto-
ber/November 2017), Handsuche nach potentiell relevanten HTA-Berichten sowie der 
Suche nach laufenden Studien (Clinical Trials Registry Platform [ICTRP] und Clini-
caltrials.gov) gewonnen.  
Es wurden nur Studien mit Vergleichsgruppen eingeschlossen. Für die Beurteilung der 
klinischen Wirksamkeit wurden nur Ergebnisse aus RCTs berücksichtigt.  
Zur Beurteilung der internen Validität der eingeschlossenen randomisierten kontrol-
lierten Studien (RCTs) wurde das Cochrane Risk of Bias (RoB) Tool verwendet. Die 
Qualität der Evidenz wurde mit der GRADE-Methode (Grading of Recommendations, 
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Assessment, Development and Evaluation) evaluiert, welche die Klassifikation der Qua-
lität der Evidenz in „hoch“, „mittelgradig“, „niedrig“ und „sehr niedrig“ erlaubt.  
Ergebnisse: Wirksamkeit und Sicherheit 
Es wurden zwei Industrie-gesponserte, multizentrische RCTs, die PARTNER 2-Studie 
(NCT01314313) und die SURTAVI Studie (NCT01586910, derzeit noch laufend) mit 
insgesamt 3.778 PatientInnen, sowie zwei Registerstudien eingeschlossen. Das längste 
Follow-up fand nach 24 Monaten statt.  
Die wichtigsten Endpunkte zur Wirksamkeit waren die Gesamtsterblichkeit, die kardia-
le Mortalität und die Aortenklappen-Reintervention, jeweils zum Zeitpunkt des 30-
Tage- und 2-Jahres-Follow-up sowie die Länge des Spitalsaufenthaltes, die Verbesse-
rung von Symptomen (entsprechend einem niedrigerem Stadium in der NYHA-
Klassifikation) und die Lebensqualität der PatientInnen.  
Die Ergebnisse zeigen, dass….. 
 die Gesamtmortalität zum Zeitpunkt des 30-Tage-Follow-up mit TAVI der 
SAVR wahrscheinlich nicht  unterlegen ist (3,1% versus 2,9%, RR [Risk Ratio] 
1,07, 95% CI [Konfidenzintervall] 0,74-1,55; GRADE Evidenz: mittelgradig).  
 die kardiale Mortalität zum Zeitpunkt des 30-Tage-Follow-up mit TAVI der 
SAVR wahrscheinlich nicht  unterlegen ist (2,6% versus 2,4%, RR 1,11, 95% CI 
0,75-1,66, GRADE Evidenz: mittelgradig).  
 Unsicher ist, ob TAVI der SAVR hinsichtlich der kardialen Mortalität auch zum 
Zeitpunkt des 2-Jahres-Follow-up (12,9% versus 12,7%, RR 1,01, 95% CI 0,86-
1,20; GRADE Evidenz: sehr niedrig) nicht unterlegen ist.  
 TAVI könnte, verglichen mit SAVR, das Risiko einer Aortenklappen-
Reintervention zum Zeitpunkt des 30-Tage-Follow-up erhöhen (0,6% versus 
0,1%, RR 7,58, 95% CI 1,38-41,55; GRADE Evidenz: niedrig).  
 Auch ist unsicher, ob TAVI das Risiko einer Aortenklappen-Reintervention 
zum Zeitpunkt des 2-Jahres-Follow-up (1,7% versus 0,4%, RR 3,86, 95% CI 
1,76-8,44; GRADE Evidenz: sehr niedrig) erhöht. 
 Unklar ist, ob TAVI verglichen mit SAVR zum Zeitpunkt des 1- und 2-Jahres 
Follow-up eine Auswirkung auf die Verbesserung von Symptomen hat (die Da-
ten konnten nicht zusammengefasst werden, GRADE Evidenz: sehr niedrig).  
 Wahrscheinlich verkürzt TAVI, verglichen mit SAVR, die Dauer des Spitalsauf-
enthaltes um 2 oder 3 Tage (Daten nicht zusammengefasst, GRADE Evidenz: 
mittelgradig). 
Alle Nebenwirkungen, sowohl geringfügige als auch schwerwiegende, wurden als we-
sentlich für die Beurteilung der Sicherheit von TAVI im Vergleich mit SAVR erachtet. 
Die wichtigsten sicherheitsrelevanten Endpunkte, die in den RCTs berichtet wurden, 
sind akutes Nierenversagen (30-Tage-Follow-up), schwerwiegende vaskuläre Kompli-
kationen (30-Tage-Follow-up), paravalvuläre Regurgitation (30-Tage-Follow-up), 
Schlaganfall (30-Tage-Follow-up), Schlaganfall (2-Jahres-Follow-up), Einsetzen von 
Vorhofflimmern (30-Tage-Follow-up), lebensbedrohliche und/oder invalidisierende 
Blutung (30-Tage-Follow-up), neu implantierter, permanenter Herzschrittmacher (30-
Tage-Follow-up).  
Die Ergebnisse zeigen, dass… 
 Es ist unsicher, ob TAVI, verglichen mit SAVR, einen Einfluss auf Schlaganfälle 
zum Zeitpunkt des 30-Tage-Follow-up (4,4% versus 5,6%, RR 0,80, 95% CI 
0,58-1,10; GRADE Evidenz: sehr niedrig) und des 2-Jahres-Follow-up (7,4% 
versus 7,6%, RR 0,97, 95% CI 0.74-1,26; GRADE Evidenz: sehr niedrig) hat.  
 Wahrscheinlich reduziert TAVI, verglichen mit SAVR, die Inzidenz von neu 
auftretendem Vorhofflimmern (11% versus 34%, RR 0,32, 95% CI 0,27-0,37, 
GRADE Evidenz: mittelgradig). 
 Es ist unklar, ob TAVI verglichen mit SAVR einen Einfluss auf lebensbedrohli-
che und/oder invalidisierende Blutungen zum Zeitpunkt des 30-Tage-Follow-
up (zwei Studien, Daten nicht zusammengefasst; GRADE Evidenz: sehr nied-
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rig) hat und unsicher bei 2-Jahres-Follow-up (eine Studie, RR 1,02, 95% CI 
0,74-1,41; GRADE Evidenz: sehr niedrig. 
 Unsicherheit besteht darüber, ob TAVI verglichen mit SAVR das Risiko für  
akutes Nierenversagen nach 30-Tages-Follow-up (1,0% versus 2,2%, RR 0,47, 
95% CI 0,27-0,80, GRADE Evidenz: sehr niedrig) und nach 2-Jahres-Follow-up 
(2,2% versus 3,5%, RR 1,02, 95% CI 0,74-1,41), GRADE Evidenz: sehr niedrig) 
reduziert.  
 TAVI könnte, verglichen mit SAVR, die Inzidenz schwerwiegender vaskulärer 
Komplikationen (3-Tage-Follow-up: 6,9% versus 3,1%, RR 3,03, 95% CI 0,79-
11,67; GRADE Evidenz: niedrig) erhöhen. 
 Die Daten zur Implantation von Herzschrittmachern (30-Tage-Follow-up) wa-
ren uneinheitlich und die Ergebnisse waren nicht zusammengefasst (GRADE 
Evidenz: sehr niedrig).  
 Verglichen mit SAVR erhöht TAVI wahrscheinlich das Risiko für paravalvuläre 
Regurgitation (3,2% versus 0,3%, RR 9,30, 95% CI 4,02-21,48; GRADE Evi-
denz: mittelgradig).  
 In der PARTNER 2 Studie lag die Inzidenz der Endokarditis zum Zeitpunkt des 
2-Jahres-Follow-up bei 1,2% bei PatientInnen der TAVI-Gruppe und bei 0,7% 
bei PatientInnen der Kontrollgruppe (RR 1,85%, 95% CI 0,69-4,99).  
 In keiner der Studien wurde die Rehospitalisierung aufgrund von Myokardin-
farkt (< 72 Stunden nach TAVI) evaluiert. 
In Bezug auf laufende Studien konnten zwei aktive RCTs gefunden werden. Für die 
SURTAVI-Studie (NCT01586910, Fertigstellung im November 2026) wurde die Daten-
sammlung zu den primären Endpunkten für Juli 2018 erwartet, zum Zeitpunkt der Er-
stellung dieses Berichtes (August 2018) waren allerdings noch keine Ergebnisse ver-
fügbar. Die zweite laufende Studie (NCT03112980) soll 2023 fertiggestellt werden. Es 
konnten auch sechs RCTs identifiziert werden, im Rahmen derer TAVI mit SAVR oder 
Medikation bei PatientInnen mit niedrigem Risiko oder asymptomatischen PatientIn-
nen verglichen werden (Fertigstellung zwischen 2018 und 2021).  
Diskussion  
Sowohl TAVI als auch SAVR sind komplexe medizinische Interventionen,  welche lau-
fend weiterentwickelt werden. Umfangreiche und auch kleinere Änderungen betreffen 
sowohl die Implantate als auch das Implantationsverfahren selbst. 
Im Rahmen der systematischen Suche wurden Daten von zwei RCTs, die TAVI mit der 
Operationsmethode am offenen Herzen bei PatientInnen mit schwerer Aortenstenose 
und mittlerem Operationsrisiko verglichen, identifiziert. Das Bias-Risikos wurde für die 
Evidenz zu Kurzzeit-Ergebnissen von Wirksamkeit und Sicherheit  (Gesamtsterblich-
keit und kardiale Mortalität zum Zeitpunkt des 30-Tage-Follow-up, Dauer des Spitals-
aufenthaltes, bedeutende Gefäßkomplikationen, paravalvuläre Regurgitation und Ein-
setzen von Vorhofflimmern) als mittelgradig beurteilt. Aufgrund ernster Bedenken 
hinsichtlich Attrition-Bias (Nicht-Einhalten des Protokolls und vorzeitiges Ausscheiden 
von PatientInnen) bei den Ergebnissen von Gesamtsterblichkeit und kardialer Mortali-
tät  zum Zeitpunkt des 1- und 2-Jahres-Follow-up wurde der Grad der Evidenz herab-
gesetzt und mit sehr niedrig bewertet. Auch in Bezug auf die Verbesserung der Symp-
tomatik, die Aortenklappen-Reintervention, die Herzschrittmacher-implantation, 
Schlaganfall (zu allen Zeitpunkten) und die lebensbedrohlichen und/oder invalidisie-
renden Blutungen wurde der Grad der Sicherheit der Evidenz aufgrund ernster oder 
sehr ernster Bedenken bezüglich Inkonsistenz und/oder Ungenauigkeit ebenfalls her-
abgesetzt (niedrig oder sehr niedrig).  
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Basierend auf mittelgradiger Qualität der Evidenz wird TAVI, verglichen mit SAVR, hin-
sichtlich der 30-Tage Gesamtsterblichkeit und der 30-Tage kardialen Mortalität als 
nicht unterlegen beurteilt. Jedoch wurde zum Zeitpunkt des 2-Jahres-Follow-up die 
Evidenz zur Nicht-Unterlegenheit als sehr niedrig erachtet und es konnte keine 
Schlussfolgerung gezogen werden. Auch bezüglich einer Verbesserung der Symptoma-
tik (entsprechend der NYHA-Klassifikation) wurde die Evidenz zur Nicht-
Unterlegenheit als sehr niedrig erachtet und es konnten keine Schlussfolgerungen ge-
zogen werden. 
Basierend auf mittelgradiger Qualität der Evidenz wurde gefunden, dass TAVI, vergli-
chen mit SAVR wahrscheinlich die Dauer des Spitalsaufenthaltes verkürzt. Zum Zeit-
punkt des 30-Tage- und des 2-Jahres-Follow-up war die Aortenklappen-Reintervention 
in der TAVI-Gruppe höher als in der SAVR-Gruppe. Jedoch wurde die Evidenz diesbe-
züglich als sehr niedrig beurteilt und es kann nicht definitiv festgestellt werden, ob 
TAVI, verglichen mit SAVR das Risiko der Aortenklappen-Reintervention erhöht.   
Basierend auf mittelgradiger Qualität der Evidenz konnte festgestellt werden, dass 
durch TAVI zum Zeitpunkt des 30-Tage-Follow-up das Risiko für neu auftretendes Vor-
hofflimmern wahrscheinlich gesenkt wird, das Risiko für paravalvuläre Regurgitation 
jedoch verstärkt wird. In Bezug auf Risiko für Schlaganfall und für akutes Nierenversa-
gen wurde die Evidenz für Nicht-Unterlegenheit als sehr niedrig beurteilt und es konn-
te keine Schlussfolgerung gezogen werden. 
Bezüglich lebensbedrohlicher oder invalidisierender Blutungen und dem Bedarf an 
Herzschrittmacherimplantation wurden widersprüchliche Ergebnisse der eingeschlos-
senen Studien beobachtet. Obwohl nur geringe bzw. keine Unterschiede bei invalidisie-
renden Blutungen zwischen TAVI und SAVR im Rahmen der SURTAVI-Studie festge-
stellt werden konnten, wurde in der PARTNER 2-Studie bessere Ergebnisse mit TAVI 
erzielt. Während im Rahmen der PARTNER 2-Studie nur geringe bzw. keine Unter-
schiede bezüglich implantierter Herzschrittmacher festgestellt werden konnten, war 
das Ergebnis für SAVR im Rahmen der SURTAVI-Studie besser. Angesichts des Bias-
Risikos und der Heterogenität wurde die Gesamtqualität der Evidenz für diese beiden 
Endpunkte als sehr niedrig erachtet. Es werden weitere Studien benötigt, um festzu-
stellen, ob die beobachtete Heterogenität auf das jeweilige TAVI-System zurückzufüh-
ren ist oder ob es dafür eine andere Erklärung gibt. 
Limitationen  der Ergebnisse der RCTs sind das Fehlen von Langzeitergebnissen, eine 
signifikante Häufigkeit von Widerrufen der Einwilligungserklärung und unsichere Da-
ten zur Lebensqualität der PatientInnen. Eine derzeit noch laufende, unabhängige Stu-
die (NCT03112980) könnte mehr zuverlässige Daten zum Zeitpunkt des 5-Jahres-
Follow-up und zur Lebensqualität der PatientInnen bringen. Im Rahmen der Literatur-
suche konnten keine bereits publizierten oder noch laufenden Studien, die TAVI-
Systeme miteinander vergleichen, gefunden werden. Zusätzlich zu Patientendaten soll-
ten in Registern auch geräteabhängige Daten und Informationen zum Setting gesam-
melt werden, um Analysen zur Leistung verschiedener Produkte und den Einfluss ver-
schiedener Settings auf Sicherheitsergebnisse zur ermöglichen. Weitere Evidenz könn-
te durch effizientere und komplexere Analyse von hochqualitativen, realen Daten ge-
wonnen werden. Durch die große Anzahl an laufenden Studien, die PatientInnen mit 
niedrigem Operationsrisiko einschließen, ist anzunehmen, dass es zu weiteren Indika-
tionsausweitungen von TAVI kommen wird. 
Schlussfolgerung 
Basierend auf der verfügbaren Evidenz aus zwei RCTs kann zusammengefasst werden, 
dass die Wirksamkeit von TAVI bei PatientInnen mit schwerer Aortenklappenstenose 
und mittlerem Operationsrisiko in Bezug auf die 30-Tages-Gesamtsterblichkeit und die 
kardialen Mortalität dem chirurgischen Aortenklappenersatz (SAVR) wahrscheinlich 
nicht unterlegen ist. Darüber hinaus reduziert TAVI, verglichen mit SAVR mutmaßlich 
die Dauer des Spitalsaufenthaltes. Es bleiben allerdings wesentliche Unsicherheiten be-
stehen, ob TAVI oder SAVR die bessere Methode zur Verbesserung von Symptomen ist. 
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Spitalaufenthaltes durch 
TAVI wahrscheinlich 
verkürzt 
Reinterventionen 
unsicher 
durch TAVI wird Risiko 
für Vorhofflimmern 
wahrscheinlich erhöht, 
aber Risiko für 
Regurgitation erhöht 
widersprüchliche 
Ergebnisse der Studien 
SURTAVI  und 
PARTNER 2 
bezüglich Blutungen 
und Herzschrittmacher-
implantationen 
Langzeitergebnisse und 
Daten zur 
Lebensqualität fehlen 
 
weitere Indikations- 
ausweitungen 
voraussehbar 
 
TAVI ist SAVR bei 
kurzfristiger 
Gesamtsterblichkeit und 
kardialer Mortalität 
nicht unterlegen  und 
reduziert Dauer des 
Spitalsaufenthaltes 
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Zu längerfristiger Gesamtsterblichkeit und kardialer Mortalität können keine Aussagen 
gemacht werden. 
Die qualitativ mittelgradige Evidenz legt nahe, dass TAVI im Vergleich mit SAVR wahr-
scheinlich das Auftreten von Vorhofflimmern reduziert und das Risiko für paravalvulä-
re Regurgitation erhöht. Dennoch bleiben wesentliche Unsicherheiten bezüglich der 
Evidenz hinsichtlich der Ergebnisse zu Schlaganfall, akutes Nierenversagen, neu im-
plantierter permanenter Herzschrittmacher, größere Gefäßkomplikationen, Aorten-
klappen-Reintervention sowie lebensbedrohliche und/oder invalidisierende Blutungen 
bestehen. 
 
 
TAVI reduziert ev.  
Vorhofflimmern,  
Risiko für paravalvuläre 
Regurgitation aber 
erhöht 
viele Unsicherheiten 
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SUMMARY OF RELATIVE EFFECTIVENESS OF TRANSCATHETER AORTIC 
VALVE IMPLANTATION (TAVI) IN PATIENTS AT INTERMEDIATE SURGICAL 
RISK
Scope
The scope of the present assessment can be found here.
Introduction
Description of the technology and comparators
The technology
Transcatheter aortic valve implantation (TAVI), also referred to as transcatheter aortic valve 
replacement (TAVR), is the deployment of a bioprosthesis in the aortic valve using a catheter. In 
contrast to traditional open-heart surgery (i.e. surgical aortic valve replacement, SAVR), the 
procedure is minimally invasive when performed through transfemoral access and can be 
performed with light sedation and without cardiopulmonary bypass. The diseased valve is not 
excised, and there is no need for suturing to deploy the valve. The choice of the access route 
depends on the shape of the arteries and the anatomy of the patient. The most common and 
preferred route is transfemoral (through the upper leg). Other access routes are transapical (through 
the wall of the heart), subclavian (beneath the collar bone), direct aortic (transaortic, through a 
minimally invasive surgical incision into the aorta), and transcaval (through the skin into the inferior 
vena cava and then into the adjoining abdominal aorta) (B0001). For patients at intermediate 
surgical risk, claimed benefits of TAVI compared with SAVR are decreased or similar rates of 
mortality, decreased or similar rates of short-term risks, and improved or similar functional benefits. 
Other claimed benefits are related to length of hospital stay and recovery time [1–3] (B0002). 
The first TAVI systems received the Conformité Européene (CE) mark in 2007. Until 2016, the 
indication for use covered by CE marking was restricted to treatment of patients with severe 
symptomatic aortic valve stenosis (referred to here as aortic stenosis) that was either inoperable or 
put them at high surgical risk of mortality or of complications from SAVR. At the time of scoping for 
this report (June 2017), two manufacturers (Edwards Lifesciences and Medtronic) were offering 
TAVI systems where the indication for use, according to the CE mark, also covered treatment of 
patients with severe aortic stenosis at intermediate surgical risk (Edwards SAPIEN 3 and Medtronic 
Evolut R) (A0020).
In 2013, reimbursement of TAVI was available in 11 European countries [4]. A survey performed 
as part of the present assessment between October and November 2017 among EUnetHTA 
partners showed that TAVI was reimbursed in all 20 responding countries and regions. However, 
decisions about reimbursement in patients at intermediate risk were pending in some countries 
(A0011).
The comparators
In most patients, SAVR is the first choice of treatment for severe symptomatic aortic valve stenosis. 
SAVR is performed under general anaesthesia via an incision in the chest (thoracotomy), through 
different approaches. Level of invasiveness may vary by approach. he procedure requires patients 
to be on cardiopulmonary bypass [5, (6).. Recently, sutureless SAVR has been suggested as an 
alternative to both traditional SAVR and TAVI. Sutureless SAVR resembles TAVI in the way in which 
the prostheses are deployed, but is based on open surgery (sternotomy or mini-sternotomy) for 
accessing the aortic valve [7], (B0001).
Health problem
Aortic stenosis, the narrowing of the aortic valve leading to impaired outflow of blood from the left 
ventricle to the aorta, is the most common valvular heart disease in developed countries (A0002). 
The impaired heart function is usually progressive and eventually leads to left ventricular 
hypertrophy and development of heart failure, which, if left untreated, is associated with a poor 
prognosis. It is a slowly progressive disease and the majority of new diagnoses of clinically 
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significant aortic stenosis occur among the older patients (age >70 years) (A0004). The most 
common cause of aortic stenosis in older patients is the calcific degeneration of aortic leaflets, 
whereas the leading causes in younger patients are congenital heart defects, particularly bicuspid 
aortic valves [8] (A0002). The prevalence of severe aortic stenosis in Europe is approximately 3.4% 
among older patients, of whom 75.6% are symptomatic [9]. The overall incidence rate is ~0.49% 
per year [10] and in those aged above 65 is 2–7% [11]. Approximately 20% of patients over 60 
years of age with aortic stenosis have severe aortic stenosis and ~71% of those with severe aortic 
stenosis are symptomatic [12] (A0023).
Treatment of severe and symptomatic aortic stenosis with medication alone can only be palliative 
and has limited clinical effect. Timely valve replacement therapy is considered an effective 
treatment [5]. Given that open-heart surgery involves risks of complications, SAVR might not be 
suitable for some patients, whereas, for others, the risks might outweigh the benefits. Surgical risk 
rises with increased age and the presence of comorbidities. The most commonly used risk 
algorithms include Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM), logistic 
European System for Cardiac Operative Risk Evaluation (EuroSCORE), and EuroSCORE II, which 
has been used since 2011. A surgical risk score <4% (STS-PROM or EuroSCORE II) is normally 
defined as low risk, risk score 4–8% as intermediate risk, and risk score >8% as high. The most 
recent update of the European Society of Cariology/European Association for Cardio-Thoracic 
Surgery (ESC/EACTS) guidelines, from August 2017, recommend to consider either TAVI or SAVR 
in patients at increased surgical risk, defined as STS or EuroSCORE II ≥4% or logistic EuroSCORE 
I ≥10% or with other risk factors not included in these scores (A0025). Although this includes 
patients at intermediate risk, SAVR is recommended for lower risk patients. In all cases, a heart 
team should make the decision between SAVR and TAVI based on assessment of the individual 
patient and associated risks [5].
Since its introduction in 2007, there has been a rapid but variable rise in the use of TAVI. Use across 
European countries varies, with annual rates between 20 and nearly 200 procedures per million 
inhabitants (A0011).
Methods
The selection of assessment elements was based on the HTA Core Model Application for Rapid 
Relative Effectiveness Assessments (REA) (4.2).
The domains Description and Technical Characteristics of Technology (TEC) and Health Problem 
and Current Use of the Technology (CUR) were developed by performing ad hoc internet searches, 
reviewing information provided by the manufacturers through a structured questionnaire, and 
performing a survey among EUnetHTA partners on the use of TAVI and its reimbursement status 
(October/November 2017).
The domains Clinical Effectiveness (EFF) and Safety (SAF) were developed by systematic literature 
searches according to the Scope of the present assessment. To identify randomised controlled 
trials (RCTs), a search for systematic reviews (SRs) and health technology assessment (HTA) 
reports published in 2013 or later was performed, followed by a search for RCTs published in 2016 
or later (update search). The searches were performed between 26th and 27th June 2017. The 
following sources of information were used: Cochrane Library, Centre for Research and 
Dissemination (CRD), Embase, and Medline, and Medline Pub status ahead of print. In addition to 
the systematic searches, a hand search for potentially relevant HTA reports available on the 
websites of a selected number of HTA agencies was performed. To identify studies of ‘real-world 
data’ from prospective national registries, a search for publications from 2013 and later was 
performed on 5th September 2017. The following sources of information were used: Cochrane 
Library, Embase, and Medline. To describe upcoming evidence, relevant RCTs registered in 2016 
and later were identified by searching the following information sources on 12th January 2018: 
International Clinical Trials Registry Platform (ICTRP) and Clinicaltrials.gov. Detailed descriptions 
of the search strategies are provided in Appendix 1. 
Internal validity of the included RCTs was assessed in accordance with the criteria established by 
the Cochrane tool for assessing risk of bias [13]. All analyses, including risk of bias, meta-analyses, 
and grading of evidence, were performed by the authors and checked by the co-authors. 
Disagreements were solved by consensus. 
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The quality of the body of evidence collected was evaluated with The Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE) method [14]. The GRADE method defines the 
quality of a body of evidence as the extent to which one can be confident that an estimate of effect 
or association is close to the quantity of specific interest. GRADE assessment takes into 
consideration the within-study risk of bias, consistency of results across the available studies 
(heterogeneity), precision of the effect estimate, directness of evidence, and the likelihood of 
publication bias. This method also entails an assessment of the quality of a body of evidence for 
each individual outcome. 
The GRADE system classifies the quality of evidence into four categories: (1) high (we are very 
confident that the true effect lies close to that of the estimate of the effect); (2) moderate (we are 
moderately confident in the effect estimate. The true effect is likely to be close to the estimate of 
the effect, but there is a possibility that it is substantially different); (3) low (our confidence in the 
effect estimate is limited: the true effect might be substantially different from the estimate of the 
effect); and (4) very low (we have very little confidence in the effect estimate: The true effect is likely 
to be substantially different from the estimate of effect).
For the most important outcomes, summary of findings (SoF) tables were prepared using the 
GRADE template. 
The inclusion criteria for assessing the clinical effectiveness and safety outcomes of TAVI were 
restricted to studies with a comparison group. For assessing clinical effectiveness outcomes, only 
RCTs were considered. For assessing safety outcomes, in addition to RCTs, studies reporting real-
world data from national registries were also considered.
Results
Available evidence
In total, 56 potentially relevant SRs, out of 377 unique records after the removal of duplicates, were 
identified by the systematic search for SRs. One additional guideline/HTA report was included 
based on hand searches. Full-text examination of the SRs identified seven potentially relevant 
RCTs (Appendix 2), whereas 18 references of potentially relevant RCTs were identified out of 268 
unique records. After removing duplicates, the full text of 22 references of potentially relevant RCTs 
was checked.
Two industry-sponsored multicentre RCTs [PARTNER 2 trial (NCT01314313) and SURTAVI trial 
(NCT01586910)], with data from three references [2,15,16] involving a total of 3778 patients, were 
included in accordance to the scope. One of the RCTs (SURTAVI) is ongoing. 
The scope (Population, Intervention, Comparator, Outcome, Design; PICOD) for safety in addition 
to RCTs allowed the inclusion of comparative studies of prospective national registries. In total, 48 
records of potentially relevant studies out of 565 unique records from the systematic search were 
identified. Of these, 41 were noncomparative (Appendix 3). The full text of seven comparative 
studies was examined and only two studies, one reporting on data from Germany [17] and one from 
USA [18], were included according to the scope of the study. The full text of excluded 
noncomparative studies was also examined with the purpose of retrieving any safety outcome data 
related to the intermediate-risk population; only one study was identified [19] and, given that it was 
noncomparative, is only described within the Discussion. 
Excluded but potentially relevant RCTs are presented in Table 2.1; excluded comparative registry 
studies are presented in Table 2.2; and included RCTs are presented in Table 2.3.
Clinical effectiveness
Evidence was found for most outcomes defined by the scope (PICOD) with exception of procedural 
success and rehospitalisation for myocardial infarction (>72 h following TAVI). The longest follow-
up was 24 months. The most important reported efficacy outcomes were overall mortality at 30-day 
and 2-year follow-up and cardiac mortality at 30-day and 2-year follow-up (D0001), aortic valve 
reintervention at 30-day and 2-year follow-up (D0006), hospital length of stay (D0011), and 
improvement of symptoms [reduction in New York Heart Association (NYHA) class] (D0005) and 
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quality of life (D0013). Results for the most important outcomes and certainty in estimates (GRADE 
level of evidence) are detailed in the SoF table for effectiveness data (Table 5.1). 
We considered that TAVI is probably non-inferior to SAVR in terms of mortality at 30-day follow-up 
[3.1% versus 2.9%, risk ratio (RR) 1.07, 95% confidence interval (CI) 0.74–1.55; GRADE evidence: 
moderate]. 
We are uncertain whether TAVI is non-inferior to SAVR in terms of mortality at 2-year follow-up 
(12.9% versus 12.7%, RR 1.01, 95% CI 0.86–1.20; GRADE evidence: very low). 
We considered that TAVI is probably non-inferior to SAVR in terms of cardiac mortality at 30-day 
follow-up (2.6% versus 2.4%, RR 1.11 95% CI 0.75–1.66; GRADE evidence: moderate). 
We are uncertain whether TAVI is non-inferior to SAVR in terms of cardiac mortality at 2-year follow-
up (12.9% versus 12.7%, RR 1.01, 95% CI 0.86–1.20; GRADE evidence very low). 
We concluded that TAVI might increase the risk of aortic valve reintervention at 30-day follow-up 
compared with SAVR (0.6% versus 0.1%, RR 7.58, 95% CI 1.38–41.55; GRADE evidence: low). 
However, we are uncertain whether TAVI increases the risk of aortic valve reintervention at 2-year 
follow-up (1.7% versus 0.4%, RR 3.86, 95% CI 1.76–8.44; GRADE evidence very low).
We are uncertain whether TAVI has any effect on improving symptoms compared with SAVR at 1-
and 2-year follow-up (data could not be pooled. GRADE evidence: very low).
We are moderately confident that TAVI probably reduces the length of hospital stay by 2 or 3 days 
compared with SAVR (data not pooled. GRADE evidence: moderate).
Safety
Any major or minor adverse events were considered important for the assessment of the safety of 
TAVI compared with SAVR. Most importantly, both RCTs reported the following safety-related 
events [C0008]: acute kidney injury (30-day follow-up); major vascular complications (30-day follow-
up); paravalvular regurgitation (30-day follow-up); stroke (30-day follow-up); stroke (2-year follow-
up); atrial fibrillation onset (30-day follow-up), life-threatening and/or disabling bleeding (30-day 
follow-up); and new permanent pacemaker (30-day follow-up). Results for these outcomes and 
certainty in estimates (GRADE level of evidence) are shown in the SoF table for effectiveness data 
(Table 6.1. Summary of findings for the safety comparison of TAVI versus SAVR for 
patients with aortic stenosis at intermediate surgical risk
Compared with SAVR, we are uncertain whether TAVI has any effect on stroke at 30-day follow-up 
(4.4% versus 5.6%, RR 0.80, 95% CI 0.58–1.10; GRADE evidence: very low) and at 2-year follow-
up (7.4% versus 7.6%, RR 0.97, 95% CI 0.74–1.26; GRADE evidence: very low).
We are moderately confident that TAVI probably reduces the incidence of new atrial fibrillation 
compared with SAVR (11% versus 34%, RR 0.32, 95% CI 0.27–0.37; GRADE evidence: moderate).
We are uncertain whether TAVI has any effect on life-threatening or disabling bleeding at 30-day 
follow-up (two studies, data not pooled; GRADE evidence: very low) and 2-year follow-up (one 
study, RR 1.02, 95% CI 0.74–1.41; GRADE evidence: very low) compared with SAVR.
We are uncertain whether TAVI reduces the risk of acute kidney injury at 30-day follow-up (1.0% 
versus 2.2%, RR 0.47, 95% CI 0.27–0.80; GRADE evidence: very low) and 2-year follow-up (2.2% 
versus 3.5%, RR 1.02, 95% CI 0.74–1.41; GRADE evidence: very low) compared with SAVR.
We conclude that, compared with SAVR, TAVI might increase the incidence of major vascular 
complications at 30-day follow-up (6.9% versus 3.1%, RR 3.03, 95% CI 0.79–11.67; GRADE 
evidence: low).
Data regarding pacemaker implantation at 30-day follow-up were heterogenous among studies and 
the results were not pooled. Quality of evidence was rated as very low. 
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We are moderately confident that TAVI probably increases the risk of paravalvular regurgitation 
compared with SAVR (3.2% versus 0.3%, RR 9.30, 95% CI 4.02–21.48; GRADE evidence 
moderate).
In the PARTNER 2 trial, the incidence of endocarditis at 2-year follow-up was 1.2% in the TAVI 
group and 0.7% in the control group (RR 1.85, 95% CI 0.69–4.99).
None of the trials evaluated rehospitalisation for myocardial infarction (>72 h following TAVI).
Given that more-complete safety data from RCTs with longer follow-up were available, the real-
world data studies were only presented narratively, and the level of evidence was not formally 
graded. The German study [17] reported two safety-related outcomes [in-hospital mortality and 
postoperative delirium (POD)] in a matched group of 470 patients (out of 3407 patients who 
underwent valve replacement) with a mean surgical EuroSCORE risk 13.5±2.7. The American study 
[18] reported the incidence of stroke at 1 year in two groups of 4732 patients each with a median 
surgical risk of STS 5.6% (IQR: 4.2–8.2%). The patients were matched using propensity scores and 
results were reported for three different subgroups of surgical risk. Risk of in-hospital mortality in 
the TAVI group was 3.3% and 5.1% in the SAVR group. The difference was reported as significant 
(p <0.01) in favour of TAVI. The incidence of POD was 3.9% for TAVI and 12.8% for SAVR (p 
<0.01). Risk of stroke at 1 year was reported with hazard ratios (HR) revealing no significant 
differences between the TAVI and SAVR groups at either risk rate.
Ongoing studies
Two active RCTs relevant to the scope of the study were identified. The SURTAVI trial 
(NCT01586910) had a final completion date of November 2026 and data collection for primary 
outcome measures was expected in July 2018; however, the results had not been posted at the 
time of writing (August 2018). The second trial was an ongoing German trial (NCT03112980), with 
completion expected in 2023. Interestingly, six RCTs comparing TAVI with SAVR or medication in 
patients at low risk or who were nonsymptomatic were also identified (Appendix 1). For these RCTs, 
the primary completion date varied from 2018 to 2021.
Discussion
Both TAVI and SAVR are complex procedures under constant development, with both substantial 
and small incremental changes relating to the devices and all aspects of the procedures being 
made. 
We performed a systematic search oriented towards the identification of SRs and an updated 
search of primary studies. We identified published data from two RCTs that compared TAVI with 
open surgery for patients with severe aortic stenosis at intermediate surgical risk. The evidence 
was rated using the GRADE approach. Given the risk of bias, the level of certainty for important 
short-term efficacy and safety outcomes (overall mortality at 30-day follow-up, cardiac mortality at 
30-day follow-up, length of hospital stay, major vascular complications, paravalvular regurgitation, 
and atrial fibrillation onset) was regarded as moderate. Further downgrading was done for overall 
and cardiac mortality at 1- and 2-year follow-up because of serious concerns caused by attrition 
bias. For the improvement of symptoms, aortic valve reintervention, new permanent pacemaker, 
stroke (at all time points), and life-threatening and/or disabling bleeding outcomes, the evidence 
was further downgraded by one or more level because of serious or very serious concerns 
regarding inconsistency and/or imprecision. 
In terms of efficacy, based on moderate-level evidence, we considered TAVI to be non-inferior to 
SAVR in terms of all-cause and cardiac mortality at 30-day follow-up. However, at 2-year follow-up, 
the evidence regarding non-inferiority was considered very low and no conclusion could be reached. 
In terms of improvement in symptoms according to the NYHA classification, the evidence for non-
inferiority was also considered very low and no conclusion could be reached. 
Based on moderate evidence, we found that TAVI probably reduces the duration of hospital stay 
compared with SAVR. There was a higher proportion of aortic valve reintervention in the TAVI group 
than in the SAVR group at 30-day and 2-year follow-up. However, the evidence was considered 
very low and we were not able to determine definitively whether TAVI increases the risk of aortic 
valve reintervention compared with SAVR. 
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In terms of safety, based on a moderate level of evidence, we considered that TAVI at 30-day follow-
up probably reduces the risk of new atrial fibrillation, but enhances the risk of paravalvular 
regurgitation. With regard to the stroke, disabling stroke, and risk of acute kidney injury outcomes, 
we considered the evidence for non-inferiority to be very low and no conclusion could be reached. 
Conflicting results between the included trials were observed in terms of life-threatening or disabling 
bleeding and the need for new permanent pacemaker replacement. Although there was little or no 
difference in the disabling bleeding outcome between TAVI and SAVR in the SURTAVI trial, the 
results were in favour of TAVI in the PARTNER 2 trial. Whereas there was little or no difference in 
the permanent pacemaker replacement outcome in the PARTNER 2 trial, the proportion of 
implanted pacemakers was in favour of SAVR in the SURTAVI trial. Given the risk of bias and 
important heterogeneity, we considered the overall quality of evidence for these two outcomes to 
be very low. Future studies will be needed to confirm whether the observed heterogeneity was 
related to the TAVI system or if there are alternative explanations. 
Limitations of the RCTs included a lack of long-term follow-up, a significant frequency of 
withdrawals, and uncertain data on quality of life. The ongoing German RCT (NCT03112980) is an 
industry-independent study that could provide more reliable 5-year follow-up data and quality of life 
data. 
Available evidence (restricted to the inclusion criteria) did not provide answers to the following 
assessment elements: C0002, C0004, C0005, and C0007. From our search, we were unable to 
identify published or ongoing RCTs comparing outcomes of one TAVI system with another TAVI 
system. 
The real-world studies identified were not considered relevant to assessing the safety of TAVI in a 
more extensive way because RCT data with longer follow-up were available and pooled. In addition 
to patients’ data, registries should also collect device-related data and setting information to allow 
analyses of performance between different products and to assess the impact of different settings 
on safety outcomes. Upcoming evidence could be derived from more efficient and sophisticated 
analysis of high-quality real-world data (B0010).
Based on comments from clinical experts, some issues remain. Moreover, the high number of 
ongoing studies involving patients at low surgical risk could result in an increase in the use of TAVI 
in future years.
Conclusion
Based on available evidence from two RCTs, we conclude that the effectiveness of TAVI for patients 
with severe aortic stenosis at intermediate surgical risk is probably non-inferior to SAVR in terms of 
all-cause mortality and cardiac mortality at 30-day follow-up. Moreover, TAVI probably reduces the 
length of hospital stay compared with SAVR. However, important uncertainties remain regarding 
whether TAVI is better or worse than SAVR in terms of symptom improvement. 
Moderate-quality evidence suggests that, compared with SAVR, TAVI probably reduces new-onset 
atrial fibrillation and to enhance the risk of paravalvular regurgitation. However, important 
uncertainties remain regarding the evidence on the following outcomes: stroke, acute kidney injury, 
new permanent pacemaker, major vascular complications, aortic valve reintervention, and life-
threatening and/or disabling bleeding.
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1 SCOPE
Description Project scope
Population International Classification of Diseases (ICD)-10 code: I35.0 - Nonrheumatic aortic (valve) 
stenosis; I35.2 - Nonrheumatic aortic valve stenosis with insufficiency; I06.0 - Rheumatic 
aortic stenosis; Q23.0 - Congenital stenosis of aortic valve
Medical Subject Headings (MeSH) terms: C14.280.484.150, C14.280.955.249
The population of interest in this report is represented by patients with severe aortic stenosis 
(AS) at intermediate risk of death or complications associated with SAVR. The indication 
should at least be defined by NYHA class, and either STS risk model score (STS score), 
EuroSCORE or EuroSCORE II
Intervention TAVI as a therapeutic intervention for the defined target population. The assessment will be 
restricted to systems with a CE mark for the defined population
MeSH terms: E04.100.376.485.500, E04.650.410.500, E04.928.220.410.500
TAVI involves the insertion of a prosthetic valve, which functionally replaces the damaged 
aortic valve, using fluoroscopic and echographically guided minimally invasive procedures. 
The prosthetic valve is compressed within a dedicated delivery system and, once in place 
within the diseased aortic valve, its deployment allows its expansion and the compression 
of the native diseased valve against the wall of the aorta. Depending on the anatomy of the 
patient and device characteristics, the procedure can be performed by one of four different 
approaches. The transfemoral (TF) route is the most common, whereas the others are 
performed when the anatomy of the patient precludes access via the TF route. These 
approaches are the subclavian/transaxillary (S/T) approach, the transapical (TA) approach, 
and the transaortic (TAo) approach. Subgroup analyses based on the risk assessment tool 
used, the TAVI system used (i.e., model dependent), and the procedural approach (i.e., TF, 
S/T, TA, and TAo) will be performed if there are sufficient data
Comparison SAVR can be performed using different approaches (full sternotomy and more minimally 
invasive procedures), different kinds of valves, and different kinds of valve-anchoring 
techniques (i.e., sutured and sutureless). Subgroup analyses based on these comparators 
will be performed if possible
MeSH terms: E04.100.376.485, E04.650.410, E04.928.220.410
Rationale: the comparator has been chosen based on information from relevant published 
clinical guidelines [20] and EUnetHTA guidelines [21,22] 
Outcomes Efficacy outcomes:
 Mortality at 30-day follow-up and at the longest follow-up (all-cause mortality, 
cardiovascular mortality, and noncardiovascular mortality)
 Improvement of symptoms (reduction in NYHA class)
 Improvement in health-related quality-of-life indicators [e.g., EQ-5D score, SF-12 
score, or Kansas City Cardiomyopathy Questionnaire (KCCQ) score]
 Procedural success (i.e., successful valve implantation)
 Haemodynamic function of the valve
 Intensive care unit (ICU) length of stay (days)
 Hospital length of stay (days)
 Rehospitalisation for myocardial infarction (>72 h following TAVI)
Safety outcomes: 
 Any major or minor adverse event (e.g., vascular complications; stroke; TIA; 
disabling or life-threatening bleeding; aortic valve reintervention; myocardial infarction ≤72 
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Description Project scope
h post procedure; new or worsening atrial fibrillation or atrial flutter; moderate or severe 
aortic valve regurgitation; acute kidney injury; pain; or need for permanent pacemaker 
implantation)
 Radiation causing harm to both patient and staff
Rationale: outcomes have been chosen based on information from relevant published 
clinical guidelines [20,23] and EUnetHTA guidelines [21,22]
Study design Efficacy:
 RCTs (the most recent systematic reviews and/or meta-analysis of RCTs will be 
used to retrieve potential eligible studies and to compare the overall results)
Safety:
 RCTs (the most recent systematic reviews and/or meta-analysis of RCTs will be 
used to retrieve potential eligible studies and to compare the overall results)
 Real-world data derived from published studies from prospective national registries
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2 METHODS AND EVIDENCE INCLUDED 
2.1 Assessment team
Description of roles and workload within the assessment team:
1st author (AGENAS):
 Developed the first draft of the EUnetHTA project plan and amended the draft when 
necessary.
 Carried out the assessment (domains EFF and SAF): answered assessment elements, 
completed checklist regarding potential ‘ethical, organisational, patient and social and legal aspects’ 
of the HTA Core Model® for rapid REA (Table 3.2).
 Sent “draft versions” to reviewers, compiled feedback from reviewers and performed changes 
according to reviewers’ comments (domains EFF and SAF).
 Prepared final assessment and wrote a final summary of the assessment.
Co-author (NIPHNO)
 Assisted to develop the first draft of EUnetHTA project plan.
 Carried out the assessment (domains TEC and CUR): answered assessment elements, 
filled-in checklist regarding potential “ethical, organisational, patient and social and legal 
aspects” of the HTA Core Model® for rapid REA (see Table 3.2).
 Compiled feedback from reviewers and performed changes according to reviewers’ 
comments (domains TEC and CUR).
 Performed structured literature searches for domains EFF and SAF.
 Assisted in the preparation of the final assessment and final summary.
Dedicated reviewers (KCE, Onassis Cardiac Surgery Centre, HIQA, SNHTA, Regione Veneto)
 Reviewed the draft and final version of the project plan.
 Reviewed the draft and final version of the assessment.
2.2 Involvement of stakeholders
Stakeholder involvement was restricted to manufacturers and health professionals (external 
experts). Manufacturers were identified by a call on the author’s website according to the internal 
procedures of the author. Responding companies were involved in the early stages of project 
development and were invited to contribute to the project by providing information through a 
structured questionnaire prepared by the author and reviewed by the co-author. Individual face-to-
face meetings with the manufacturers were held at AGENAS to present the project objectives and 
clarify information needs. Both Norwegian and Italian external experts were recruited. The 
Norwegian Regional Health Services appointed Norwegian experts at commission of the 
assessment. The Italian expert was recruited through a call to the Italian Regions.
Manufacturers and external experts were involved in the Description and Technical Characteristics 
of Technology (TEC) and Health Problem and Current Use of the Technology (CUR) domains and 
in the final draft factual check in relation to the information provided and used within the report. 
External experts provided input during the scoping phase and final assessment report within the 
dedicated review process. 
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2.3 Source of assessment elements
For all domains, the selection of assessment elements was based on the HTA Core Model 
Application for Rapid Relative Effectiveness (REA) Assessments (ver. 4.2). The selected issues 
(generic questions) were translated into actual research questions (answerable questions).
2.4 Search
Detailed search strategies for efficacy and safety outcomes (including registry data) are provided 
in Appendix 1. All search strategies were developed by an information specialist and checked by 
another information specialist by the co-author. 
To identify relevant RCTs, a search of systematic reviews (SRs) published in 2013 or later, followed 
by a search for RCTs published in 2016 or later (up-date search) were performed by the co-author. 
The searches were performed between 26th and 27th June 2017. The following sources of 
information were used: Cochrane Library, Centre for Research and Dissemination (CRD), Embase, 
and Medline, and Medline Pub status ahead of print. In addition to the systematic search, a hand 
search of selected members of the International Network of Agencies for Health Technology 
Assessment (INAHTA) home pages (see Appendix 1 for inspected pages) was also performed. 
Only reports produced in 2017 and later were included for full-text searches. 
To assess safety, a search for ‘real-world data’ from prospective national registries was performed 
by the co-author. The search was performed on 5th September 2017. Publications from 2013 and 
later were considered. The following sources of information were used: Cochrane Library, Embase, 
and Medline. 
To describe upcoming evidence, relevant ongoing RCTs were identified by the co-author by 
searching the following information sources: ICTRP and Clinicaltrials.gov. The search strategy is 
provided in Appendix 1. 
Ad hoc internet searches were performed for the CUR and TEC domains. A survey among 
EUnetHTA partners was performed in October and November 2017 to receive information on the 
use of TAVI and on the reimbursement status to be used in the CUR domain. 
2.5 Study selection for effectiveness and safety
The systematic searches for the effectiveness (EFF) and safety (SAF) domains were each followed 
by three rounds of title and abstract screening: the first two rounds were performed by the co-author, 
and the third round by the author. The two searchers by the co-author included potentially relevant 
records according to the scope based on the independent screening of abstract and titles (round 
one), followed by inclusion based on consensus (round two). The co-author sent a list of potentially 
relevant SRs, RCTs, and real-world studies to the author. The author checked the study selection 
process (third round) and retrieved potentially relevant records for full-text examination. The author 
used the included SRs to identify records of potentially relevant RCTs. Final full-text retrieval of all 
studies was carried out by two independent researchers from the author with final approval from 
the co-author. Any disagreement was solved through discussions before the final inclusion. 
Inclusion was limited to articles in English.
The flow chart screening processes in relation to PICOD are revealed detailed in Figures 2.1, 2.2 
and 2.3.
Study selection for systematic reviews and HTA reports (2013–June 2017)
In total, 865 unique records were identified using search terms for TAVI and a time limit to the year 
of publication from 2013 onwards. From these records, 488 were excluded with the use of a search 
filter for systematic reviews (Appendix 1: METHODS AND DESCRIPTION OF THE 
EVIDENCE USED). The co-author provided a list of 56 from the remaining 377 records based 
on screening abstracts and titles. In addition, one guideline with a systematic search for evidence 
was provided by the co-author based on hand searches. The author included all SRs and the 
guideline for full-text inspection. The methodological quality of SRs was not assessed by the author 
but all SRs comparing TAVI with SAVR were checked to identify relevant RCTs (primary studies). 
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Seven potentially relevant RCTs (CoreValve, PARTNER A, PARTNER 2, Rex 2016, SAPIEN 3, 
STACCATO, and SURTAVI) were identified based on the SRs. A list of included and excluded SRs 
is provided in Appendix 2.
Study selection for RCTs (2016–June 2017)
In total, 865 unique records were identified before the use of specific search filters. Of these, 597 
records were excluded by restricting the time limit to year of publication from 2016 onwards, and 
the use of a search filter for RCTs (Appendix 1: METHODS AND DESCRIPTION OF THE 
EVIDENCE USED). The co-author provided a list of 18 from the remaining 268 records based on 
screening abstracts and titles. The author removed duplicates between the SR search and the RCT 
list, leaving 22 records (see Figure 2.2) analysed by the author in full text. Studies in which a 
population of patients at intermediate operative risk could not be distinguished from patients who 
were inoperable, at high risk, or at low risk were excluded. Both study eligibility criteria and reported 
risk scores of included patients were used to determine the relevance. Two RCTs [PARTNER 2 A 
trial (NCT01314313) and SURTAVI trial (NCT01586910)] with data from three references [2,15,16], 
involving a total of 3778 patients were included in accordance to the scope. One of the RCTs 
(SURTAVI) is ongoing. Excluded RCTs are shown in Table 2.1; excluded comparative registry 
studies are detailed in Table 2.2; included RCTs are detailed in Table 2.3; included registry studies 
are detailed in Table 2.4.
Study selection for real-world data analysis (2013–September 2017)
In total, 565 unique records were identified by the search. Of those records, the co-author provided 
a list of 48 potentially relevant titles identified for real-world data from registry studies after the title 
and abstract screening process. Of the 48 records provided by the co-author, 41 were 
noncomparative registry studies and were excluded against the defined PICOD (Appendix 3).
The authors identified seven comparative studies for a more in-depth full-text examination. Two 
comparative (TAVI versus SAVR) prospective studies of national registry data were included, one 
from Germany [17] and one from USA [18]. The five excluded comparative studies are listed in 
Table 2.2. In an attempt to identify any safety outcome data related to the intermediate risk 
population, the author checked the full text of those 41 excluded studies. Only one study reporting 
relevant data was identified [19] and is briefly described in Section 9.
Study selection for upcoming evidence
Study selection for upcoming evidence was performed by the co-author. One researcher identified 
those RCTs comparing TAVI with SAVR with completion dates in 2016 or later, and then another 
researcher checked whether eligibility criteria and outcomes were fulfilled. A list of all identified 
ongoing RCTs comparing TAVI with SAVR is provided in Appendix 1.
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database searching 
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Records included by SR/HTA 
(n=377 from search)
SRs included by NIPHNO based on title and 
abstract 
(n=56 from search)
Records excluded by 
NIPHNO based on 
title and abstract:
(n=321)
SRs inspected by AGENAS in full 
text as source of RCTs
(n=56+1)
Records excluded
by SR/HTA filter: 
(n=488)
Hand search 
(n=1)**
Figure 2.1. Flow chart of efficacy and safety studies: search for SRs published in 2013 
onwards
*The same 865 records were identified by both the SR and RCT searches.
**Inspection of HTA agency websites (see list in Appendix 1); only the most updated websites were included.
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Records included by trial filter and 
publication date 2013 onwards (n 
= 268)
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Records excluded based on 
title and abstract
(n=250)*
Records assessed in full text for 
eligibility 
(n=22)
Records included in quantitative synthesis 
(meta-analysis)
(n=3 from two RCTs)
Records identified through 
database searching 
n=865 references in total* (1279 
including duplicates)
Excluded by trial filter and 
publication date before 2013
(n=597)
Records included from 
SRs not identified by 
search (n=4)
Records excluded
based on full text 
(n=19)
Figure 2.2. Flow chart of efficacy and safety studies: search for RCTs published in 2016 
onwards
*The same 865 records were identified by both the SR and RCT searches.
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Unique records after searching 
for registry studies 
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through other sources 
(n=0)
Records after duplicates removed 
(n=565)
Records screened
(n=565)
Records excluded based on 
abstract and title
n=517
Full-text articles assessed 
for eligibility 
(n=48)
Full-text articles excluded
with reasons
(n=46)
Exclusion criteria:
 Not comparative (n=41
 Other population (n=4)
 Not in English (n=1)
Studies included
in qualitative synthesis 
(n=2)
Type of study:
observational studies
Studies included in quantitative synthesis (meta-
analysis)
(n=0)
Figure 2.3. Flow chart of registry studies
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Table 2.1. Excluded potentially relevant RCTs
Reference Reason for exclusion
Deeb 2016 [24] Wrong population: ‘Patients with severe aortic stenosis deemed at increased risk 
for surgery’ (mean STS score 7.3±3.0) (Inclusion criteria: patients were 
considered to be at increased surgical risk if two cardiac surgeons and one 
interventional cardiologist at the investigative site estimated that the risk of death 
within 30 days after surgery was 15% or more and the risk of death or irreversible 
complications within 30 days after surgery was <50%.)
Gleason 2016 [25] Wrong population: ‘High-risk patients (predicted SAVR mortality 15%) with severe 
aortic stenosis’ (mean STS score 7.0±3.0) (NCT01240902)
Gronlykke 2017 [26] 
(NOTION trial)
Wrong population: post-hoc analysis of NOTION trial (see below)
Gronlykke 2016 [27]
(NOTION trial)
Wrong population: post-hoc analysis of NOTION trial (see below)
Jorgensen 2017 (28)
(NOTION trial)
Wrong population: post-hoc analysis of NOTION trial (see below)
Kodali 2016 [29] 
(SAPIEN 3 trial)
Wrong population: post-hoc analysis of SAPIEN 3 trial (Inoperable patients with 
an estimated probability of death or serious irreversible morbidity after SAVR of 
>50% [30]
Kodali 2016a [31] 
(SAPIEN 3 trial)
Wrong population: post-hoc analysis of SAPIEN 3 trial
Kodali 2012 [32] 
(PARTNER A trial)
Wrong population: high-risk patients with severe aortic stenosis
Little 2016 [33]
(CoreValve US High-
Risk Clinical Study)
Wrong population: patients with severe aortic stenosis and high surgical risk 
(mean STS score: 7.3±3.0); Patients were considered by two clinical site cardiac 
surgeons to have a >15% estimated surgical mortality rate at 30-day follow-up
Mack 2015 [34]
(PARTNER A trial)
Wrong population: high-risk patients with severe aortic stenosis
Makkar 2012 [35] 
(PARTNER A trial)
Wrong population: high-risk patients with severe aortic stenosis
Miller 2012 [36] 
(PARTNER A trial)
Wrong population: high-risk patients with severe aortic stenosis
NGO 2017 [37]
(NOTION trial)
Wrong population: post-hoc analysis: ‘This is an echocardiographic sub study of 
the NOTION trial’
Nielsen 2012 [38] 
(STACCATO trial)
Unclear population, risk score not reported; in addition: prematurely terminated 
study because of early adverse events, few participants, and an early version of 
the TAVI device 
Reardon 2016 [39] Wrong population: post-hoc analysis CoreValve US Pivotal High-Risk Trial; 
patients at increased risk for surgery
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(CoreValve US Pivotal 
High-Risk Trial)
Rex 2016 [40] Wrong population: low-risk patients; long-term health-related quality-of-life 
(HRQoL) in low-risk patients randomised to TAVI or SAVR
Smith 2011 [41]
(PARTNER A trial)
Wrong population: high-risk patients with severe aortic stenosis
Sondergaard 2016 [42]
(NOTION trial)
Wrong population: patients with severe aortic valve stenosis; low and 
intermediate risk (STS-PROM score 3.0±1.7)
Zorn 2016 [43] Wrong population and outcome: the study aimed to determine the influence of 
prosthesis–patient mismatch on clinical outcomes; patients at increased risk for 
surgery
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Table 2.2. Excluded comparative registry studies
Reference Reason for exclusion
Brennan 2014 [44] Unclear population: safety-related outcome data not reported by risk score of 
interest (intermediate)
Mohr 2014 [45] Unclear population: safety-related outcome data not reported by risk score of 
interest (intermediate)
Eggebrecht 2016 [46] Unclear population: safety-related outcome data not reported by risk score of 
interest (intermediate)
Hamm 2014 [47] Unclear population: safety-related outcome data not reported by risk score of 
interest (intermediate)
Yucel 2016 [48] Full text not in English (German).
2.6 Data extraction and analyses
Data extraction was performed by the author and checked by the co-author. Absolute numbers for 
event rates were based on numbers reported by the studies. For the SURTAVI trial, absolute 
numbers were provided by authors of the trial; extraction of data was only checked by AGENAS. 
Where possible, a meta-analysis of the included RCTs was performed. All analyses were performed 
by the author and checked by the co-author. Review Manager (Revman 5.3) was used for data 
synthesis. Data were pooled using both the random-effects model and the fixed-effect model to 
ensure robustness.
Tables of findings were prepared for presenting results from selected studies using the Summary 
of Findings template of the GRADE approach [49]. Dichotomous outcomes results were expressed 
as RRs. When continuous scales of measurement are used to assess the effects of treatment, the 
mean difference (MD) or standard mean difference (SMD) are used; all RRs, MDs, and SMDs were 
presented with 95% CIs where possible. 
Both studies were of non-inferiority in design and provided analyses based on intention-to-treat and 
modified intention-to-treat approaches. To perform meta-analyses, data were extracted from both 
trials using absolute events at different time points. Analyses were based on an intention-to-treat 
basis. 
Heterogeneity was evaluated using a Chi2 test with n–1 degrees of freedom, with an alpha of 0.10 
used for statistical significance and with the I2 test [13]. Sources of heterogeneity were sought by 
assessing differences in characteristics of patients, interventions, comparators, and outcomes 
across the included studies and by visually assessing the forest plots. 
No subgroup analysis was performed based on the type of TAVI model and/or systems because 
there were only two trials, and these used different TAVI systems. Only one of the studies 
(PARTNER) reported data for two different access routes. Given that the trial was not powered for 
analysis of the subgroups, data were not evaluated based on the subgroups. 
To verify the validity of the document, input was received from experts on the final draft and from 
manufacturers in terms of factual checks of information used in the report.
Registry studies
Data extraction and analysis were performed by the author. Two reviewers extracted and analysed 
the studies independently.
2.7 Quality rating 
Assessment of the methodological quality of included RCTs was performed by the author and 
checked by the co-author. Disagreements were resolved by consensus. For RCTs, the 
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methodological quality of included RCTs was assessed in accordance with the criteria established 
by the Cochrane tool for assessing risk of bias [14]. The following domains for the risk of bias were 
considered: (i) random sequence generation (selection bias); (ii) allocation concealment (selection 
bias); (iii) blinding of patients and personnel (performance bias); (iv) blinding of outcome 
assessment (detection bias); v) incomplete outcome data (attrition bias); and (vi) selective reporting 
(reporting bias). Nonrandomised studies were rated by default as at high risk of bias [14,50].
The quality of the body of evidence was evaluated with the GRADE method [14]. The GRADE 
method defines the quality of a body of evidence as the extent to which one can be confident that 
an estimate of effect or association is close to the quantity of specific interest. GRADE assessment 
takes into consideration the within-study risk of bias, consistency of results across the available 
studies (heterogeneity), precision of the effect estimate, directness of evidence, and the likelihood 
of publication bias. The GRADE method also entails assessment of the quality of a body of evidence 
for each individual outcome. 
The following is how the GRADE system classifies the quality of evidence into four categories, their 
interpretation, and the wording used in the results to express the efficacy and safety of TAVR versus 
SAVR for the current report. 
(1) high-quality evidence: we are very confident that the true effect lies close to that of the estimate 
of the effect; this means that the intervention improves and/or reduces a specific outcome;
 (2) moderate-quality evidence: we are moderately confident in the effect estimate: the true effect 
is likely to be close to the estimate of the effect, but there is a possibility that it is substantially 
different; this means that the intervention probably improves and/or reduces a specific outcome;
(3) low-quality evidence: our confidence in the effect estimate is limited: the true effect might be 
substantially different from the estimate of the effect: this means that the intervention might improve 
and/or reduce a specific outcome;
(4) very low-quality evidence: we have little confidence in the effect estimate: the true effect is likely 
to be substantially different from the estimate of effect; in other words, it is uncertain that the 
intervention improves and/or reduces a specific outcome.
A ‘Summary of findings’ table was presented to provide key pieces of information in a quick and 
accessible forma
2.7 Description of the evidence used
Table 2.3. Main characteristics of the effectiveness and safety RCT studies included in the 
analysis
Author and year 
and/or study 
name (number)
Study type Number of 
patients
Intervention 
(s)
Main 
endpoints
Included in 
clinical 
effectiveness 
and/or safety 
domain?
Arora 2016 [16] 
Leon 2016 [15]
PARTNER 2 trial 
(NCT01314313)
RCT, 
multicentre
2032 
intermediate-
risk patients 
with severe 
aortic stenosis 
(1011 TAVI; 
1021 SAVR)
Intervention: 
TAVI via TF or 
transthoracic 
placement of 
Edwards 
balloon-
expandable 
SAPIEN XT 
heart valve (26 
mm)
Control: SAVR
Mortality from 
any cause
Disabling 
stroke at 2-year 
follow-up
Effectiveness and 
safety
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Author and year 
and/or study 
name (number)
Study type Number of 
patients
Intervention 
(s)
Main 
endpoints
Included in 
clinical 
effectiveness 
and/or safety 
domain?
Reardon 2017 [2]
SURTAVI trial 
(NCT01586910)
RCT, 
multicentre
1746 
intermediate-
risk patients 
with severe 
aortic stenosis 
(879 TAVI; 867 
SAVR)
Intervention: 
Medtronic 
CoreValve 
System or 
Medtronic 
CoreValve 
Evolut R 
System TAVI
Control: SAVR 
Composite of 
mortality from 
any cause or 
disabling stroke 
at 2-year 
follow-up
Effectiveness and 
safety
Table 2.4. Main characteristics of registry studies included in the analysis
Author and 
year and/or 
study name
Study type Number of 
patients
Intervention (s) Main endpoints Included in clinical 
effectiveness 
and/or safety 
domain?
Bestehorn 
2015 [17]
Cohort 1526 TAVI versus 
SAVR
Incidence of POD
In-hospital 
mortality
Safety
Brennan 
2017 [18] 
Cohort 9464 TAVI versus 
SAVR
Incidence of 
stroke
Safety
Evidence included for effectiveness and safety
For effectiveness and safety based on RCTs, the search strategy allowed the identification of 22 
articles that evaluated the use of TAVI for aortic stenosis: of these, three were publications of two 
trials that fulfilled our inclusion [2,15,16]; the other 19 were excluded and are listed in Table 2.1.
Prospective national registries studies presenting analyses of real-world data were used within the 
safety domain. Two studies were included for the qualitative analysis of safety outcomes [17,18]. 
However, these two studies were not included in the meta-analysis.
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3 DESCRIPTION AND TECHNICAL CHARACTERISTICS 
OF TECHNOLOGY (TEC)
3.1 Research questions 
Element ID Research question
B0001 What are TAVI and SAVR?
A0020
For which indications has TAVI received marketing authorisation or CE 
marking?
B0002 What is the claimed benefit of TAVI in relation to SAVR?
B0003 What is the phase of development and implementation of TAVI and SAVR?
A0021 What is the reimbursement status of TAVI?
3.2 Results
[B0001] What are TAVI and SAVR?
TAVI and SAVR differ in both the procedures used and the designs of the implants. 
Technology: TAVI
TAVI is the replacement of the aortic valve of the heart with a prosthesis delivered through a blood 
vessel using a catheter (transluminal via a large artery or vein) or via a small incision through the 
heart wall (apex of the left ventricle). The prostheses are balloon-expandable or self-expandable 
bioprostheses compressed in size during delivery and expanded when in place in the aortic heart 
valve. TAVI is also referred to as TAVR and, for some procedures, can be referred to as 
percutaneous aortic valve replacement (PAVR). The prosthesis is most commonly delivered via 
one of several access routes: TF (through the upper leg), TA (through the apex of the left ventricle), 
S/T (beneath the collar bone), TAo (through a minimally invasive surgical incision into the aorta), 
and transcaval (through the skin into the inferior vena cava and then into the adjoining abdominal 
aorta). The choice of access route depends on the shape of the arteries and the anatomy of the 
patient. The most common and preferred route is TF [3], whereas the others are performed when 
the anatomy of the patient precludes access via the TF route.
In contrast to SAVR, the diseased valve is not excised and there is no need for suturing. TAVI can 
be carried out under general anaesthesia, although, in most cases, it is performed under local 
anaesthesia with sedation. Prophylactic antibiotics and anticoagulation are administrated during the 
procedure [3,51].
Correct placement of the implant is assured by intraprocedural radiographic imaging using 
fluoroscopy (angiography). Echocardiography can be used to complement angiographic imaging. 
Computed tomography (CT) is routinely performed for preprocedural imaging and for long-term 
postprocedural assessment [52]. 
An interdisciplinary team with specialist training and experience in complex endovascular cardiac 
interventions is needed during the TAVI procedure, and for patient selection, choice of implant, and 
access route. TAVI can be performed either in a catheterisation laboratory or in a hybrid operating 
theatre. TAVI should be performed in a center with a cardiac surgical division given that cardiac 
and vascular surgical support for emergency treatment of complications must be in place [3]. The 
use of a hybrid theatre allows emergency cardiosurgery to be performed in the same room as the 
TAVI procedure. If performed in a catheterisation laboratory, the patient needs to be transferred to 
an operating theatre if emergency surgery is required.
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TAVI is a less invasive alternative to SAVR, avoiding the need for cardiopulmonary bypass. Specific 
concerns related to TAVI compared with SAVR have been uncertainties regarding the risk for 
stroke, the need for a permanent pacemaker implant, access-related complications, and concerns 
regarding the positioning and lifetime of the implant. Compared with SAVR, TAVI is associated with 
higher radiation doses for both patient and personnel (see Appendix 4). In addition to being easier 
to handle, the latest TAVI devices aim to reduce the introducer sheath diameter, to minimise or 
avoid paravalvular leakage (PVL), and to offer reposition of the valve prosthesis before final 
deployment [1]. Other improvements aimed at with new designs and techniques are a reduction in 
complications and in the need for permanent pacemaker implantations.
TAVI systems 
There are several TAVI systems commercially available. However, not all have a CE mark and/or 
marketing authorisation for patients at intermediate surgical risk (see A0020). At the time of writing, 
to our knowledge, only two manufacturers (Edwards Lifesciences and Medtronic) were offering 
TAVI systems to be used outside clinical trials for patients at intermediate surgical (operative) risk 
of death or complications from SAVR ([3,16,53]; manufacturers’ websites; submission files from 
manufacturers; Google search for press releases). The TAVI systems assessed in the present 
report are described below and in Table 3.1. 
Edwards SAPIEN 3TM system
Edwards SAPIEN TAVI systems are delivered by Edwards Lifesciences (www.edwards.com) and 
are available in both the USA and Europe for use outside clinical trials. The first-generation Edwards 
TAVI system received a CE mark in 2007 for patients at high surgical risk. Edwards SAPIEN was 
approved by the US Food and Drug Administration (FDA) in 2012 for patients at high surgical risk. 
The first-generation SAPIEN system was replaced by the second-generation Edwards SAPIEN-XT 
(S-XT) and then by the third-generation Edwards SAPIEN 3 (S3). Both S-XT and S3 received FDA 
approval in 2016 for patients at intermediate surgical risk. The Edwards SAPIEN prostheses are 
balloon expandable and comprise a cobalt-chromium frame and bovine (made from cow heart 
tissue) pericardium transcatheter heart valves. The S-XT and S3 systems are improvements to the 
original Cribier and Edwards SAPIEN systems. According to the supplier’s submission file, there 
are differences in the stent-frame design of the two systems. S3 is given a high radial strength, 
based on its stent frame. The S3 also has an additional outer polyethylene terephthalate cuff to 
enhance paravalvular leak sealing. Both S-XT and S3 are available in four diameter sizes: 20 mm, 
23 mm, 26 mm, and 29 mm, although S-XT 20 mm is only available for TF use. The European 
Medical Device Risk Class for Edwards S3 is Risk Class III.
Medtronic Evolut™ R and Evolut™ Pro Systems 
The Evolut systems are delivered by Medtronic (www.medtronic.com) and are available in both the 
USA and Europe for use outside clinical trials. The first-generation CoreValve systems received a 
CE mark in 2007 for patients at high surgical risk and FDA approval for the same patient group in 
2014. The second-generation CoreValve Evolut R System received a CE mark in 2014 and FDA 
approval in 2015 for treating patients at high or extreme risk for surgery. In Europe, this indication 
was extended in 2016 to patients with aortic stenosis at intermediate risk for open-heart surgery as 
determined by a heart team. In the USA in 2017, the FDA approved the use of EvolutTM R to treat 
patients at intermediate surgical risk. Furthermore, in 2017, a new Evolut R 34-mm valve received 
a CE mark for patients with severe aortic stenosis at intermediate, high, or extreme risk for surgery. 
In July 2017, while the assessment was ongoing, Medtronic launched Evolut PRO, a new TAVI 
system with a CE mark and FDA approval for patients at intermediate risk. 
The Medtronic CoreValve Evolut R system is a recapturable transcatheter aortic valve implantation 
system that includes the CoreValve Evolut R transcatheter aortic valve, the EnVeo R delivery 
catheter system, and the EnVeo™ R loading system. The bioprosthesis comprises a self-
expandable, nitinol frame with porcine (made from pig heart tissue) pericardial transcatheter heart 
valves. Both systems can be delivered via the TF or alternative access routes, such as S/T and 
TAo. Evolut R valves are provided with a specific anticalcification treatment; they can be recaptured 
and repositioned if needed and are available in four diameter sizes (23 mm, 26 mm, 29 mm, and 
34 mm). The European Medical Device Risk Class for Evolut R is Risk Class III. 
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The Evolut PRO valve has an outer wrap that adds surface area contact between the valve and the 
native aortic annulus to further improve valve sealing performance. Evolut Pro is available in three 
sizes (23 mm, 26 mm, and 29 mm). The European Medical Device Risk Class for Evolut Pro is Risk 
Class III.
Table 3.1. Features of TAVI systems available for use outside clinical trials in Europe for 
patients with severe symptomatic aortic stenosis at intermediate surgical risk 
Proprietary 
name
Manufacturer Indications Expansion Valve Stent Delivery 
approach
Edwards 
SAPIEN 3 
Valve*
Edwards Life 
Sciences
Inoperable; high 
risk; 
intermediate risk
Balloon 
expanding
Bovine 
pericardium
Cobalt 
chromium
TF, TA, 
TAo
CoreValve 
Evolut R*
Medtronic 
(formerly 
delivered by 
CoreValve)
Inoperable; high 
risk; 
intermediate risk 
Self-
expanding
Porcine 
pericardium
Nitinol TF, SC, 
DA
Medtronic Evolut 
Pro
Medtronic Extreme high 
risk; high risk; 
intermediate risk
Self-
expanding
Porcine 
pericardium
Nitinol (with 
an outer 
wrap)
TF, SC, 
DA
Abbreviations: DA=direct aortic access, SC=subclavian, TA=transapical, TAo=transaortic, TF=transfemoral. 
*Information from 2017.
Comparator: SAVR
The existing standard treatment of patients with symptomatic aortic stenosis at intermediate surgical 
risk is SAVR. The surgery is performed under general anaesthesia and cardiopulmonary bypass. 
Access to the heart is either by full sternotomy or via less invasive approaches. A minimally invasive 
approach can be carried out via mini-thoracotomy and/or port access using direct vision, 
thoracoscopic, or robotic assistance. During SAVR, a cardiac surgeon removes the native aortic 
valve and replaces it with a prosthetic valve. There are many different prostheses and generations 
of prostheses available for SAVR. Although the prosthetic valve can be a mechanical valve, the use 
of bioprosthetic valves is the most common choice. Conventional prostheses for SAVR are 
anchored using surgical sutures (i.e., sutured valves) [5,54]. 
More recent approaches to SAVR include sutureless valves and rapid deployment valves. In the 
same manner as traditional sutured SAVR, these approaches require surgical incisions and can be 
performed with either full sternotomy or minimally invasive approaches under general anaesthesia 
and cardiopulmonary bypass. As in TAVI, there is no need for surgical sutures when fitting valves. 
The potential benefits of sutureless valves compared with conventional SAVR can include a 
reduction in operation time. Unlike TAVI, the diseased valve is excised during the procedure [7,55].
[A0020] For which indications has TAVI received marketing authorisation or CE marking?
Several TAVI systems are holders of a CE mark for use in inoperable patients and patients with 
high surgical risk. To our knowledge, only two manufacturers of TAVI devices hold a CE mark for 
use in patients with intermediate operative risk. These are Edwards Lifesciences (SAPIEN 3) and 
Medtronic (Evolut R and Evolut Pro).
Table 3.2. CE marking of TAVI systems 
Device Manufacturer CE mark for inoperable 
patients and patients 
with high surgical risk 
CE mark for patients 
with intermediate 
surgical risk
SAPIEN 3 Edwards Lifesciences 2014 2016
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SAPIEN XT 2010 No
Evolut R Medtronic (formerly 
CoreValve)
2014 2016
Evolut Pro* Medtronic 2017 2017
CENTERA* Edwards Lifesciences 2018 No
CoreValve Medtronic:
(formerly CoreValve)
2007 No
ACURATE TA
ACURATE TF
Boston Scientific 
(formerly Symetis)
2011
2014
No
No
Engager Medtronic 2013 No
Lotus Edge** Boston Scientific 2013 (Lotus Valve)*
2016 (Edge Valve)*
No 
Direct Flow*** Direct Flow Medical 
(company closed in 
2017)
2013 No
JenaValve*** Jena Technology 2011 (stenosed and 
calcified valves)
2013 
No
Portico St. Jude Medical 2012 
2015 (update)
No
*Launched during assessment.
**Voluntarily recalled from the market in 2017; possible re-introduction after improvements in 2018.
***JenaValve and Direct Flow Medical (DFM) aortic valve are no longer on the market.
[B0002] What is the claimed benefit of TAVI in relation to SAVR?
SAVR is a high-risk procedure and can be contraindicated in some patients for medical and 
anatomical reasons. TAVI provides a less invasive alternative to SAVR and can be undertaken 
without the use of cardiopulmonary bypass and thoracotomy. For patients with intermediate surgical 
risk, the claimed benefits of TAVI compared with SAVR are decreased or similar rates of mortality, 
decreased or similar rates of short-term risks, and improved or similar functional benefits. Other 
claimed benefits are related to the length of hospital stay, recovery time, and post-discharge 
rehabilitation.
[B0003] What is the phase of development and implementation of the technology and the 
comparator(s)? 
TAVI
The first-in-human TAVI implantations were performed in 2002 using the balloon-expandable 
bioprosthetic Cribier–Edwards valve (Edwards Lifesciences), followed by first-in-human studies 
with the self-expandable bioprosthetic CoreValve (Medtronic) in 2004. Both systems were awarded 
CE marks in 2007. The first FDA approvals came in 2012 (Edwards) and 2014 (CoreValve). Since 
these first CE marks and FDA approvals, there have been substantial and incremental 
developments for both systems. Although there are other TAVI systems and manufacturers, 
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currently only Edwards Lifesciences and Medtronic provide systems for patients at intermediate risk 
available for use outside clinical trials. 
Between 2006 and 2016, over 100 000 TAVI procedures were performed worldwide [51]. Until 
recently, TAVI was primarily indicated for patients with symptomatic aortic stenosis considered 
ineligible for SAVR or at high surgical risk [3,20], There is variation in use across Europe. In 2011, 
46% of all TAVI procedures in Europe were performed in Germany, and 40% of all aortic valve 
replacement procedures in Germany were carried out with the use of TAVI [51]. The rate of adoption 
in other countries has been slower. Lack of evidence on improved effectiveness, uncertainty with 
regard to prosthesis lifetime and uncertainty with regard to risks of early complications and long-
term outcomes, as well as higher device costs and need for organisational changes, influence the 
use of TAVI, and have restricted its use in particular for younger patients and those at lower surgical 
risk. However, at least in some countries, there has been a shift towards the use of TAVI for patients 
at intermediate or low surgical risk [12].
Manufacturers have been focussing on improvements related to specific risks associated with the 
implants, such as aortic regurgitation, the need for a permanent pacemaker, risk of stroke, access-
related complications, and the need to reposition the valve prosthesis before final deployment. 
SAVR
The first successful aortic valve replacement was performed in 1960. Since then, SAVR has been 
the established and preferred treatment for patients with severe symptomatic aortic stenosis. The 
benefits, risks, and long-term outcomes of SAVR using conventional sutured valves are considered 
to be well documented. By contrast, SAVR with sutureless valves is less documented and not 
considered an established treatment [5,6].
[A0021] What is the reimbursement status of the technology/comparator?
According to a publication from 2016, TAVI had reimbursement available in 11 European countries 
in 2013 (Table 3.3). Diagnosis-related groups (DRG) for entire hospitalisation, add-on 
reimbursement, and fee-for-services and devices were the main payment models in Europe in 2013 
[51]. 
Table 3.3. Payment models in European Countries in 2013
European country Payment model
Sweden, Norway, Germany, Denmark, Switzerland, 
Austria, the Netherlands
DRG
Belgium Fee for services and device
UK, France DRG + add-on reimbursement
Italy DRG + (regional) add-on reimbursement
In most of these 11 countries, reimbursement was established for the class of device, except in 
Belgium and France, where brand-specific reimbursement was available. In France, Germany, and 
Switzerland, the reimbursement varied according to the type of access for the procedure; for 
example, there was a higher reimbursement for procedures with transapical access in Germany 
and Switzerland. The use of TAVI and reimbursement has steadily increased since 2013 and TAVI 
is now available and reimbursed in several other European countries in addition to those mentioned 
here (for more information, see A0011).
Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk
1/8/2019 EUnetHTA Joint Action 3 WP4 32
4 HEALTH PROBLEM AND CURRENT USE OF THE TECHNOLOGY (CUR)
4.1 Research questions
Element ID Research question
A0002
What is severe symptomatic aortic stenosis with intermediate operative risk 
(intermediate risk for death or complications associated with SAVR)? 
How is the condition defined?
A0003 What are the known risk factors for severe aortic stenosis?
A0004 What is the natural course of severe aortic stenosis?
A0005
What are the symptoms and the burden of severe aortic stenosis for the 
patient?
A0025
Are there European professional society guidelines describing best practice for 
the treatment of patients with severe aortic stenosis at intermediate operative 
risk?
A0023
How many people with both severe aortic stenosis and intermediate operative 
risk are there in Europe?
A0011 How much is TAVI used in Europe?
4.2 Results
Overview of the disease or health condition
[A0002] What is severe symptomatic aortic stenosis with intermediate operative risk? How 
is the condition defined?
The aortic valve is one of four valves in the human heart. It is placed between the left ventricle and 
the main artery (aorta). The aortic valve regulates blood flow from the heart to the aorta. The valve 
normally has three cusps or leaflets, although ~1.4% of the population congenitally have two 
(bicuspid aortic valve) leaflets [8].
Aortic stenosis is the thickening, fibrosis, and calcification of aortic leaflets that impair outflow of 
blood to the rest of the circulation. The narrowing of the aortic valve increases workload to the heart 
as it attempts to maintain normal circulation. The impaired heart function is usually progressive and 
eventually leads to left ventricular hypertrophy and heart failure [8,56]. 
The NYHA Functional Classification provides a simple way of classifying the extent of heart failure 
[57]. It places patients into one of four categories based on how much they are limited during 
physical activity. NYHA classification is widely used as a measure of patient functionality in study 
eligibility criteria and study outcomes. The following classes are recognised: 
NYHA class I: no symptoms and no limitation in ordinary physical activity (e.g., no shortness of 
breath when walking or climbing stairs).
NYHA class II: mild symptoms (mild shortness of breath and/or angina) and slight limitation during 
ordinary activity.
NYHA class III: marked limitation in activity because of symptoms, even during less-than-ordinary 
activity [e.g., walking short distances (20–100 m)]. Comfortable only at rest.
NYHA class IV: severe limitations; experience symptoms even when at rest; mostly bedbound 
patients.
Assessment of the severity of aortic stenosis utilises echocardiographic examinations and function 
tests together with age, symptoms, and comorbidities. Doppler, 2D, and M-mode echocardiography 
are the preferred tools for assessing major indicators of severity, such as valve area, transvalvular 
pressure gradients, flow rate, ventricular function, size and wall thickness, degree of valve 
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calcification, and blood pressure [20]. Severe aortic stenosis is typically described as the presence 
of severe leaflet calcification, severely reduced leaflet opening (≤1.0 cm2), significantly increased 
mean pressure gradient (≥40 mmHg), and a peak transvalvular velocity ≥4 m/s. Exercise testing is 
recommended in physically active patients for unmasking symptoms [5,58,59]. 
Risk stratification is required for weighing the risk of intervention against the expected natural history 
of valvular heart disease. Aortic valve replacement by open-heart surgery (SAVR) is an established 
and effective treatment for severe symptomatic aortic stenosis. The procedure requires 
thoracotomy and takes place under general anaesthesia and cardiopulmonary bypass. Therefore, 
SAVR might not be suitable for some patients and, for others, the risks might outweigh the benefits 
[5,58,59]. 
A contraindication for SAVR is a high surgical risk of 30-day mortality because of medical and 
anatomical causes as well as frailty and comorbidity. Surgical risk rises with increased age and the 
presence of comorbidities. 
Most commonly used risk algorithms include STS Predicted Risk of Mortality (STS-PROM), logistic 
EuroSCORE and EuroSCORE II (http://euroscore.org/calc.html). These systems aim to identify and 
quantify several risk factors that help to predict mortality from cardiac surgery. STS-PROM 
calculates the risk on the basis of the demographic and clinical characteristics of each patient. It is 
available as an online statistical tool. EuroSCORE assigns scores to patient-related, cardiac-
related, and surgery-related risk factors. In its first version, published in 1999, the predicted mortality 
(in percent) was simply a sum of weights assigned to the risk factors. The tool was later refined into 
a logistic regression equation (logistic EuroSCORE). The latest version of the model (EuroSCORE 
II) was launched in 2011 as an online tool and is constantly updated and enhanced. The exact cut-
off values for risk scores vary across the literature and can be arbitrary. However, for STS-Prom 
and EuroSCORE II, intermediate and low risk are defined by the ESC/EACTS guidelines as shown 
in Table 4.1.
Table 4.1. Surgical risk for 30-day mortality in patient stratification for SAVR and TAVI
Surgical risk for 30-day mortality based on STS-PROM 
or EuroSCORE II
Classification of risk
4–8% Intermediate
<4% Low 
To estimate overall risks in individual patients and to stratify them to receive either palliative medical 
treatment (no valve replacement), medical treatment with reassessment on follow-up, SAVR, or 
TAVI, the surgical risk scores are used along with assessment of frailty as well as major organ 
complications not covered by the scores. This assessment is normally conducted by a specialised 
team [5,59]. 
A clear definition of what is understood by severe symptomatic aortic stenosis with intermediate 
surgical risk might not be possible because the criteria vary across different classification systems. 
Stratification will always depend on the classification system used as well as on subjective input 
from the specialised team, and can vary across different studies and contexts.
[A0003] What are the known risk factors for severe aortic stenosis?
The most common cause of aortic stenosis in patients older than 70 is the calcific degeneration of 
aortic leaflets, leading to narrowing and/or leaking of the valve. The leading causes in younger 
patients are congenital heart defects, particularly a bicuspid aortic valve. Other causes include 
previous rheumatic fever and infections, such as infective endocarditis [60,61].
Increased age, male gender, chronic renal insufficiency, and cardiovascular risk factors can also 
be associated with the progression of aortic stenosis [3].
[A0004] What is the natural course of severe aortic stenosis?
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Aortic stenosis is a chronic, slowly progressive disease. Patients can remain asymptomatic for a 
long period until the disease is fairly advanced. Duration of the latent period varies widely among 
patients. However, once symptoms develop, there is a rapid increase in mortality rate for untreated 
patients [20]. Progressing stenosis causes an increase in pressure in the left ventricle, leading to 
compensatory left ventricular hypertrophy, impaired heart function, and eventually heart failure [60]. 
The only curative treatment is timely valve replacement therapy [62]. Treatment with medication 
alone for symptomatic aortic stenosis has limited clinical effect and can only be palliative (easing 
some symptoms). Patients with severe, symptomatic, untreated aortic stenosis have a mean life 
expectancy of <5 years from the onset of symptoms [3,60].
Effects of the disease or health condition
[A0005] What are the symptoms and burden of severe aortic stenosis for the patient?
Patients with aortic stenosis are initially asymptomatic with an incidental finding of crescendo-
decrescendo heart murmur. Symptoms usually appear late during the course of the illness. Aortic 
stenosis resulting from age-related calcification typically occurs in normal tricuspid valves in patients 
aged 70 or over. In patients with bicuspid valve, age-related calcification typically appears earlier, 
during their fourth or fifth decade [61]. Fatigue and intolerance of exercise are some of the early 
symptoms. Depending on the degree of left ventricular hypertrophy and heart function insufficiency, 
patients can develop dyspnoea (shortness of breath) and angina pectoris (chest pain) if the heart 
becomes ischaemic. Some patients can experience syncope (episodes of fainting), or presyncope 
(dizziness) on exertion. Without treatment, pressure overload on the left ventricle leads to systolic 
dysfunction and left ventricular failure, and patients can report symptoms of pulmonary oedema, 
including shortness of breath, fatigue, and palpitations [60].
Current clinical management of the disease or health condition
[A0025] Are there European professional society guidelines describing best practice for the 
treatment of patients with severe aortic stenosis at intermediate operative risk?
According to the latest guidelines from ESC/EACTS [5], either TAVI or SAVR can be considered 
for patients at increased surgical risk, defined as STS or EuroSCORE II ≥4% or logistic EuroSCORE 
I ≥10% (class of recommendation: I). SAVR is recommended for lower risk patients with absence 
of other risks not included in these scores, such as frailty, porcelain aorta (extensive calcification of 
the aorta),or sequelae of chest radiation (class of recommendation: I). 
The guidelines also recommend that a heart team should make the decision between SAVR and 
TAVI according to assessment of the individual risk and characteristics of the patient. The 
guidelines list aspects for consideration for the individual decision, and make recommendations in 
favour of either TAVI or SAVR [5].
Selection of aspects in favour of TAVI: 
 STS or EuroSCORE II ≥4% or logistic EuroSCORE I ≥10%
 Presence of severe comorbidity 
 Age ≥75
 Previous cardiac surgery 
 Frailty
 Favourable access for transfemoral TAVI 
 Porcelain aorta
Selection of aspects in favour of SAVR:
 STS or EuroSCORE II <4% or logistic EuroSCORE I <10%
 Age <75
 Suspicion of endocarditis
 Unfavourable access (any) for TAVI
 Size of aortic valve annulus out of range for TAVI
 Presence of thrombi in aorta or left ventricle
 Presence of cardiac conditions in addition to aortic stenosis that require consideration for 
concomitant intervention 
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Based on the above, we conclude that the 2017 ESC/EATC guidelines recommend that TAVI can 
be considered a treatment alternative for patients with severe symptomatic aortic stenosis at 
intermediate risk in conjunction with other aspects.
Target population
[A0023] How many people with severe aortic stenosis and intermediate risk are there in 
Europe?
Aortic stenosis is the most common valvular heart disease, accounting for nearly half of cases in 
developed countries. It is a slowly progressive disease and most new diagnoses of clinically 
significant aortic stenosis occur among older people [63]. Prevalence increases with age, reflecting 
an accelerated progression of the aortic mean gradient as the disease advances [10]. Various 
prevalence estimates have been reported in literature, with approximate average values being: 
0.02% in people aged 18–44 years, 0.2% in the 50–59-year-old cohort, 1.3% in the 60–69-year-old 
cohort [3], 3.9% in the 70–79-year-old cohort, and 9.8% in the 80–89-year-old cohort [10]. Among 
older patients (>70), the prevalence of severe aortic stenosis in Europe is ~3.4%. It is reported that 
75.6% of people with severe aortic stenosis are symptomatic [9]. Overall incidence rate is reported 
to be ~0.49% per year [10]. The annual incidence in the population over the age 65 is 2–7% [11].
A model calculation assuming the overall prevalence of aortic stenosis among people aged >60 to 
be 4.5%, suggested that 7.5 million people in Europe are likely to have aortic stenosis. 
Approximately 20% of these have severe aortic stenosis and ~71% of those with severe aortic 
stenosis are symptomatic. Based on this model, it is estimated that 873 700 patients in Europe are 
eligible for open-heart surgery. The calculated proportion of these patients with intermediate 
surgical risk is ~28.9% [12], resulting in an estimate of 252 500 patients. 
The prevalence of aortic stenosis is likely to increase with progressive ageing of the population in 
Europe. Currently, 20% of this population is ≥65, with predictions that this proportion will rise to 24% 
by 2030 [64].
[A0011] How much is TAVI used in Europe?
Since the introduction of CE marked systems in 2007, there has been a rapid increase in the 
adoption of TAVI. In 2012 expert guidelines, the technology was recommended only for selected 
inoperable patients and patients with high surgical risk. However, in many countries, the use has 
extended to patients at intermediate and low risk, that is, not included by 2012 guideline 
recommendations [12,65].
Despite the rapid adoption of TAVI in most parts of Europe, there are important discrepancies in 
practice, particularly when it comes to patient selection. According to a survey performed in 2016 
by the European Association of Percutaneous Coronary Interventions (EAPCI), 89% of European 
centres performed TAVI in inoperable patients; 95% in patients at high surgical risk, 45% in 
intermediate-risk patients, and 10% in low-risk patients. TAVI was restricted only to inoperable 
patients in 5% of centres [65].
An analysis of registry data revealed an overall increase in the number of aortic valve replacement 
procedures in recent years, whereas numbers of SAVR procedures are moderately but steadily 
declining [46,51]. This decline is most prominent in younger groups of patients with lower risk 
profiles. There is a suggestion that, in older patient groups (≥80 years), TAVI and SAVR are 
complementary procedures, with older patients treated with TAVI who otherwise would not have 
been able to have a heart valve replacement. However, in younger cohorts, the increase in TAVI 
offsets the reduction in the number of SAVR procedures, suggesting that TAVI competes with open-
heart surgery in younger patients at lower risk [12,66]. 
In several European countries, most patients who undergo TAVI are included in national databases 
on cardiac surgery and Germany, UK, France, Italy, Spain, Switzerland, and Belgium have set up 
national TAVI registries to follow up patients who undergo the procedure.
For the purpose of this assessment, the authors performed a survey among the EUnetHTA partners 
taking part in WP4. The survey included questions about the reimbursement status of TAVI in the 
respondents’ country or region as well as the number of TAVI procedures performed in 2015 and/or 
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2016. EUnetHTA partners from 19 countries and one region (Scotland) responded to the survey. 
The results show that the use of TAVI varied across these 20 European countries or regions (Table 
4.2). Germany had the highest annual rate per million inhabitants, followed closely by Switzerland 
and France. These three countries accounted for >60% of all TAVI procedures performed in Europe.
Table 4.2. Reimbursement status of TAVI among EUnetHTA partners
Country/Region 
(million 
inhabitants, 
2015*)
Reimbursement status Number of procedures 
2015/2016
Number of 
procedures per 
million 
inhabitants*
Austria (8.7) Reimbursed 807 (2015) 93
Belgium (11.3) Reimbursed for patients with severe 
symptomatic AS with high risk or 
inoperable
500 44
Czech Republic 
(10.6)
Reimbursed for patients with severe 
symptomatic AS with high risk or 
inoperable
382 (2015); 528 (2016) 50
Finland (5.5) Reimbursed 419 (2015) 76
France (64.5) Reimbursed for patients with severe, 
symptomatic AS contraindicated for 
surgery or at high surgical risk. For 
patients with intermediate risk, HAS 
also recommended reimbursement 
(September 2017) but decision 
remains to be taken 
10 000 (2016) 155
Germany (81.7) Reimbursed 15 277 (2015) 187
Greece (11.2) Reimbursed only for inoperable and 
high-risk patients
295 (2016) 26
Ireland (4.7) Reimbursed for inoperable and high-
risk patients
192 (2015) 41
Malta (0.43) Reimbursed for patients with severe 
symptomatic AS turned down for SAVR
21 (2015); 26 (2016) 60
Netherlands (16.9) Reimbursed for patients for whom 
SAVR is unsuitable
995 (2012) 59
Norway (5.2) Reimbursed for patients with severe 
symptomatic aortic stenosis, mainly 
used for high risk and patients >80 
years
356 (2015); 524 (2016) 100
Poland (38.3) Reimbursed 625 (2015); 867 (2016) 22
Portugal (10.4) Reimbursed 313 (2015) 30
Scotland, UK 
(5.3**)
Reimbursed for inoperable and high-
risk patients
180/year 34
Slovenia (20.1) Partly reimbursed 120 (2016) 6
Spain (46.4) Reimbursed for patients with severe AS 
evaluated by a multidisciplinary clinical 
committee from a clinical centre with a 
cardiovascular surgery unit and a 
written protocol for selection of TAVI 
candidate available
1586 (2015);
2026 (2016)
43
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Sweden (9.8) Reimbursed 577 (2015); 
661 (2016)
67
Switzerland (8.3) Reimbursed for inoperable and high-
risk patients, re-evaluation ongoing
1300 156
UK (65.4) Reimbursed based on NICE guidance 
IPG 506
3250 (2016) 50
Italy (60.7**) Some regions introduced 
supplementary payment in addition to 
standard DRG; some others used 
procedure-specific payments
3466 (2015)
4592 (2016)
76
* Inhabitants of countries based on: World Population Prospects, the 2017 Revision, United Nations Department of Economic 
and Social Affairs, Population Division.
** Inhabitants of country/region based on Google search. 
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5 CLINICAL EFFECTIVENESS (EFF)
5.1 Research questions
Element ID Research question
D0001 What is the expected beneficial effect of TAVI on mortality (disease specific and 
all cause) in patients with severe aortic stenosis at intermediate surgical risk?
D0005 How does TAVI affect the symptoms and findings (severity and frequency) of 
aortic stenosis?
D0006 How does TAVI affect the progression of aortic stenosis?
D0011 What is the effect of TAVI on the physiological functions of patients?
D0016 How does TAVI affect activities of daily living?
D0012 What is the effect of TAVI on generic health-related quality of life?
D0013 What is the effect of TAVI on disease-specific quality of life?
5.2 Results
Included studies
The two included trials (PARTNER 2a) [15, 16]a and SURTAVI [2] were multicentre trials conducted 
in several countries (USA, Europe, and Canada) and included 3778 patients with 2 years of follow-
up. The mean age of patients (mean 80 and 82, respectively) and female percentage (43% and 
45%, respectively) were similar between the two trials. 
The patient eligibility criteria of the PARTNER 2 trial were: symptomatic severe aortic valve stenosis 
and intermediate surgical risk according to the Society of Thoracic Surgeons (STS) score of at least 
4% with an (not prespecified) upper limit of 8%. Patients with an STS score <4% could also be 
included if there were coexisting conditions not represented in the STS risk score algorithm. 
Patients included in the trial had a mean STS score of 5.8±2.1 for the TAVI group and 5.8±1.8 for 
the SAVR group [15]. 
Patient eligibility criteria of the SURTAVI were: symptomatic severe aortic stenosis and intermediate 
surgical risk according to an STS score of 3–15% [2]. Patients included in the trial had a mean STS 
score of 4.5±1.6 [2].
In the PARTNER 2 trial, 2032 patients were stratified into cohorts according to access route (TF or 
transthoracic) and then randomised in a 1:1 ratio to either TAVI or SAVR. Of these, 1550 patients 
were deemed suitable for TF access and 775 were then allocated to TAVI; 482 patients (23.7%) 
were deemed suitable for transthoracic access and 236 were then allocated to TAVI. Patients 
assigned to TAVI cohorts received an Edwards balloon-expandable SAPIEN XT heart valve (26 
mm). Details for the SAVR procedures were not provided in the publications.
In the SURTAVI trial, 84% of the patients in the TAVI group received CoreValve self-expanding 
valves, whereas the remaining 16% received the Evolut R self-expanding valves. Most patients in 
aThe main author and co-author disagreed as to whether Aurora 2016 [16] should be included as a study presenting data 
from the PARTNER2 trial. Given that no information presented in Leon 2016 [15] can be found in Aurora 2016 [16], the 
decision by the main author to include this publication does not change any results or conclusions.
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the TAVI group were treated iliofemorally (93.6%). The choice of implant and access route was 
decided after randomisation.
Primary outcomes in both trials were composite of death from any cause and disabling stroke at 2-
year follow-up; however, both studies reported most outcomes at follow-ups after 30 days, 1 year, 
and 2 years. Secondary outcomes and basic characteristics of the included studies are provided in 
Table A1 in Appendix 1. The follow-up time was 2 years for both studies. Both studies were funded 
by the manufacturers. 
Both studies reported a secured central randomisation method and were considered to be at low 
risk of selection bias. Given the nature of the interventions, patients and investigators could not be 
blinded, but performance bias was not taken into account when the outcome of interest (e.g., 
mortality) was objective. The PARTNER 2 trial was considered at low risk of detection bias because 
all patients were visited by trained neurologists who were unaware of treatment allocation. In the 
SURTAVI trial, it was unclear whether the outcome assessor was blinded to the treatment 
assignment.
In the PARTNER 2 trial, 1011 patients were enrolled in the TAVI cohort and 1021 in the SAVR 
cohort (intention-to-treat population). Ninety-four patients [17 (1.7%) in the TAVI group and 77 
(7.6%) in the SAVR group] were withdrawn from the study mainly owing to a decision after 
randomisation not to undergo surgery. It is unclear whether differences in withdrawal between the 
two groups might have created an imbalance in the prognostic characteristics of the two groups. In 
the PARTNER 2 trial, outcomes were reported using Kaplan Meier time-to-event analyses on 
available evidence at each time point. For various outcomes, the population at risk varied at each 
time point. As an example, at 2-year follow-up, 774 patients in the TAVI group and 695 patients in 
the SAVR group were available for the overall mortality outcome. This important attrition generated 
serious concerns regarding the available evidence at the 2-year follow-up.
In the SURTAVI trial, 1746 patients were randomised (879 in the TAVI group and 867 in the SAVR 
group); of these 1660 (864 in the TAVI group and 796 in the SAVR group) received the intervention. 
For the SURTAVI trial, the reported data represented the results of a Bayesian statistical method 
interim analysis after 1 year. Most patients reached this follow-up point; however, at the 2-year 
follow-up, there were considerably fewer patients. Thus, data for patients without a known outcome 
were used at the 2-year follow-up. As an example, for the mortality outcome at the 2-year follow-
up, 280 patients were available for outcome measures in the TAVI group and 249 in the SAVR 
group. The SURTAVI trial reported both standard and modified intention-to-treat analysis with 
outcome imputation and sensitivity analysis. Hence, the study was considered at low risk of attrition 
bias at 30-day and 1-year follow-up but not at the 2-year follow-up.
No concerns were identified in terms of selective reporting. Risk of bias for the two included trials 
is reported in Appendix 1.
Mortality
[D0001] What is the expected beneficial effect of TAVI on mortality (disease specific and all 
cause) in patients with severe aortic stenosis at intermediate surgical risk?
All-cause mortality 
All-cause mortality was reported by both trials. At 30-day follow-up, 3.1% of patients in the TAVI 
group had died, whereas 2.9% of patients had died in the control group: TAVI was probably non-
inferior to SAVR in terms of mortality [RR 1.07, 95% CI 0.74–1.55; GRADE evidence: moderate). 
We downgraded the quality for this outcome at 30-day follow-up because of risk of bias (i.e., 
imbalance in withdrawals between the groups). See Table 5.1 for the efficacy comparison.
At 2-year follow-up, 12.9% of patients had died in the TAVI group, whereas 12.7% had died in the 
control group: it is uncertain whether TAVI is non-inferior to SAVR [RR 1.01, 95% CI 0.86–1.20; 
GRADE evidence: very low) (Figure 5.1). We downgraded the quality for this outcome at 2-year 
follow-up because of a serious concern of risk of bias (i.e., important attrition). See Table 5.1 for 
the efficacy comparison.
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Figure 5.1. All-cause mortality at 30-day, 1-year, and 2-year follow-up
Cardiac mortality 
Cardiac mortality was reported by both trials at 30-day, 1-year, and 2-year follow-up. At 30-day 
follow-up, cardiac mortality was reported for 2.6% of patients in the TAVI group compared with 2.4% 
of patients in the control group: TAVI is probably non-inferior to SAVR in terms of cardiac mortality 
(RR 1.11, 95% CI 0.75–1.66; GRADE evidence: moderate) (Figure 5.2). We downgraded the quality 
for this outcome at 30-day follow-up because of a risk of bias (i.e., imbalance in withdrawals 
between the groups). See Table 5.1 for the efficacy comparison.
At 2-year follow-up, cardiac mortality was reported for 7.9% of patients in the TAVI group, compared 
with 8.2% in the control group. In terms of cardiac mortality at patients -year follow-up, it is uncertain 
whether TAVI is non-inferior to SAVR [RR 0.96, 95% CI 0.78–1.19; GRADE evidence: very low) 
(Figure 5.2). We downgraded the quality for this outcome at 2-year follow-up because of serious 
concerns of a risk of bias (i.e., important attrition). See Table 5.1 for the efficacy comparison.
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Figure 4.2. Cardiac mortality at 30-day, 1-year, and 2-year follow-up
Morbidity
[D0005] How does TAVI affect the symptoms and findings (severity and frequency) of aortic 
stenosis?
Improvement of symptoms (reduction in NYHA class)
In the PARTNER 2 trial, 80% of patients were NYHA class III or higher at baseline. The investigators 
reported a significant reduction in symptoms to NYHA class II or I at 30-day follow-up in both the 
TAVI and control groups, and the NYHA class was maintained for 2 years (p <0.001). At 2-year 
follow-up, ~48% of patients in the TAVI group and ~52% in the surgery group remained in NYHA 
class I. No differences in effect was observed between the two groups at 1- or 2-year follow-up.
In the SURTAVI trial, 60% of the TAVI group and 58% of the SAVR group were NYHA class III or 
higher at baseline. After 2-year follow-up, there was a significant reduction to NYHA class II or I, 
with 62% NYHA class I in the TAVI and 58% in the SAVR group. No differences in effect were 
observed between the two groups at 1- or 2-year follow-up. 
Thus, we conclude that it is uncertain whether TAVI has any effect on improving symptoms 
compared with SAVR at 1- or 2-year follow-up (GRADE evidence: very low). We downgraded the 
quality for this outcome because of serious concerns of risk of bias (i.e., imbalance in withdrawals 
between the groups, important attrition, and performance bias) and imprecision (i.e., no evidence 
of effect).
[D0006] How does TAVI affect the progression of aortic stenosis?
The outcome ‘Rehospitalisation for myocardial infarction (>72 h following TAVI)’ reported in our 
protocol was not evaluated by either study. However, the PARTNER 2 trial assessed any 
rehospitalisation at 30-day, 1-year, and 2-year follow-up, with no reported differences between the 
TAVI and SAVR groups.
Aortic valve reintervention 
At 30-day follow-up, aortic valve reintervention was performed in 0.6% of patients in the TAVI group 
and 0.1% in the SAVR group: thus, TAVI might increase the risk of aortic valve reintervention 
compared with SAVR (RR 7.58, 95% CI 1.38–41.55; GRADE evidence: low) (Figure 5.3). We 
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downgraded the quality for this outcome at 30-day follow-up because of a risk of bias (i.e., 
imbalance in withdrawals between the groups) and serious concerns regarding imprecision (i.e., 
few events and wide CIs). See Table 5.1 for the efficacy comparison.
At 2-year follow-up, aortic valve reintervention was performed in 1.7% of the TAVI group and 0.4% 
of the SAVR group: thus, compared with SAVR, it is uncertain whether TAVI increases the risk of 
aortic valve reintervention (RR 3.86, 95% CI 1.76–8.44; GRADE evidence: very low) (Figure 5.3). 
We downgraded the quality for this outcome at 2-year follow-up because of serious concerns 
regarding a risk of bias (i.e., owing to important attrition) and imprecision (i.e., very few events with 
wide CIs). See Table 5.1 for the efficacy comparison.
Figure 5.3. Aortic reintervention at 30-day, 1-year, and 2-year follow-up
In addition, the SURTAVI trial assessed rehospitalisations because of aortic valve dysfunction at 
30-day, 1-year, and 2-year follow-up with no reported difference between the TAVI and SAVR 
groups.
[D0011] What is the effect of TAVI on the physiological functions of patients?
Evidence for the following outcomes was identified: haemodynamic function of the valve, and 
hospital and intensive care unit length of stay. For procedural success and rehospitalisation for 
myocardial infarction (>72 h following TAVI), no evidence was found from either of the included 
studies.
Haemodynamic function of the valve
In the SURTAVI trial, from baseline to discharge, the mean aortic gradient improved in both the 
TAVI group (8.9±4.1 mmHg) and the SAVR group (12.4±5.7 mmHg); the difference between the 
two groups was statistically significant (p <0.001). This difference persisted throughout the 2-year 
follow-up. In addition, from baseline to discharge, the TAVI group had larger aortic valve areas than 
the SAVR group (2.1±0.6 cm2 versus 1.8±0.6 cm2, respectively) with a statistically significant 
difference. These improvements persisted throughout the 2-year follow-up.
In the PARTNER 2 trial, in both the TAVI and SAVR groups, there was an improvement in the aortic 
valve area (1.7±0.5 cm2 versus 1.5 cm2 ± 0.4, respectively; p <0.001) and LVEF (56.9±10.2% versus 
55.0±11.0%, respectively; p <0.004) as well as a decrease in the mean aortic valve gradients 
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(9.7±3.5 mmHg versus 10.9±4.3 mmHg, respectively; p <0.001). These improvements persisted 
throughout the 2-year follow-up.
Hospital and intensive care unit length of stay
In the PARTNER 2 trial, patients in the TAVI group had a significantly shorter duration of the index 
of hospitalisation (median, 6 versus 9 days; p <0.001) as well as a shorter duration of stay in the 
intensive care unit than those in the surgery group (median, 2 versus 4 days; p <0.001).
In the SURTAVI trial, the duration of the index of hospitalisation was shorter in the TAVI than in the 
SAVR group (5.75±4.85 days versus 9.75±8.03 days, respectively). No data regarding intensive 
care unit stays were provided. 
The overall GRADE level of evidence for hospital stay was considered moderate. We downgraded 
the quality for this outcome because of risk of bias (i.e., imbalance in withdrawals between the 
groups).
Health-related quality of life
[D0016] How does TAVI affect activities of daily living?
[D0012] What is the effect of TAVI on generic health-related quality of life?
[D0013] What is the effect of TAVI on disease-specific quality of life?
Improvement in health-related quality of life indicators
In the PARTNER 2 trial, 80% of patients were NYHA class III or higher at baseline. Investigators 
reported a significant reduction in symptoms to NYHA class II or I at 30-day follow-up in both the 
TAVI group and the SAVR group, and the NYHA class was maintained for 2 years (p <0.001). At 2-
year follow-up, ~48% of patients in the TAVI group and ~52% in the SAVR group maintained NYHA 
class I. No difference of effect was observed between the two groups at 1- or 2-year follow-up.
In the SURTAVI trial, 60% in the TAVI group and 58% in the SAVR group were NYHA class III or 
higher at baseline (KCCQ). After 2-year follow-up, there was a significant reduction to NYHA class 
II or I, with 62% in the TAVI and 58% in the SAVR group in NYHA class I. No difference of effect 
was observed between the two groups at 1- or 2-year follow-up. The overall GRADE level of 
certainty was considered to be low.
Hence, we conclude that it is uncertain whether TAVI has any effect on improving symptoms 
compared with SAVR at 1- or 2-year follow-up (GRADE evidence: low).
No other generic or disease-specific quality-of-life instrument data were reported in either of the two 
trials.
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Table 5.1. Summary of findings for the efficacy comparison of TAVI versus SAVR for patients with aortic stenosis at intermediate surgical risk
Certainty assessment № of patients (%) Effect
№ of 
studie
s
Study 
design
Risk 
of 
bias
Inconsist
ency
Indire
ctnes
s
Impr
ecisi
on
Other 
conside
rations
TAVI SAVR Relative
(95% CI)
Absolute
(95% CI)
Certaint
y
Mortality from any cause: 30-day follow-up
2 Rando
mised 
trials 
Serio
us a
Not 
serious 
Not 
seriou
s 
Not 
serio
us b
None 58/1890 (3.1%) 54/1888 (2.9%) RR 1.07
(0.74–1.55) 
2 more per 1000
(from 6 fewer to 16 more) 
⨁⨁⨁◯
moderat
e 
Mortality from any cause: 2-year follow-up
2 Rando
mised 
trials 
Very 
seriou
s c
Not 
serious 
Not 
seriou
s 
Not 
serio
us b
None 243/1890 (12.9%) 240/1888 (12.7%) RR 1.01
(0.86–1.20) 
0 fewer per 1000
(from 21 fewer to 24 more) 
⨁⨁◯◯
low 
Cardiac mortality: 30-day follow-up
2 Rando
mised 
trials 
Serio
us a
Not 
serious 
Not 
seriou
s 
Not 
serio
us b
None 50/1890 (2.6%) 45/1888 (2.4%) RR 1.11
(0.75–1.66) 
3 more per 1000
(from 6 fewer to 16 more) 
⨁⨁⨁◯
moderat
e 
Cardiac mortality: 2-year follow-up
2 Rando
mised 
trials 
Very 
seriou
s c
Not 
serious 
Not 
seriou
s 
Not 
serio
us b
None 149/1890 (7.9%) 155/1888 (8.2%) RR 0.96
(0.78–1.19) 
3 fewer per 1000
(from 16 fewer to 18 more) 
⨁⨁◯◯
low
Improvement of symptoms (reduction in NYHA class)
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Certainty assessment № of patients (%) Effect
№ of 
studie
s
Study 
design
Risk 
of 
bias
Inconsist
ency
Indire
ctnes
s
Impr
ecisi
on
Other 
conside
rations
TAVI SAVR Relative
(95% CI)
Absolute
(95% CI)
Certaint
y
2 Rando
mised 
trials 
Very 
seriou
s d
Not 
serious 
Not 
seriou
s 
Serio
use
Not 
serious
PARTNER 2 trial: at baseline, 80% of patients were NYHA class III or higher; at 30-day follow-up, 
both groups had significant reduction of symptoms; at 2-year follow-up, ~48% of patients in the TAVI 
group and 52% in the SAVR group maintained NYHA class I. There was no significant difference 
between the two groups.
SURTAVI trial: at baseline, 60% in the TAVI group and 58% in the SAVR group were NYHA class 
III or higher. After 2-year follow-up, there was a significant reduction to NYHA class II or I in the TAVI 
(63%) and SAVR (58%) groups. There was no significant difference between the two groups
⨁◯◯◯
very low 
Aortic valve reintervention: 30-day follow-up
2 Rando
mised 
trials 
Serio
us f
Not 
serious 
Not 
seriou
s 
Serio
usg
None 11/1890 (0.6%) 1/1888 (0.1%) RR 7.58
(1.38 to 41.55) 
3 more per 1000
(from 0 fewer to 21 more) 
⨁⨁◯◯
low 
Aortic valve reintervention: 2-year follow-up
2 Rando
mised 
trials 
Very 
seriou
s h
Not 
serious 
Not 
seriou
s 
Very 
serio
usg 
None 33/1890 (1.7%) 8/1888 (0.4%) RR 3.86
(1.76 to 8.44) 
12 more per 1000
(from 3 more to 32 more) 
⨁◯◯◯
very low 
Length of hospital stay
2 Rando
mised 
trials 
Serio
us i
Not 
serious 
Not 
seriou
s 
Not 
serio
us 
None Both trials reported significantly shorter durations of hospital stay in the TAVI group, but data could 
not be pooled. PARTNER 2 reported a median of 6 days for TAVI and 9 days for SAVR (p <0.001).
In the SURTAVI trial, length of hospital stay was shorter by 4 days in the TAVI group than in the 
SAVR group (media: –4.00 days, 95% CI –4.58 to –3.42)
⨁⨁⨁◯
moderat
e
Quality of life (improvement of symptoms only)
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Certainty assessment № of patients (%) Effect
№ of 
studie
s
Study 
design
Risk 
of 
bias
Inconsist
ency
Indire
ctnes
s
Impr
ecisi
on
Other 
conside
rations
TAVI SAVR Relative
(95% CI)
Absolute
(95% CI)
Certaint
y
2 Rando
mised 
trials 
Very 
seriou
s d
Not 
serious 
Not 
seriou
s 
Serio
use
Not 
serious
PARTNER 2 trial: at baseline, 80% of patients were NYHA class III or higher; at 30-day follow-up, 
both groups had significant reduction of symptoms; at 2-year follow-up, ~48% of patients in the TAVI 
group and 52% in the SAVR group maintained NYHA class I. There was no significant difference 
between the two groups.
SURTAVI trial: at baseline, 60% of the TAVI group and 58% of the SAVR group were NYHA class 
III or higher. After 2-year follow-up, there was a significant reduction to NYHA class II or I for the 
TAVI (63%) and SAVR (58%) groups. There was no significant difference between the two groups.
⨁◯◯◯
very low 
GRADE Working Group grades of evidence:
High evidence: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate evidence: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low evidence: our confidence in the effect estimate is limited: the true effect might be substantially different from the estimate of the effect.
Very low evidence: we have little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
Explanations:
a. Serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. Given that mortality was considered an objective outcome, we considered 
that absence of blinding could not introduce any performance bias and, therefore, there was no downgrading. However, the quality of evidence was downgraded by one level because, in one of the two trials, 
94 enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; we are uncertain 
whether this imbalance in withdrawals between the two groups might have introduced bias. 
b. We did not downgrade for imprecision: the sample size was sufficiently large (N=3778) and rates of events were low; the absolute difference in mortality rates between the two procedures was very small 
(absolute difference of +0.2% with a 95% CI of –0.7% to 1.6%).
c. Very serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. Given that mortality was considered an objective outcome, we considered 
that absence of blinding could not introduce the performance bias and, therefore, no downgrading was done. However, the quality of evidence was downgraded by two levels given that: (i) in one of the two 
trials, 94 enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; we are 
uncertain whether this imbalance in withdrawals between the two groups might have introduced bias; and (ii) at 2-year follow-up, >30% and >50% of patients were lost to follow-up in each trial, respectively.
d. Very serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. The quality of evidence was downgraded by two levels given that: (i) in 
one of the two trials, 94 enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo 
surgery; we are uncertain whether this imbalance in withdrawals between the two groups might have introduced bias; (b) at 2-year follow-up, >30% and >50% of patients were lost to follow-up in each trial, 
respectively; and (c) performance bias or detection bias might affect the results because the outcome was considered subjective.
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e. No effect of treatment.
f. Serious concern regarding risk of bias: blinding patients and personnel was not because of the type of intervention. Given that aortic valve intervention was an objective outcome, we considered that 
absence of blinding could not introduce the performance bias and, therefore, no downgrading was done. However, the quality of evidence was downgraded by one level because, in one of the two trials, 94 
enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; we are uncertain 
whether this imbalance in withdrawals between the two groups might have introduced bias.
g. Large CI.
h. Very serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. Given that aortic valve reintervention was an objective outcome, we 
considered that absence of blinding could not introduce the performance bias and, therefore, no downgrading was done. However, the quality of evidence was downgraded by two levels given that: (i) in one 
of the two trials, 94 enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; 
we are uncertain whether this imbalance in withdrawals between the two groups might have introduced bias; and (ii) at 2-year follow-up, >30% and >50% of patients were lost to follow-up in each trial, 
respectively.
i. Serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. Given that length of hospital stay was an objective outcome, we considered 
that absence of blinding could not introduce the performance bias and, therefore, no downgrading was done. However, the quality of evidence was downgraded by one level because, in one of the two trials, 
94 enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; we are uncertain 
whether this imbalance in withdrawals between the two groups might have introduced bias.
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6 SAFETY (SAF)
6.1 Research questions
Element ID Research question
C0008 How safe is TAVI compared with SAVR?
C0002 Are the harms device related?
C0004 How does the frequency or severity of harm change in different settings?
C0005 What are the susceptible patient groups that are more likely to be harmed 
through TAVI?
C0007 Are TAVI and SAVR associated with user-dependent harms?
B0010 What kind of data/records and/or registry is needed to monitor the use of TAVI?
6.2 Results
Included studies
Other than the studies presented in the EFF domain, comparative prospective national registries 
studies presenting analyses of real-world data were included for the SAF domain. Overall, two 
RCTs [2,15,16] and two registry studies [17,18] were included for the analysis of safety outcomes.
RCT studies
The included RCTs are described in detail within the EFF domain.
Real-world data studies
Given that data on safety outcomes were available from RCTs, the real-world data studies were 
only presented narratively and the level of evidence was not graded. The two registry studies were 
not included in any meta-analysis. Results were only presented and discussed narratively.
The study by Bestehorn et al. [17] presented the analysis of the incidence of POD and in-hospital 
mortality in patients with comparable risk treated with either SAVR or TAVI (TF route only) in 
Germany during 2013. From a data set of 3407 procedures performed in patients with a 
EuroSCORE between 10% and 20%, two homogeneous groups of 763 patients each with 
EuroSCORE 13.5±2.7 were extracted for a first analysis. A second analysis was performed using 
two groups of 470 patients each matched according to sex, ASA classification, left ventricular 
ejection fraction, previous PCI, previous cardiac surgery, peripheral artery disease, lung disease, 
neurological disease, and diabetes mellitus.
The study by Brennan et al. [18] presented the analysis of the incidence of stroke at 1 year in 
patients treated with either SAVR or TAVI in the USA between 2011 and 2015. From a data set of 
40 528 procedures, two groups of 4732 patients each were matched using propensity scores: 
median age: 82 years (IQR: 77–85 years); sex: 47.9% women; median STS PROM score: 5.6% 
(IQR: 4.2–8.2%).
Patient safety
Analysis of RCT data
[C0008] How safe is TAVI in relation to SAVR?
Stroke and disabling stroke
Stroke and disabling stroke were reported by both trials at 30-day, 1-year, and 2-year follow-up. 
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At 30-day follow-up, stroke occurred in 4.4% of patients in the TAVI group and 5.6% in the SAVR 
group: compared with SAVR, it is uncertain whether TAVI has any effect on stroke at 30-day follow-
up  (RR 0.80, 95% CI 0.58–1.10; GRADE evidence: very low) (Figure 6.1). We downgraded the 
quality for this outcome at 30-day follow-up because of the risk of bias (i.e., imbalance in 
withdrawals between the groups), inconsistency (i.e., substantial heterogeneity: I2 = 64), and 
imprecision (i.e., wide CIs that crossed the line of no effect). See Table 6.1 for the safety 
comparison.
At 2-year follow-up, the overall stroke occurrence was 7.4% in the TAVI group and 7.6% in the 
SAVR group: it is uncertain whether TAVI is non-inferior to SAVR in terms of stroke (RR 0.97, 95% 
CI 0.74–1.26; GRADE evidence: very low) (Figure 6.1). We downgraded the quality for this outcome 
at 2-year follow-up because of a risk of bias (i.e., very serious concern owing to important attrition), 
and imprecision (i.e., wide CIs that crossed the line of no effect). See Table 6.1 for the safety 
comparison.
Figure 6.1. Incidence of stroke at 30-day, 1-year, and 2-year follow-up
At 30-day follow-up, disabling stroke occurred in 2.3% of patients in the TAVI group and 3.3% in 
the SAVR group: it is uncertain whether TAVI has any effect on disabling stroke compared with 
SAVR (RR 0.70, 95% CI 0.48–1.02; GRADE evidence: low) (Figure 6.2). 
We downgraded the quality for this outcome at 30-day follow-up because of a risk of bias (i.e., 
imbalance in withdrawals between the groups) and imprecision (i.e., wide CIs that crossed the line 
of no effect). See Table 6.1 for the safety comparison.
At 2- year follow-up, the overall disabling stroke occurrence was 4.2% in the TAVI group and 4.9% 
in the SAVR group: it is uncertain whether TAVI has any effect on disabling stroke compared with 
SAVR (RR 0.83, 95% CI 0.56–1.25; GRADE evidence: very low) (Figure 6.1). 
We downgraded the quality for this outcome at 2-year follow-up because of the risk of bias (i.e., 
very serious concern owing to important attrition), and imprecision (i.e., wide CIs that crossed the 
line of no effect). See Table 6.1 for the safety comparison.
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Figure 6.2. Incidence of disabling stroke at 30-day, 1-year, and 2-year follow-up
New atrial fibrillation
New atrial fibrillation occurred in 11% of patients in the TAVI group and 34% in the SAVR group. 
Moderate-quality evidence suggested that TAVI is probably superior to SAVR in terms of new atrial 
fibrillation occurrence (RR 0.32, 95% CI 0.27–0.37; I2 = 11%) (Figure 6.3). 
We downgraded the quality for this outcome only because of risk of bias (i.e., imbalance in 
withdrawals between the groups). See Table 6.1 for the safety comparison.
Figure 6.3. Incidence of new atrial fibrillation at 30-day follow-up
Life-threatening or disabling bleeding
In the PARTNER 2 trial, life-threatening or disabling bleeding at 30-day follow-up occurred in 10% 
of the TAVI group compared with 43% of patients in the SAVR group (pooled RR 0.24, 95% CI 
0.20–0.29).
In the SURTAVI, there was no evidence of differences between the two treatments at 30-day, 1-
year, and 2-year follow-up in terms of life-threatening or disabling bleeding. Data were not pooled 
because the heterogeneity was high (I2 = 99%) (Figure 6.4). 
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The overall GRADE level of certainty for this outcome at 30-day follow-up was rated as very low. 
We downgraded the quality because of a risk of bias (i.e., imbalance in withdrawals between the 
groups), inconsistency (i.e., very serious concern owing to considerable heterogeneity), and 
imprecision (i.e., wide CIs that crossed the line of no effect). See Table 6.1 for the safety 
comparison.
Figure 6.4. Incidence of life-threatening or disabling bleeding at 30-day, 1-year, and 2-year 
follow-up
Acute kidney injury
Acute kidney injury was reported by both trials at 30-day, 1-year, and 2-year follow-up. 
At 30-day follow-up, acute kidney injury occurred in 1.0% of patients in the TAVI group and 2.2% in 
the SAVR group: compared with SAVR it is uncertain whether TAVI reduces the occurrence of 
acute kidney injury (RR 0.47, 95% CI 0.27–0.80); GRADE evidence: very low) (Figure 6.5). We 
downgraded the quality for this outcome at 30-day follow-up because of a risk of bias (i.e., 
imbalance in withdrawals between the groups), and imprecision (i.e., few events and wide CI). See 
Table 6.1 for the safety comparison.
At 2-year follow-up, the overall acute kidney injury occurrence was 2.2% in the TAVI group and 
3.5% in the SAVR group: compared with SAVR, it is uncertain whether TAVI reduces the occurrence 
of acute kidney injury (RR 0.63, 95% CI 0.43–0.92; GRADE evidence: very low) (Figure 6.5). We 
downgraded the quality for this outcome at 2 years follow-up because of a risk of bias (i.e., very 
serious concern owing to important attrition) and imprecision (i.e., wide CI). See Table 6.1 for the 
safety comparison.
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Figure 6.5. Incidence of acute kidney injury at 30-day, 1-year, and 2-year follow-up.
Major vascular complications
At 30-day follow-up, major vascular complications occurred in 6.9% of patients in the TAVI group 
and 3.1% in the SAVR group: compared with SAVR, TAVI might increase the incidence of major 
vascular complications (RR 3.03, 95% CI 0.79–11.67; GRADE evidence: low) (Figure 6.6). We 
downgraded the quality for this outcome at 30-day follow-up because of a risk of bias (i.e., 
imbalance in withdrawals between the groups), and imprecision (i.e., wide CI). We did not 
downgrade for inconsistency even though heterogeneity was substantial (I2 = 90%) because the 
direction of the effect of treatment was the same for the two trials with statistically significant results: 
the inconsistency was between studies that showed moderate and large effects. See Table 6.1 for 
the safety comparison.
At 2-year follow-up, the overall occurrence of major vascular complications increased modestly in 
both groups (7.7% in the TAVI group and 3.3% in the SAVR group) and the treatment effect 
remained substantially the same (RR 3.27, 95% CI 0.73–14.57) (Figure 6.6).
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Study or Subgroup
2.2.1 30 DAYS
PARTNER 2
SURTAVI
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.86; Chi² = 11.02, df = 1 (P = 0.0009); I² = 91%
Test for overall effect: Z = 1.61 (P = 0.11)
2.2.2 ONE YEAR
PARTNER 2
SURTAVI
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 1.09; Chi² = 13.97, df = 1 (P = 0.0002); I² = 93%
Test for overall effect: Z = 1.54 (P = 0.12)
2.2.3 TWO DAYS
PARTNER 2
SURTAVI
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 1.08; Chi² = 13.93, df = 1 (P = 0.0002); I² = 93%
Test for overall effect: Z = 1.55 (P = 0.12)
Events
80
51
131
84
59
143
86
59
145
Total
1011
879
1890
1011
879
1890
1011
879
1890
Events
51
8
59
54
8
62
55
8
63
Total
1021
867
1888
1021
867
1888
1021
867
1888
Weight
53.0%
47.0%
100.0%
52.4%
47.6%
100.0%
52.4%
47.6%
100.0%
IV, Random, 95% CI
1.58 [1.13, 2.23]
6.29 [3.00, 13.17]
3.03 [0.79, 11.67]
1.57 [1.13, 2.19]
7.27 [3.50, 15.13]
3.26 [0.73, 14.61]
1.58 [1.14, 2.19]
7.27 [3.50, 15.13]
3.27 [0.73, 14.57]
TAVI Open surgery Risk Ratio Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
TAVI Open surgery
Figure 6.6. Incidence of major vascular complications at 30-day, 1-year, and 2-year follow-
up
Permanent pacemaker implantation
Pacemaker implantation at 30-day follow-up was performed in 6.7% of patients in the SAVR groups 
in both studies. Data were not pooled because of considerable heterogeneity (I2 >90%). In the 
PARTNER 2 trial, the incidence of permanent pacemaker implantation was higher in the TAVI group 
than in the SAVR group; however, there was no statistically significant difference between the 
groups at any follow-up point. In the SURTAVI trial, the incidence of permanent pacemaker 
implantation was significantly higher in the TAVI group (25.9%) than in the control group (6.6%) at 
all follow-up points (Figure 6.7).
The overall GRADE level of certainty was considered very low. We downgraded the quality for this 
outcome at 30-day follow-up because of a risk of bias (i.e., imbalance in withdrawals between the 
groups), inconsistency (i.e., very serious concern owing to substantial heterogeneity), and 
imprecision (i.e., wide CI). See Table 6.1 for the safety comparison.
Figure 6.7. Incidence of permanent pacemaker implantation at 30-day, 1-year, and 2-year 
follow-up
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Paravalvular regurgitation
Paravalvular aortic regurgitation was reported in both trials. 
At 30-day follow-up, paravalvular regurgitation occurred in 3.2% of patients in the TAVI group and 
0.3% in the SAVR group: compared with SAVR, TAVI probably increases the risk of paravalvular 
regurgitation (RR 9.30, 95% CI 4.02–21.48; GRADE evidence: Moderate) (Figure 6.8). We 
downgraded the quality for this outcome at 30-day follow-up because of a risk of bias (i.e., 
imbalance in withdrawals between the groups). See Table 6.1 for the safety comparison.
At 1- and 2-year follow-up, additional paravalvular regurgitation occurred in similar proportions. At 
2-year follow-up, compared with SAVR, TAVI might increase the risk of paravalvular regurgitation 
(RR 14.74, 95% CI 5.04–43.08; GRADE evidence: low). (Figure 6.8).
Study or Subgroup
2.3.1 At discharge
PARTNER 2
SURTAVI
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.65, df = 1 (P = 0.42); I² = 0%
Test for overall effect: Z = 5.19 (P < 0.00001)
2.3.2 ONE YEAR
PARTNER 2
SURTAVI
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.84); I² = 0%
Test for overall effect: Z = 4.81 (P < 0.00001)
2.3.3 TWO YEARS
PARTNER 2
SURTAVI
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.10, df = 1 (P = 0.75); I² = 0%
Test for overall effect: Z = 4.92 (P < 0.00001)
Test for subgroup differences: Chi² = 0.54, df = 2 (P = 0.76), I² = 0%
Events
33
28
61
25
31
56
48
14
62
Total
872
820
1692
728
580
1308
600
287
887
Events
4
2
6
2
3
5
3
0
3
Total
757
867
1624
611
488
1099
514
223
737
Weight
65.7%
34.3%
100.0%
40.3%
59.7%
100.0%
85.5%
14.5%
100.0%
IV, Random, 95% CI
7.16 [2.55, 20.12]
14.80 [3.54, 61.94]
9.18 [3.97, 21.22]
10.49 [2.49, 44.11]
8.69 [2.67, 28.26]
9.38 [3.77, 23.33]
13.71 [4.29, 43.74]
22.56 [1.35, 376.06]
14.74 [5.04, 43.08]
TAVI Open surgery Risk Ratio Risk Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
TAVI Open surgery
Figure 6.8. Incidence of severe or moderate paravalvular aortic regurgitation at 30-day, 1-
year and 2-year follow-up
Endocarditis
In the PARTNER 2 trial, the occurrence of endocarditis at 2-year follow-up was 1.2% in the TAVI 
group and 0.7% in the control group (RR 1.85, 95% CI 0.69–4.99).
Rehospitalisation for myocardial infarction (>72 h following TAVI)
Neither of the trials assessed this outcome.
Analysis of real-world data
Three safety outcomes identified were reported by the two real-world data studies included: risk of 
POD and in-hospital mortality in the German study [17] and risk of stroke in the US study [18].
The authors of the German study reported that, in the homogeneous groups (EuroSCORE 
13.5±2.7) the incidence of POD was around three times higher after SAVR compared with TAVI: 
12.8% for SARV versus 3.9% for TAVI (p <0.01). In-hospital mortality was higher in the SAVR group 
than in the TAVI group: 5.1% versus 3.3%, respectively (p <0.01). In accordance with this, the 
results from a second analysis of two groups matched according to other parameters and the 
authors reported that the incidence of POD as well as in-hospital mortality were higher in the SAVR 
versus TAVI groups (14.5% versus 4.9% and 6.2% versus 2.3%, respectively; p <0.001).
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Risk of stroke at 1 year follow-up, presented in one study [18], was reported for three subgroups 
but differences were not significant between the two procedures. In particular, the group with STS 
PROM ≥3% and <5% (1953 TAVI versus 1850 SAVR patients) showed a risk of stroke at 1-year 
follow-up of 3.8 versus 3.3; HR 1.06 (95% CI: 0.73–1.54). The group with STS PROM ≥5% and 
<8% (1596 TAVI versus 1545 SAVR patients) showed a risk of stroke at 1-year follow-up of 4.5 
versus 3.5; HR 1.22 (95% CI: 0.83–1.79), whereas the group with STS PROM >8% (1183 TAVI 
versus 1337 SAVR patients) showed a risk of stroke at 1 year follow-up of 4.4 versus 3.1; HR 1.33 
(95% CI: 0.8–-2.03).
[C0002] Are the harms device related?
It is not possible to confirm or exclude whether the reported adverse events, such as new 
pacemaker implantation, paravalvular regurgitation, or major vascular complications, could be 
related to the type of device used. The devices were not directly compared in the same study for 
the same patients; therefore, further research is required.
TAVI is potentially associated with high radiation doses for both patient and personnel. Details 
concerning TAVI and radiation doses in terms of the risk of radiation-induced cancer are described 
in Appendix 4.
[C0004] How does the frequency or severity of harms change in different settings?
[C0005] What are the susceptible patient groups that are more likely to be harmed through 
TAVI?
Neither the included RCT nor the real-world data studies included in our analysis provided data to 
answer either of these questions.
[C0007] Are TAVI and SAVR associated with user-dependent harms?
Long learning curves and procedural volume in the operating centre or the specific user could be 
important factors that might influence the clinical outcomes of TAVI and SAVR. However, neither 
the included RCT nor the real-world data studies included in our analysis provided data to answer 
this question directly.
Safety risk management
[B0010] What kind of data/records and/or registry is needed to monitor the use of TAVI?
The real-world data studies included in our analysis did not provide relevant data that enabled us 
to assess the technology more extensively. To compare different TAVI systems, registries should 
also collect, other than patient data, device-related data, such as mean aortic valve gradient, risk 
of paravalvular leak, need for pacemaker implantation, vascular complications, reintervention rate, 
and durability of the prosthesis. For this latter outcome, it is important to agree and adopt the same 
definitions of structural deterioration and valve failure across the different registries [67]. Moreover, 
setting information should also be collected to assess the impact of different settings on safety 
outcomes.
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Table 6.1. Summary of findings for the safety comparison of TAVI versus SAVR for patients with aortic stenosis at intermediate surgical risk
Certainty assessment № of patients (%) Effect
№ of 
studie
s
Study 
design
Risk 
of bias
Inconsist
ency
Indire
ctness
Impre
cision
Other 
consider
ations
TAVI SAVR Relative
(95% CI)
Absolute
(95% CI)
Certainty
Stroke: 30-day follow-up
2 Randomi
sed trials 
Seriou
s a
Serious Not 
serious 
Seriou
sb
None 78/1890 (4.1%) 103/1888 (5.5%) RR 0.72
(0.44 to 1.20) 
15 fewer per 1000
(from 11 more to 31 fewer) 
⨁◯◯◯
very low 
Stroke: 2-year follow-up
2 Randomi
sed trials 
Seriou
s c
Not 
serious 
Not 
serious 
Seriou
sb
None 145/1890 (7.7%) 159/1888 (8.4%) RR 0.89
(0.60 to 1.33) 
9 fewer per 1000
(from 28 more to 34 fewer) 
⨁◯◯◯
very low
Atrial fibrillation onset: 30-day follow-up
2 Randomi
sed trials 
Seriou
s d
Not 
serious 
Not 
serious 
Not 
seriou
s 
None 204/1890 (10.8%) 641/1888 (34.0%) RR 0.32
(0.27 to 0.37) 
231 fewer per 1000
(from 214 fewer to 248 fewer) 
⨁⨁⨁◯
moderate 
Life threatening/disabling bleeding: 30-day follow-up
2 Randomi
sed trials 
Seriou
s e
Seriousf Not 
serious 
Seriou
sg
None In the PARTNER 2 trial: the risk of life-threatening or disabling bleeding occurred in 10% of 
the TAVI group versus 43% of the SAVR group (RR 0.24, 95% CI 0.20–0.29; at 30-day 
follow-up). 
In the SURTAVI trial: the risk of life-threatening or disabling bleeding was higher in the TAVI 
group (12.2%) than in the SAVR group (9.3%) with no statistical significance (RR 1.31, 95% 
CI 0.99–1.73).
⨁◯◯◯
very low 
Acute kidney injury: 30-day follow-up
2 Randomi
sed trials 
Seriou
s h
Not 
serious 
Not 
serious 
Very 
seriou
si 
none 19/1890 (2.3%) 41/1888 (0.3%) RR 0.47
(0.27 to 0.80) 
12 fewer per 1000
(from 4 fewer to 16 fewer) 
⨁◯◯◯
very low 
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Certainty assessment № of patients (%) Effect
№ of 
studie
s
Study 
design
Risk 
of bias
Inconsist
ency
Indire
ctness
Impre
cision
Other 
consider
ations
TAVI SAVR Relative
(95% CI)
Absolute
(95% CI)
Certainty
Acute kidney injury: 2-year follow-up
2 Randomi
sed trials 
Very 
seriou
s j
Not 
serious
Not 
serious
Very 
seriou
si
none 42/1890 (1.5%) 67/1888 (3.5%) RR 0.63
(0.43 to 0.92)
13 fewer per 1000
(from 3 fewer to 20 fewer)
⨁◯◯◯
very low
Major vascular complications: 30-day follow-up
2 Randomi
sed trials 
Seriou
s k
Not 
seriousl
Not 
serious 
Seriou
sm 
none 131/1890 (6.9%) 59/1888 
(3.1%) 
RR 3.03 
(0.79 to 11.67)
63 more per 1000
(from 7 more to 333 more) 
⨁⨁◯◯
low
New permanent pacemaker: 30-day follow-up
2 Randomi
sed trials 
Seriou
s n
Very 
seriouso 
Not 
serious 
Not 
seriou
s 
none In the PARTNER 2 trial, the proportion of new permanent pacemakers was 8.4% in the TAVI 
group and 6.7% in the control group with no evidence of significant differences (RR 1.26, 
95% CI 0.93– 1.72).
In the SURTAVI trial, the proportion of implanted pacemakers was higher in the TAVI group 
(25.1%) than in the SAVR group (6.7%) with a statistically significant difference (RR 3.78, 
95% CI 2.84–5.02).
⨁◯◯◯
very low 
Paravalvular regurgitation: 30-day follow-up
2 Randomi
sed trials 
Seriou
s p
Not 
serious 
Not 
serious 
Not 
seriou
s 
none 255/1890 (13.5%) 32/1888 (1.7%) RR 7.93
(5.54 to 11.35) 
117 more per 1000
(from 77 more to 175 more) 
⨁⨁⨁◯
moderate 
GRADE Working Group grades of evidence:
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: our confidence in the effect estimate is limited: the true effect might be substantially different from the estimate of the effect.
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Very low quality: we have little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
Explanations
a. Serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. Given that stroke was an objective outcome, we considered that absence of 
blinding could not introduce the performance bias and, therefore, no downgrading was done. However, the quality of evidence was downgraded by one level because, in one of the two trials, 94 enrolled 
patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; we are uncertain whether this 
might have generated an imbalance between the two trials.
b. Wide CI. 
c. Very serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. However, because stroke was an objective outcome, we considered that 
absence of blinding could not introduce the performance bias and, therefore, no downgrading was done. However, the quality of evidence was downgraded by two levels given that: (i) in one of the two trials, 
94 enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; we are uncertain 
whether this might have generated an imbalance between the two trials; and (ii) at 2-year follow-up, >30% and >50% of patients were lost to follow-up in each trial, respectively.
d. serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. However, because atrial fibrillation was an objective outcome, we considered 
that absence of blinding could not introduce the performance bias and, therefore, no downgrading was done. However, the quality of evidence was downgraded by one level because, in one of the two trials, 
94 enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; we are uncertain 
whether this might have generated an imbalance between the two trials. 
e. Serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. However, because bleeding was an objective outcome, we considered that 
absence of blinding could not introduce the performance bias and, therefore, no downgrading was done. However, the quality of evidence was downgraded by one level because, in one of the two trials, 94 
enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; we are uncertain 
whether this might have generated an imbalance between the two trials. 
f. Considerable heterogeneity.
g. One study had a wide CI crossing the null effect.
h. serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. Given that acute kidney injury was an objective outcome, we considered that 
absence of blinding could not introduce the performance bias and, therefore, no downgrading was done. However, the quality of evidence was downgraded by one level because, in one of the two trials, 94 
enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; we are uncertain 
whether this might have generated an imbalance between the two trials.
i. Wide CI and/or very few events.
j. Very serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. Given that acute kidney injury was an objective outcome, we considered 
that absence of blinding could not introduce the performance bias and, therefore, no downgrading was done. However, the quality of evidence was downgraded by two levels given that: (i) in one of the two 
trials, 94 enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; we are 
uncertain whether this imbalance in withdrawals between the two groups might have introduced bias; and (ii) at 2-year follow-up, >30% and >50% of patients were lost to follow-up in each trial, respectively.
k. Serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. However, because vascular complication was an objective outcome, we 
considered that absence of blinding could not introduce the performance bias and, therefore, no downgrading was done. However, the quality of evidence was downgraded by one level because, in one of 
the two trials, 94 enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; we 
are uncertain whether this imbalance in withdrawals between the two groups might have introduced bias.
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l. We found an unexplained important heterogeneity (I2 = 90%) because of the lower frequency of the outcome in the SAVR group in one of the two trials. However, we decided not to downgrade because 
the direction of the treatment was consistent between the trials and the inconsistency was between studies that showed moderate and large effects. 
m. Wide CI.
n. Serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. However, because pacemaker implantation was an objective outcome, we 
considered that absence of blinding could not introduce the performance bias and, therefore, no downgrading was done. However, the quality of evidence was downgraded by one level because, in one of 
the two trials, 94 enrolled patients (4.6%; 17 patients in the TAVI group and 77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; we 
are uncertain whether this might have generated an imbalance between the two trials. 
o. Very serious concern regarding heterogeneity.
p. Serious concern regarding risk of bias: blinding patients and personnel was not possible because of the type of intervention. Downgrading by one level was done because of a risk of bias: (i) paravalvular 
regurgitation was considered a subjective outcome and the trial could be subject to performance and detection bias; (ii) in one of the two trials, 94 enrolled patients (4.6%; 17 patients in the TAVI group and 
77 in the SAVR group) were withdrawn from the study mainly owing to a decision after randomisation not to undergo surgery; despite the minimal percentage of attrition, there was an imbalance between the 
two groups in terms of withdrawal.
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7 UPCOMING EVIDENCE (ONGOING STUDIES)
Two active relevant RCTs were identified according to the PICOD (Table 7.1). One of these was 
the SURTAVI trial (NCT01586910), for which we assessed an interim analysis published in 2017. 
The final completion date of the SURTAVI trial is October 2018. The planed number of patients to 
be recruited was 2500. The entry was last updated in November 2017.
The second trial was an ongoing German trial (NCT03112980), which appears to be the first 
independent RCT aiming to answer questions relevant to the present assessment. A total of 17 
German university hospitals will contribute to the trial. Its estimated completion is 2023, with no 
information available on possible publications of interim analyses. The entry was last updated on 
October 2017. The trial is still recruiting patients.
Interestingly, six RCTs comparing TAVI versus SAVR or medication in patients at low risk or non-
symptomatic were also identified (Appendix 1). For these RCTs, primary completion dates varied 
from 2018 to 2021.
Table 7.1. Ongoing RCTs according to PICOD
Trial (trial number and 
name)
Number 
of 
patients
P (study inclusion 
criteria)
I C O Estimat
ed 
complet
ion date
NCT01586910: Safety and 
Efficacy Study of the 
Medtronic CoreValve® 
System in the Treatment of 
Severe, Symptomatic 
Aortic Stenosis in 
Intermediate Risk Subjects 
Who Need Aortic Valve 
Replacement (SURTAVI)
2500 Severe AS, 
comorbidities such 
that the heart team 
agrees predicted risk 
of operative mortality 
is ≥3% and <15% at 
30-day follow-up
Medtroni
c 
CoreVal
ve® 
Evolut R 
System
SAVR All-cause 
mortality or 
disabling 
stroke (time 
frame: 2 
years); 
safety and 
efficacy 
outcomes; 
QoL (not 
specified)
2018 
(publish
ed 
Interim 
results 
included 
in this 
report)
NCT03112980: 
Randomized Trial of TAVI 
versus SAVR in Patients 
with Severe Aortic Valve 
Stenosis at Intermediate 
Risk of Mortality 
(PARTNER 2)
1600 Severe symptomatic 
AS; intermediate risk 
(STS-score 2–6%)
TAVI 
using 
most 
appropri
ate CE 
marked 
device 
available
SAVR Overall 
survival 5 
years after 
last patient 
enrolled; 
safety and 
efficacy 
outcomes; 
QoL (EQ-
5D)
2023
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8 POTENTIAL ETHICAL, ORGANISATIONAL, PATIENT, SOCIAL, AND 
LEGAL ASPECTS (ETH, ORG, SOC, LEG)
8.1 Research questions
1. Ethical
1.2 Does comparing the new technology to the defined, existing comparators 
point to any differences that might be ethically relevant?
Yes
Patient autonomy might be an issue. Currently, the indication for TAVI does not include 
low-risk patients. However, patients with indication for SAVR do increasingly demand 
TAVI regardless of risk. Denying TAVI to low-risk patients might challenge patient 
autonomy.
2. Organisational
2.1 Does the introduction of the new technology and its potential use and/or 
non-use instead of the defined, existing comparator(s) require 
organisational changes?
Yes
According to the latest guidelines from ESC/EACTS [5], aortic valve interventions should 
only be performed in centres with both departments of cardiology and cardiac surgery on 
site and with structured collaboration between the two. In the case of TAVI, the presence 
of a heart team is considered crucial to perform proper patient selection. In particular, in 
patients who are at increased surgical risk, the decision between SAVR and TAVI should 
be made by the heart team according to the characteristics of the individual patient. The 
presence of a heart team could be particularly complex from an organisational point of view 
because it typically involves cardiologists, cardiac surgeons, imaging specialists, 
anaesthetists and, if needed, general practitioners, geriatricians, and heart failure, 
electrophysiology, or intensive care specialists. Moreover, centres performing TAVI should 
have the proper imaging equipment, hybrid operating rooms, or catheterisation laboratory 
facilities.
2.2  Does comparing the new technology to the defined, existing comparator(s) 
point to any differences that might be organisationally relevant?
Yes
The RCTs included in the present assessment indicate that TAVI is linked to shorter 
length of hospital stay. This should impact the availability of beds within the health centre.
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9 DISCUSSION
TAVI and SAVR are both complex procedures under constant development in terms of both 
substantial and small incremental changes related to the devices and all aspects of the procedures. 
When initiating the present assessment, only two TAVI systems had the CE mark with indication 
for intermediate-risk patients (received in during 2016). Another TAVI system, Medtronic's Evolut 
PRO, received the CE mark for intermediate-risk patients when this assessment was ongoing 
(Summer 2017). Thus, it is possible that the TAVI systems used in the included clinical trials might 
not be identical to those currently used across Europe. We performed a search for published and 
registered RCTs of TAVI compared with SAVR or another TAVI system. No RCTs involving Evolut 
Pro were either excluded or identified. Thus, evidence on the newly introduced TAVI system is likely 
to be limited to nonrandomised studies and does not meet the criteria defined within the scope of 
this assessment
TAVI is widely available and reimbursed across European countries. Our survey from October to 
November 2017 revealed substantial variations in use (a factor of 10 in difference) and 
reimbursement policies across European countries. To investigate the reasons for this variation is 
outside the scope of this assessment. However, among the factors potentially influencing the 
diffusion we can list the local presence of skilled health professionals and reimbursement schemes.
The two included studies showed non-inferiority in design and had comparable outcome measures 
that allowed meta-analyses to be performed for most outcomes. Limitations associated with both 
studies were a high frequency of unplanned withdrawals in the SAVR group and the lack of long-
term follow-up data. Limitations of the SURTAVI study included the fact that results were based on 
an interim analysis with only a fraction of the included patients followed for 2 years. Thus, event 
rates for the meta-analysis, in particular for the 2-year results, depend on a model for imputation of 
data. Furthermore, the newest generation of the CoreValve device (CoreValve Evolut R) was only 
used in 20% of patients. The PARTNER 2 trial was planned as a cohort trial with randomisation 
based on access route. In the PARTNER 2 trial, the SAPIEN XT device was used, whereas the 
newest CE marked device (SAPIEN 3) was not. In the SURTAVI trial, patients were randomised 
before access route determination; thus, there might be differences in the characteristics of the 
enrolled patients that were not addressed in our meta-analysis. Despite these limitations, we did 
not downgrade with respect to any uncertainties these limitations might provide, except for attrition 
bias when outcomes were evaluated at 1- and 2-year follow-up.
Given that both systems are widely used in Europe, we looked at results across the two RCTs and 
pooled the data for outcomes using a random effects model if there was no substantial 
heterogeneity observed in the meta-analysis (I2 <50). For outcomes with heterogeneity between 
the data reported by the trials, unpooled results were provided. There are arguments for and against 
the pooling of data from two trials, in particular if differences in risk of bias are observed. According 
to the Cochrane Handbook, a random-effects meta-analysis model involves an assumption that the 
effects being estimated in the different studies are not identical but follow some distribution (ref). 
Pooling or not a pooling data is a matter of decision for the meta-analyst. We cannot exclude that 
reasons for the observed heterogeneity are associated with the choice of system, procedures, or 
differences in the population. Although the imprecision will be somewhat higher, the main 
conclusions with regard to the most important outcomes (i.e., confidence in estimates either pooled 
or un-pooled) is unlikely to be greatly affected by pooling or not pooling the results. 
Making a clear and unequivocal definition of severe symptomatic aortic stenosis with intermediate 
risk is challenging. Patient stratification builds on team-based overall assessment of the patient (i.e., 
a heart team approach) and can vary across different studies and clinical contexts. Therefore, the 
exact number of patients with severe symptomatic aortic stenosis at intermediate surgical risk 
eligible for TAVI is hard to estimate, but it is likely to increase as the population ages.
Our search strategies were oriented towards the identification of all RCTs and studies of national 
registries that compared TAVI with SAVR or another TAVI system. After thorough evaluation of the 
characteristics of the patient eligibility criteria of the studies and the patient characteristics, we 
considered eligible the PARTNER 2 and the SURTAVI trials. The eligibility criteria of SURTAVI was 
a STS score of 3–15%. Given that the included patients for the interim analysis all had an STS 
score of 4.5±1.6%, we considered the study to be in compliance in terms of including only patients 
at intermediate risk. By contrast, the NOTION trial included intermediate and low-risk patients with 
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a STS mean score of 3.1 (1.7), resulting in 81% of patients at low risk [37] and this trial was 
subsequently excluded. 
We used the GRADE approach for rating the quality of evidence. We rated the quality as moderate 
only for outcomes evaluated at 30-day follow-up (e.g., mortality, new atrial fibrillation onset, hospital 
stay, and paraventricular regurgitation). At 30-day follow-up, the quality of the following outcomes 
was further downgraded because of imprecision: stroke, acute kidney failure, and major vascular 
complications. For the remaining outcomes, further downgrading was performed when the 
outcomes were evaluated at 2-year follow-up mainly owing to serious concerns caused by attrition 
bias (mortality, improvement of symptoms, aortic valve intervention) or to serious or very serious 
concerns regarding inconsistency and/or imprecision (life-threatening and/or disabling bleeding)
Given that our protocol did not foresee a non-inferiority trial, we did not provide any non-inferiority 
margin. In this context, the PARTNER II trial estimated that a sample of 2000 patients would provide 
the trial with a power of at least 80% to show the non-inferiority of TAVI compared with SAVR with 
respect to the primary endpoint at 2 years, assuming an event rate of 30% in each group, with a 
non-inferiority margin of 0.20. Conversely, the SURTAVI trial used Bayesian methods and 
calculated a sample size of 4000 based on a standard frequentist non-inferiority power analysis and 
used a non-inferiority margin of 0.07. To provide judgment regarding the certainty of the evidence, 
we used the more conservative margin, which was that of the PARTNER II trial, also being aware 
that it is difficult to propose a delta in mortality that is not ‘clinically meaningful’. Hence, because 
there was no difference in rates of all-cause mortality (or cardiac specific mortality) between the two 
groups, we considered TAVI to be non-inferior to SAVR in terms of these outcomes at 30-day follow-
up based on moderate-level evidence. The downgrading by one level was performed because, in 
one of the two trials, there was an imbalance of withdrawals between the groups. Conversely, for 
the same outcomes at 2-year follow-up, we concluded that there was uncertainty about whether 
TAVI is non-inferior to SAVR owing to very low-level evidence. The downgrading by two levels was 
because of important attrition that occurred in both trials. In conclusion, the evidence is very limited 
regarding the most important outcomes at 2-year follow-up.
Other efficacy outcomes evaluated by both trials were aortic valve reintervention, improvement of 
symptoms, and length of hospital stay. 
The proportion of aortic valve reintervention was higher in the TAVI group than in the SAVR group 
at 30-day follow-up, but the overall number of events was 12. This led to downgrading by two levels 
because of imprecision resulting in very low-quality evidence. At 2-year follow-up, the number of 
events was 41, with a higher proportion in the TAVI group than in the SAVR group, but we graded 
the level of evidence as very low because of a risk of bias and imprecision. 
Regarding the outcome of improvement of symptoms (according to the NYHA classification), within 
each group in both trials, there was an improvement at 30-day follow-up and this improvement was 
maintained during the 2-year follow-up. No significant difference was observed between the two 
groups during follow-up, but we graded the level of evidence as very low because of the risk of bias 
and imprecision.
In terms of length of hospital stay, the data could not be pooled because of different data reporting, 
although both trials reported significant shorter duration in favour of TAVI compared with SAVR. 
Our confidence in the treatment effect was graded as moderate quality of evidence. However, this 
outcome is relevant when there is a strong evidence in favour of a clinically important outcome.
With regard to the stroke and disabling stroke outcomes, there were only small differences in the 
number of events in each group reported by the trials. Given the risk of bias and imprecision, our 
confidence in the estimates was very low and we were not able to conclude with regard to non-
inferiority. 
In the TAVI group compared with the SAVR group, there were fewer reported cases of acute kidney 
injury and atrial fibrillation, but more cases of major vascular complications and of paravalvular 
regurgitation. However, our confidence in estimates of the effects was either very low (acute kidney 
injury, atrial fibrillation, and paravalvular regurgitation) or low (major vascular complications), 
reflecting the uncertainty about whether TAVI reduces the risk of acute kidney injury and atrial 
fibrillation or enhances the risk of paravalvular regurgitation and major vascular complications.  
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Conflicting results between the included trials were observed in terms of life-threatening or disabling 
bleeding and the need for new permanent pacemaker replacement. Although there was little or no 
difference in the disabling bleeding outcome between TAVI and SAVR in the SURTAVI trial, the 
results were in favour of TAVI in the PARTNER 2 trial. In addition, although there was little or no 
difference in the permanent pacemaker replacement outcome in the PARTNER 2 trial, the 
proportion of implanted pacemakers was in favour of SAVR in the SURTAVI trial. Given the risk of 
bias and important heterogeneity, we considered the overall quality of evidence for these two 
outcomes to be very low and we were unable to provide a conclusion. The two trials used different 
TAVI systems and had slightly different inclusion criteria. Whether the observed heterogeneity is 
related to the TAVI system used, or if there are other explanations, such as differences in the 
population, will require additional studies. 
In both trials, the improvement in aortic valve haemodynamics increased significantly from baseline 
to 30-day and 2-year follow-up. Haemodynamic findings were significantly better in the TAVI group 
than in the SAVR group. This in contrast to the finding that paravalvular regurgitation was 
significantly higher in the TAVI group. A better haemodynamic performance of TAVI compared with 
SAVR could translate in a lower incidence of structural valve deterioration over time and better 
clinical outcome, especially in patients with small annulus size, reducing the risk of prosthesis–
patient mismatch. However, because our confidence in estimates for these outcomes was very low, 
future studies will need to clarify these issues.
Limitations of the RCTs include lack of long-term follow-up, a significant frequency of withdrawals, 
and uncertain data on quality of life. The ongoing German RCT (NCT03112980) is an industry 
independent study that could provide more-reliable 5-year follow-up data and quality-of-life data. 
Available evidence (restricted to the inclusion criteria) did not provide answers to the following 
assessment elements: (C0002), (C0004), (C0005), and (C0007). 
We found an extensive number of systematic reviews compared with the number of trials 
addressing the effectiveness of TAVI for patients with aortic stenosis. During the preparation of the 
present assessment (July 2017), NICE published its interventional procedures guidance (IPG) on 
transcatheter aortic valve implantation for aortic stenosis [61] and an update of the ECT/EASCT 
guidelines [5] was published. 
Most importantly, the evidence evaluations supporting the guidelines preclude the publication of 
results from the SURTAVI trial. Furthermore, neither the NICE nor ECT/EACST guidelines are 
based on the GRADE approach to evaluate confidence in each outcome. In our assessment, we 
included data from the SURTAVI trial and used the GRADE approach for the most important 
outcomes. Our confidence in TAVI being non-inferior to SAVR with regard to 30-day mortality 
across the two trials is moderate. However, we report substantial uncertainty (low and very low-
quality evidence) for several important outcomes, making us unable to provide a firm conclusion 
with regard to the benefits of TAVI versus SAVR for patients at intermediate surgical risk. 
The number of trials included differed between the reviews depending on the inclusion criteria 
applied. In particular, Arora et al. [68] performed a meta-analysis including data from the PARTNER 
2 trial and three propensity-matched observational studies. No significant differences were 
observed in terms of 30-day mortality and stroke between the two groups. Patients undergoing 
TAVI were less likely to have bleeding complications and acute kidney injury, but were more likely 
to have vascular complications, paravalvular regurgitation, and a need for pacemaker implantation. 
The choice of access route depends on the patient anatomy and TF access is less invasive than 
the transapical approach. Neither the NICE nor ECT/EASCT guidelines provide recommendations 
with regard to access route or choice of system device. The systematic review by Siemieniuk [69] 
included four RCTs for which only one fulfilled our inclusion criteria. Analysis of data was performed 
based on access routes, and the authors concluded that patients at low and intermediate surgical 
risk were likely to perceive a net benefit with TF TAVI compared with SAVR, but that SAVR performs 
better than transapical TAVI. These analyses were mainly based on data from the PARTNER trial. 
Another meta-analysis performed by Singh et al. [70] included eight comparative studies, three of 
which had a randomised design. The 30-day all-cause mortality, 30-day cardiac mortality, and 1-
year all-cause mortality were similar between the two groups. However, TAVI performed via TF 
access had a significantly lower mortality than SAVR, whereas the incidence of moderate aortic 
incompetence and pacemaker implantation was higher in the TAVI group. 
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Mainly because of the risk of bias, and uncertainty related to directness (patient inclusion criteria) 
and imprecision (lack of power), we do not consider that the additional results presented by the 
identified systematic reviews would influence our confidence in any estimates of outcomes.
The analysis of real-world comparative data from national registries did not allow us to add 
significant elements to the safety analysis performed using RCTs that had 2 years of follow-up. 
Only two comparative national registry studies were identified and presented data on a limited 
number of safety outcomes (i.e., incidence of POD and incidence of stroke) with limited follow-up 
(up to 1 year). In one German study [17], incidence of POD was three times higher after SAVR 
compared with TAVI (12.8% versus 3.9%) when two groups of 763 patients were matched 
according to EuroSCORE values. Such a safety outcome was not reported in the included RCTs. 
Risk of stroke assessed in one American registry study [18] did not show significant differences 
between the two procedures. This finding is in line with evidence from RCTs. Moreover, extending 
inclusion criteria outside the defined PICOD added no value. We reviewed in full-text the 
noncomparative registry studies identified and found that only one study [19] presented safety data 
relevant to the population of interest (i.e., patients at intermediate surgical risk). The study by 
Holmes et al. [19] presented outcomes following TAVI in the USA between 2011 and 2014. 
Outcomes from a total of 12 182 patients were reported at 1 year of follow-up. Of those patients, 
6988 (57.4%) had an STS-PROM score <8%. Incidence of stroke and heart failure for this specific 
group of patients was 3.8% (239) and 11.1% (676), respectively. By comparison, pooled incidence 
of stroke from the included RCTs was 4.1% in the TAVI group, whereas heart failure was not 
reported in the RCTs. In the other registry studies, either the cumulative data or the surgical risk 
score of the observed population ranging from low to high risk with no stratification according to risk 
were reported. In addition to patient data, registries should also collect device-related data and 
setting information to allow analyses of performance between different products and to assess the 
impact of the different settings on safety outcomes. Upcoming evidence could be derived from more 
efficient and sophisticated analysis of high-quality real-world data.
In general, the additional risk of radiation-induced cancer () (i.e., stochastic effect) following TAVI 
procedures can be considered small in relation to the natural risk of cancer morbidity and mortality. 
However, patient’s age is a key variable. Patients at intermediate surgical risk are expected to be 
younger, with a slightly increased risk of stochastic effects as a result. The radiation dose from 
preoperative investigations and follow-up also needs to be considered. The average skin dose (i.e., 
deterministic effect) for coronary angiography and TAVI gives no cause for concern. However, in 
complex cases, doses might exceed values where acute effects can be observed. Personnel 
closest to the patient will be exposed to the highest radiation doses. Radiated tissues include fingers 
(especially during a transapical approach) and the lenses of the eye.
Patient autonomy be an issue. Currently, the indication for TAVI does not include low-risk patients. 
However, patients with an indication for SAVR do increasingly demand TAVI regardless of risk. 
Denying TAVI to low-risk patients might challenge patient autonomy. The excluded NOTION trial 
as well as six ongoing RCTs were identified to be studying low-risk populations and/or symptom-
free populations (Appendix 1). Given that the use of TAVI might rapidly include more patients at 
lower risk and in lower age groups, a more extensive (re-)assessment of TAVI for all populations 
with subgroup analyses for different populations should be planned.
As emerged from the comments from clinical experts, some issues at the moment remain 
uncovered and hardly can be incorporated within a health technology assessment. It is difficult to 
reach conclusions on the diffusion of the different models of TAVI in different settings or to assess 
whether the diffusion of a specific model is related to the availability of (good-quality) supporting 
evidence. In fact, some centres show a preference for a specific model or a specific manufacturer; 
however, analysis of these variations was not within the scope of the present assessment. We 
acknowledge that the convalescence phase can be another key element in the choice of TAVI. 
However, only length of hospital stay is commonly reported within the studies. Equal durability of 
the prosthetic valves used for TAVI and SAVR is another important issue; however, given that long-
term data are not available for TAVI, it remains theoretical. Moreover, the various ongoing studies 
on patients at low surgical risk might predict an increasing trend in the use of TAVI and the 
continuous and rapid development and introduction of new TAVI models will necessarily require 
periodic evidence reviews in the near future.
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TAVI is a procedure for the deployment of bioprostheses in the aortic valve using a catheter. TAVI 
aims to constitute a less invasive alternative to SAVR, avoiding the need for cardiopulmonary 
bypass. At the time of writing, there were two manufacturers offering TAVI systems that are CE 
marked to be used for the treatment of patients with severe aortic stenosis at intermediate surgical 
risk.
Aortic stenosis is the most common valvular heart disease in developed countries. Treatment of 
symptomatic aortic stenosis with medication alone can only be palliative and has limited clinical 
effect. SAVR is an established, effective, first-choice treatment for aortic stenosis. The most recent 
guidelines from ESC/EACTS recommend either TAVI or SAVR in patients at increased surgical 
risk. According to these guidelines, a heart team should make the treatment decision based on 
assessments of individual risk and patient characteristics.
Moderate-quality evidence suggests that TAVI for patients with severe aortic stenosis at 
intermediate surgical risk is non-inferior to SAVR in terms of all-cause mortality and cardiac mortality 
at 30-day follow-up. Moderate-quality evidence also suggests that TAVI reduces hospital stay 
compared with SAVR. However, important uncertainties remain in terms of whether TAVI is better 
or worse than SAVR in terms of the improvement of symptoms. 
Moderate-quality evidence suggests that, compared with SAVR, TAVI reduces new-onset atrial 
fibrillation and enhances the risk of paravalvular regurgitation. Important uncertainties remain 
regarding evidence on the following outcomes: stroke, acute kidney injury, new permanent 
pacemaker, major vascular complications, aortic valve reintervention, and life-threatening and/or 
disabling bleeding.
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APPENDIX 1: METHODS AND DESCRIPTION OF THE EVIDENCE USED
Documentation of the Search Strategies
1.1Literature search - TAVI Collaborative Assessment
Databases: Embase (Ovid), Ovid MEDLINE(R), Cochrane Library: Cochrane Database of 
Systematic Reviews (CDSR), Other Reviews, Cochrane Central Register of 
Controlled Trials (CENTRAL). Centre for Reviews and Dissemination (CRD): 
Database of Abstracts of Reviews of Effects (DARE), Health Technology 
Assessments (HTA) database. Epistemonikos, PubMed (publication status ahead of 
print publications).
Search filter: Systematic reviews (SR) and Health Technology Assessments (HTA) amended, 
based on Ovid’s clinical queries and Cochrane Highly Sensitive Search Strategy for 
identifying randomized trials (Cochrane Handbook, ch. 6.4.11.1, Box 6.4.d).
Date Run: 2017.06.26-27
Results:   865 references in total (1279 including duplicates)
377 Systematic reviews/ Health Technology Assessments (publication year 2013-
2017)
268 Trials (publication year 2016-2017)
220 Publication status ahead of print (non-indexed) publications (publication year 
2013-2017)
Performed by: Ingrid Harboe, research librarian; peer review: Ingvild Kirkehei, research librarian
Embase 1980 to 2017 Week 24
Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, 
Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present
Date run: 2017.06.27
# Searches Results
1 heart valve prosthesis implantation/ use ppez 18532
2 heart valve replacement/ use ppez or aorta valve replacement/ use emez or 
transcatheter aortic valve implantation/ use emez or aorta valve prosthesis/ use 
emez
31001
3 Aortic Valve/ use ppez or aorta valve/ use emez or percutaneous aortic valve/ 
use emez
28941
4 ((aortic valv* or aorta* valv* or heart valv*) adj4 (prosthe* or implant* or insert* 
or replac*)).ti,ab.
55296
5 or/1-4 90174
6 (percutaneous or transapical or trans-apical or transarterial or trans-arterial or 
transcatheter or trans-catheter or transcutaneous or trans-cutaneous or 
transfemoral or trans-femoral or transaxillary or trans-axillary or transluminal or 
trans-luminal or transaortic or trans-aortic or transcarotid or trans-carotid or 
transsubclavian or trans-subclavian or transiliac or trans-iliac or transiliofemoral 
or trans-iliofemoral or TAVI or TAVR).ti,ab.
387824
7 5 and 6 23663
8 percutaneous aortic valve/ use emez and (prosthe* or implant* or insert* or 
replac*).ti,ab.
1613
9 transcatheter aortic valve replacement/ use emez 11315
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10 or/7-9 24882
11 exp animals/ not humans.sh. 27210271
12 10 not 11 9911
13 ((systematic* adj2 review*) or meta-anal* or technology assessment*).mp,pt. or 
(review.mp. and (pubmed or medline).ab.) or ((systematic* or database* or 
literature) adj2 search*).mp.
716322
14 12 and 13 298
15 limit 14 to yr="2013 -Current" (SR 2013 -2017) 264
16 remove duplicates from 15 247
17 (randomized controlled trial or controlled clinical trial).pt. or random*.mp. or 
placebo.ab. or double-blind*.ti,ab. or trial.ti.
2816368
18 12 and 17 736
19 limit 18 to yr="2016 -Current" 210
20 remove duplicates from 19 191
21 registries/ use ppez or register/ use emez or (registries or register or 
registry).mp.
399044
22 12 and 21 713
23 limit 22 to yr="2013 -Current" 555
24 remove duplicates from 23 520
Comments to the search strategy after revision from co-author (KCE):
MeSH Aortic Valve Stenosis: we considered this MeSH as too broad. We could have combined 
the term with valve implantation/replacement but assumed it was covered by the other search 
terms. A test search did not seem to add relevant unique hits (please contact NIPHNO for test 
search strategy). 
MeSH Transcatheter Aortic Valve Replacement: The MeSH Transcatheter Aortic Valve 
Replacement should have been included in the search strategy instead of the previous version 
Heart Valve Prosthesis Implantation (line 1) from a previous search strategy. The subject heading 
is included (line 9) but coded as Embase subject heading (emez) not MEDLINE MeSH (ppez). In 
Embase transcatheter aortic valve implantation is used for transcatheter aortic valve replacement. 
Nevertheless, we think the required MeSH is covered by free text terms (line 4). 
MeSH Heart valve prosthesis implantation: included in the search strategy (line 1) A quick 
revised search including the suggested MeSH (1, 2) retrieved 6 unique hits, none of which met the 
inclusion criteria.
Ovid search syntax:
.pt. denotes a Publication Type term;
.ab. denotes a word in the abstract;
.fs. denotes a ‘floating’ subheading;
.sh. denotes a Medical Subject Heading (MeSH) term;
.ti. denotes a word in the title.
* (asterisk) denotes truncation (e.g. random* for random or randomised or randomized or 
randomly, etc) 
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Database: Cochrane library
Date Run: 2017.06.26
Results: 55  Systematic Reviews/ Health Technology Assessments (publication year 2013-2017)
240 Trials (publication year 2016-2017)
ID Search Hits
#1 MeSH descriptor: (Heart Valve Prosthesis Implantation) this term only 684
#2 MeSH descriptor: (Aortic Valve) this term only 451
#3 ((aortic valv* or aorta* valv* or heart valv*) near/4 (prosthe* or implant* or 
insert* or replac*)):ti,ab,kw in Cochrane Reviews (Reviews and Protocols)
7
#4 ((aortic valv* or aorta* valv* or heart valv*) near/4 (prosthe* or implant* or 
insert* or replac*)) in Other Reviews, Trials and Technology Assessments
1985
#5 #1 or #2 or #3 or #4 2091
#6 (percutaneous or transapical or trans-apical or transarterial or trans-arterial or 
transcatheter or trans-catheter or transcutaneous or trans-cutaneous or 
transfemoral or trans-femoral or transaxillary or trans-axillary or transluminal 
or trans-luminal or transaortic or trans-aortic or transcarotid or trans-carotid or 
transsubclavian or trans-subclavian or transiliac or trans-iliac or 
transiliofemoral or trans-iliofemoral or TAVI or TAVR):ti,ab,kw in Cochrane 
Reviews (Reviews and Protocols)
173
#7 (percutaneous or transapical or trans-apical or transarterial or trans-arterial or 
transcatheter or trans-catheter or transcutaneous or trans-cutaneous or 
transfemoral or trans-femoral or transaxillary or trans-axillary or transluminal 
or trans-luminal or transaortic or trans-aortic or transcarotid or trans-carotid or 
transsubclavian or trans-subclavian or transiliac or trans-iliac or 
transiliofemoral or trans-iliofemoral or TAVI or TAVR) in Other Reviews, Trials 
and Technology Assessments
17886
#8 #6 or #7 18059
#9 MeSH descriptor: (Transcatheter Aortic Valve Replacement) this term only 73
#10 (#5 and #8) or #9 Publication Year from 2013 to 2017 505
#11 (#5 and #8) or #9 Publication Year from 2016 to 2017 244
#12 MeSH descriptor: (Registries) this term only 955
#13 registries or register or registry in Trials 8716
#15 #12 or #13 1055457
#16 #10 and #15 Publication Year from 2013 to 2017 450
Database: Centre for Reviews and Dissemination
Date run: 2017.06.27
Results: 56 Systematic Reviews/ Health Technology Assessments (publication year 2013-
2017)
Line Search Hits
1 MeSH DESCRIPTOR Heart Valve Prosthesis Implantation 138
2 MeSH DESCRIPTOR Aortic Valve 82
3 (((aortic valv* or aorta* valv* or heart valv*) near4 (prosthe* or implant* or 
insert* or replac*)))
240
4 #1 OR #2 OR #3 250
5 ((percutaneous or transapical or trans-apical or transarterial or trans-arterial or 
transcatheter or trans-catheter or transcutaneous or trans-cutaneous or 
transfemoral or trans-femoral or transaxillary or trans-axillary or transluminal or 
trans-luminal or transaortic or trans-aortic or transcarotid or trans-carotid or 
transsubclavian or trans-subclavian or transiliac or trans-iliac or 
transiliofemoral or trans-iliofemoral or TAVI or TAVR))
2241
6 #4 AND #5 118
7 MeSH DESCRIPTOR Transcatheter Aortic Valve Replacement 9
8 (#6 OR #7) FROM 2013 TO 2017 68
9 (#6 OR #7) IN HTA FROM 2013 TO 2017 29
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10 (#6 OR #7) IN DARE FROM 2013 TO 2017 27
Database: Epistemonikos
Date run: 2017.06.27
Results: 279 Systematic Reviews (publication year 2013-2017)
Search: (title:((title:(TAVI OR TAVR OR transcatheter aortic valve replacement) OR 
abstract:(TAVI OR TAVR OR transcatheter aortic valve replacement)) 
OR (title:(TAVI OR TAVR OR transcatheter aortic valve implantation) OR 
abstract:(TAVI OR TAVR OR transcatheter aortic valve implantation))
(title:(heart valve prosthesis implantation) OR abstract:(heart valve prosthesis 
implantation))))
Database: PubMed
Date run: 2017.06.27
Results: 272 references (publication year 2016-2017)
Search: ((("heart valve prosthesis implantation"(MeSH Terms)) AND pubstatusaheadofprint)) OR 
((("transcatheter aortic valve replacement"(MeSH Terms)) OR (TAVI(Title/Abstract) OR 
TAVR(Title/Abstract) OR transcatheter aortic valve replacement(Title/Abstract))) AND 
pubstatusaheadofprint)
OR
Search ((((((percutaneous(Title/Abstract) OR transapical(Title/Abstract) OR trans-
apical(Title/Abstract) OR transarterial(Title/Abstract) OR trans-arterial(Title/Abstract) OR 
transcatheter(Title/Abstract) OR trans-catheter(Title/Abstract) OR 
transcutaneous(Title/Abstract) OR trans-cutaneous(Title/Abstract) OR 
transfemoral(Title/Abstract) OR trans-femoral(Title/Abstract) OR 
transaxillary(Title/Abstract) OR trans-axillary(Title/Abstract) OR 
transluminal(Title/Abstract) OR trans-luminal(Title/Abstract) OR transaortic(Title/Abstract) 
OR trans-aortic(Title/Abstract) OR transcarotid(Title/Abstract) OR trans-
carotid(Title/Abstract) OR transsubclavian(Title/Abstract) OR trans-
subclavian(Title/Abstract) OR transiliac(Title/Abstract) OR trans-iliac(Title/Abstract) OR 
transiliofemoral(Title/Abstract) OR trans-iliofemoral(Title/Abstract))) 
AND (aortic valve Replace*(Title/Abstract) OR aortic valve implant*(Title/Abstract))) AND 
pubstatusaheadofprint))) 
OR 
((((((percutaneous(Title/Abstract) OR transapical(Title/Abstract) OR trans-
apical(Title/Abstract) OR transarterial(Title/Abstract) OR trans-arterial(Title/Abstract) OR 
transcatheter(Title/Abstract) OR trans-catheter(Title/Abstract) OR 
transcutaneous(Title/Abstract) OR trans-cutaneous(Title/Abstract) OR 
transfemoral(Title/Abstract) OR trans-femoral(Title/Abstract) OR 
transaxillary(Title/Abstract) OR trans-axillary(Title/Abstract) OR 
transluminal(Title/Abstract) OR trans-luminal(Title/Abstract) OR transaortic(Title/Abstract) 
OR trans-aortic(Title/Abstract) OR transcarotid(Title/Abstract) OR trans-
carotid(Title/Abstract) OR transsubclavian(Title/Abstract) OR trans-
subclavian(Title/Abstract) OR transiliac(Title/Abstract) OR trans-iliac(Title/Abstract) OR 
transiliofemoral(Title/Abstract) OR trans-iliofemoral(Title/Abstract))) 
AND (aorta valve Replace*(Title/Abstract) OR aorta valve implant*(Title/Abstract))) AND 
pubstatusaheadofprint)))
1.2 Literature search for “TAVI Collaborative Assessment” 
(Registry studies)
Search for Registry studies:
Date Run: 2017.09.05
Databases: Embase (Ovid), Ovid MEDLINE(R), Cochrane Central Register of Controlled Trials 
(CENTRAL), PubMed (ahead of print articles).
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Hits: 565 after removal of duplicates (1059 including duplicates)
Comment: We searched for registry studies using a combination of subject headings and text 
words. In MEDLINE and Embase we searched for text words in title, original title, 
abstract, and subject heading using the code “.mp” (multi-purpose field). 
We used the subject headings Registries (in MEDLINE, Cochrane Library, PubMed) 
and Register (in Embase), and the text words register, registry, and registries. 
We combined the search terms using the Boolean OR operator (see search strategy 
in Embase and MEDLINE, line 21). 
We added these search terms to the subject search used also for RCTs, SR and 
HTA (line 1-10 in Embase and MEDLINE) using the AND operator (12 AND 13). Line 
11 is used to exclude animal studies. 
Embase 1980 to 2017 Week 24
Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, 
Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present
Date run: 2017.09.05
Hits: 557 
# Searches (Embase and Ovid MEDLINE) Results
1 heart valve prosthesis implantation/ use ppez 18532
2 heart valve replacement/ use ppez or aorta valve replacement/ use emez or 
transcatheter aortic valve implantation/ use emez or aorta valve prosthesis/ use 
emez
31001
3 Aortic Valve/ use ppez or aorta valve/ use emez or percutaneous aortic valve/ use 
emez
28941
4 ((aortic valv* or aorta* valv* or heart valv*) adj4 (prosthe* or implant* or insert* or 
replac*)).ti,ab.
55296
5 or/1-4 90174
6 (percutaneous or transapical or trans-apical or transarterial or trans-arterial or 
transcatheter or trans-catheter or transcutaneous or trans-cutaneous or 
transfemoral or trans-femoral or transaxillary or trans-axillary or transluminal or 
trans-luminal or transaortic or trans-aortic or transcarotid or trans-carotid or 
transsubclavian or trans-subclavian or transiliac or trans-iliac or transiliofemoral or 
trans-iliofemoral or TAVI or TAVR).ti,ab.
387824
7 5 and 6 23663
8 percutaneous aortic valve/ use emez and (prosthe* or implant* or insert* or 
replac*).ti,ab.
1613
9 transcatheter aortic valve replacement/ use emez 11315
10 or/7-9 24882
11 exp animals/ not humans.sh. 27210271
12 10 not 11 9911
13 registries/ use ppez or register/ use emez or (registries or register or registry).mp. 399044
14 12 and 13 713
15 limit 14 to yr="2013 -Current" 601
16 remove duplicates from 15 557
Ovid search syntax
.pt. denotes a Publication Type term;
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.ab. denotes a word in the abstract;
.fs. denotes a ‘floating’ subheading;
.sh. denotes a Medical Subject Heading (MeSH) term;
.ti. denotes a word in the title.
emez denotes Embase
ppez denotes MEDLINE
* (asterisk) denotes truncation (e.g. random* for random or randomised or randomized or 
randomly, etc) 
Database: Cochrane Central Register of Controlled Trials 
Date Run: 2017.09.05
Hits: 450 
ID Search Hits
#1 MeSH descriptor: (Heart Valve Prosthesis Implantation) this term only 684
#2 MeSH descriptor: (Aortic Valve) this term only 451
#3 ((aortic valv* or aorta* valv* or heart valv*) near/4 (prosthe* or implant* or 
insert* or replac*)):ti,ab,kw in Cochrane Reviews (Reviews and Protocols)
7
#4 ((aortic valv* or aorta* valv* or heart valv*) near/4 (prosthe* or implant* or 
insert* or replac*)) in Other Reviews, Trials and Technology Assessments
1985
#5 #1 or #2 or #3 or #4 2091
#6 (percutaneous or transapical or trans-apical or transarterial or trans-arterial 
or transcatheter or trans-catheter or transcutaneous or trans-cutaneous or 
transfemoral or trans-femoral or transaxillary or trans-axillary or 
transluminal or trans-luminal or transaortic or trans-aortic or transcarotid or 
trans-carotid or transsubclavian or trans-subclavian or transiliac or trans-
iliac or transiliofemoral or trans-iliofemoral or TAVI or TAVR):ti,ab,kw in 
Cochrane Reviews (Reviews and Protocols) 173
#7 (percutaneous or transapical or trans-apical or transarterial or trans-arterial 
or transcatheter or trans-catheter or transcutaneous or trans-cutaneous or 
transfemoral or trans-femoral or transaxillary or trans-axillary or 
transluminal or trans-luminal or transaortic or trans-aortic or transcarotid or 
trans-carotid or transsubclavian or trans-subclavian or transiliac or trans-
iliac or transiliofemoral or trans-iliofemoral or TAVI or TAVR) in Other 
Reviews, Trials and Technology Assessments 17886
#8 #6 or #7 18059
#9 MeSH descriptor: (Transcatheter Aortic Valve Replacement) this term only 73
#10 (#5 and #8) or #9 704
#11 MeSH descriptor: (Registries) this term only 955
#12 registries or register or registry in Trials 8716
#13 #11 or #12 1055457
#14 #10 and #13 Publication Year from 2013 to 2017 450
Database: PubMed
Date run: 2017.09.05
Hits:  52 
Search: (("heart valve prosthesis implantation"(MeSH Terms)) 
OR (("transcatheter aortic valve replacement"(MeSH Terms)) OR 
(TAVI(Title/Abstract) OR TAVR(Title/Abstract) OR transcatheter aortic valve 
replacement(Title/Abstract))) OR 
(((percutaneous(Title/Abstract) OR transapical(Title/Abstract) OR 
trans-apical(Title/Abstract) OR transarterial(Title/Abstract) OR trans-
arterial(Title/Abstract) OR transcatheter(Title/Abstract) OR trans-
catheter(Title/Abstract) OR transcutaneous(Title/Abstract) OR trans-
cutaneous(Title/Abstract) OR transfemoral(Title/Abstract) OR trans-
femoral(Title/Abstract) OR transaxillary(Title/Abstract) OR trans-
axillary(Title/Abstract) OR transluminal(Title/Abstract) OR trans-
luminal(Title/Abstract) OR transaortic(Title/Abstract) OR trans-aortic(Title/Abstract) 
OR transcarotid(Title/Abstract) OR trans-carotid(Title/Abstract) OR 
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transsubclavian(Title/Abstract) OR trans-subclavian(Title/Abstract) OR 
transiliac(Title/Abstract) OR trans-iliac(Title/Abstract) OR 
transiliofemoral(Title/Abstract) OR trans-iliofemoral(Title/Abstract))) 
AND (aortic valve Replace*(Title/Abstract) OR aortic valve implant*(Title/Abstract)))) 
OR ((transcatheter aortic valve replac*(Title/Abstract) OR transcatheter aortic valve 
implant*(Title/Abstract)
AND registries(Title/Abstract) OR register(Title/Abstract) OR registry(Title/Abstract)
AND pubstatusaheadofprint))
DESCRIPTION OF THE EVIDENCE USED 
Evidence tables of individual studies included for clinical effectiveness and 
safety
Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk
EUnetHTA Joint Action 3 WP4 85
Table A1. Characteristics of randomised controlled studies
Study ID Study design
(country)
Participants Interventions
Primary
Outcomes Funding
PARTNER 2
(USA
(15, 16)
RCT, 
multicentre
- 2032 intermediate-risk patients 
with severe aortic stenosis (1011 
TAVI; 1021 SAVR);
- Mean age 82 years (TAVI 82 
±6.7; SAVR 82 ±6.7)
- 45.5% female
INCLUSION CRITERIA:
- symptomatic degenerative 
aortic valve stenosis (NYHA 
Functional Class II or greater)
- heart team agreed that valve 
implantation would likely benefit 
the patient
- STS >4 or <4 if the Heart Team 
determines intermediate risk 
patient profile with important 
comorbidities not represented in 
the STS risk score algorithm 
Intervention: 
TAVI underwent by transfemoral 
or transthoracic placement of the 
Edwards balloon-expandable 
SAPIEN XT heart-valve (26 mm). 
Control: 
Surgical aortic-valve replacement
(Following a thorough assessment 
of the iliofemoral vasculature, 
patients were categorised into 
either a transfemoral or 
transthoracic cohort)
- mortality from any cause
- disabling stroke at 2 years
Other assessed outcomes:
- severe bleeding
- atrial fibrillation
- intensive care unit stay
- index hospitalization
- vascular complication
- paravalvular regurgitation
- pacemaker implantation
- repeat hospitalisation (2-year 
follow-up)
Sponsored 
by Edwards
SAPIEN 
Lifesciences 
(Irvine, CA, 
USA), was
SURTAVI 
Reardon 2017 
(2)
RCT, 
multicentre
- 1746 intermediate-risk patients 
with severe aortic stenosis (879 
TAVI; 867 SAVR)
- 80 years± 6.2 (TAVI 80±6.2, 
SAVR 80±6.0); 
43% Female 
Definition of intermediate: 
estimated risk of 30-day surgical 
mortality of 3 to 15% (Society of 
Thoracic Surgeons Predicted 
Risk of Mortality (STS-PROM),
Definition of severe AS: aortic 
valve area <1cm2 or <0.6 
cm2/m2 body surface area and a 
mean gradient >40 mm Hg or a 
Intervention: 
TAVI 
Control: 
Surgical aortic-valve replacement
- composite of death from any 
cause or disabling stroke at 24 
months
Other assessed outcomes:
- mortality (overall; cardiac)
- stroke
- severe bleeding
- atrial fibrillation
Medtronic
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maximum velocity >4m/second 
at rest or with dobutamine in 
patients with a left ventricular 
ejection fraction <55% or 
Doppler velocity index < 0.25 on 
resting echocardiography.
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List of ongoing and planned studies
Emerging evidence
The co-author (NIPHNO) searched ClinicalTrials.gov and WHO ICTRP for entries on 
studies on TAVI entered in 2012 and later (search strategy provided below). 443 unique 
entries were identified after removal of duplicates. 
282 entries with completion date 2016 and later were considered as emerging evidence. 
42 of these were excluded based on title and study name not being TAVI and one was 
excluded as information only was available in Chinese. Of the remaining 239 entries 59 
were RCTs. All entries for RCTs were inspected for Population, Intervention and 
Comparator. (See below Search strategy for ongoing studies. The entry data for the 
SURTAVI trial data was last updated in November 2017.
Literature search for ongoing studies
Database: ClinicalTrials.gov, first posted from 01/01/2012 to 07/12/2020
Date: 2018.01.12
Search strategy: 
1. (Transcatheter aortic valve implant* OR Transcatheter aortic valve replacement OR TAVI) 
2. Aortic valve stenosis AND (Transcatheter aortic valve replacement, Transcatheter aortic 
valve implantation)
3.  ((Edwards SAPIEN) OR CoreValve OR Evolut OR ACURATE OR JenaValve OR (Jena 
Valve) OR Portico):
Results: 417 trials identified (duplicates removed)
Database: WHO ICTRP, 01/01/2012
Date: 2018.01.12
Search strategy: 
1. (Transcatheter aortic valve implant* OR Transcatheter aortic valve replacement OR TAVI)
2. ((Edwards SAPIEN) OR CoreValve OR Evolut OR ACURATE OR JenaValve OR (Jena 
Valve) OR Portico)
Results: 210 trials identified (duplicates removed)
After removal of duplicates, the total number entries were 443
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Included Excluded (reason for exclusion)
443 Unique 184 (duplicates)
282 Completion date => 2016 161 (completion date < 2016)
239 TAVI 43 (42 non-TAVI, 1 Chinese language)
59 RCT 180 non-RCT
59 568
Two RCTs were identified where the eligibility criteria clearly stated that the patients should have 
severe aortic stenosis with an intermediate surgical risk (table A2 below). One of these was the 
SURTAVI trial, for which we have assessed interim analysis published in 2017. The final completion 
date of the SURTAVI trial is October 2018. Number of patients planned to be recruited was 2500.
The second trial was an ongoing German trial NCT03112980, which seems to be the first RCT on 
relevant questions for this assessment to be developer independent. A total of 17 German 
University hospitals contribute to the trial. Estimated completion is 2023 with no information possible 
publications of interim analysis. The last update on the trial was from October 2017, the trial is still 
recruiting participants. 
A small Chinese trial (NCT03163329, see Table A4) also reported on intermediate risk patients, but 
the trial was restricted inclusion to patients with bi-cuspid AS, which was not a predefined population 
of this assessment. 
Additional emerging evidence includes six RCTs comparing TAVI with SAVR or medication were 
the patients are at low risk or non-symptomatic (Table A3 List of ongoing trials). For these RCTs 
primary completion date vary from 2018 to 2021. There were also five RCTs were the patients are 
at high or unspecified risks comparing one TAVI system with another TAVI system (see tableA4). 
The additional (excluded) 46 RCTs with TAVI relevant emerging evidence, had either studied 
various aspects of TAVI such as medication, sedation prehab and rehab or a specific sub-
population (see Table A5 or excluded RCTs on TAVI relevant emerging evidence).
Table A2. Included ongoing trials relevant for research questions of this assessment
Inclusion criteria
P: AS Intermediate risk 
I: TAVI any system/model
C: SAVR; TAVI another system/model; Clinical surveillance (medication)
O: Relevant for this assessment
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Trial (trial number and 
name)
Numbe
r of 
particip
ants
P (study inclusion 
criteria)
I C O Estimat
ed 
Compl
etion
NCT01586910 Safety 
and Efficacy Study of 
the Medtronic 
CoreValve® System in 
the Treatment of 
Severe, Symptomatic 
Aortic Stenosis in 
Intermediate Risk 
Subjects Who Need 
Aortic Valve 
Replacement 
(SURTAVI). 2017. 
2500 Severe AS, co-
morbidities such that 
Heart Team agrees 
predicted risk of 
operative mortality is 
≥3% and <15% at 30-
day follow-up
Medtronic 
CoreValve® 
Evolut R 
System
SAVR All-cause 
mortality or 
disabling stroke 
( Time Frame: 24 
months ); Safety 
and efficacy 
outcomes; QoL 
(not specified)
2018 
(Publis
hed 
Interim 
results 
include
d in this 
report)
NCT03112980 
Randomized Trial of 
TAVI vs. SAVR in 
Patients with Severe 
Aortic Valve Stenosis 
at Intermediate Risk of 
Mortality. 
1600 AS 
–severe symptomatic
Intermediate risk
STS-score 2-6% 
TAVI using 
the most 
appropriate 
CE marked 
device 
available
SAVR Overall survival 
five years after 
last patient in; 
Safety and 
efficacy 
outcomes; 
QoL (EQ-5D)
2023
Table A3. Excluded due to P: Non-symptomatic or low risk
P: AS Non-symptomatic or low risk 
I: TAVI any system/model
C: SAVR; TAVI another system/model; Clinical surveillance (medication)
O: Not extracted 
Trial (Number and name) P (study inclusion 
criteria)
I C Estimated 
Completion
1. NCT03042104  
Edwards L. Evaluation of Transcatheter 
Aortic Valve Replacement Compared to 
Surveillance for Patients with 
Asymptomatic Severe Aortic Stenosis. 
AS- Non-
symptomatic
Transcatheter 
aortic valve 
replacement 
(TAVR) arm 
will have 
intervention 
with the 
Edwards 
SAPIEN 3 
THV.
Clinical 
surveillan
ce
2021/2031
2. NCT03094143. Early Valve 
Replacement Guided by Biomarkers of 
LV Decompensation in Asymptomatic 
Patients with Severe AS. 
AS - Non-
symptomatic
TAVI (type not 
specified)
No-
interventio
n (3 arms)
2020
Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk
EUnetHTA Joint Action 3 WP4 90
Trial (Number and name) P (study inclusion 
criteria)
I C Estimated 
Completion
3. NCT02825134 
 Comparison of Transcatheter Versus 
Surgical Aortic Valve Replacement in 
Younger Low Surgical Risk Patients with 
Severe Aortic Stenosis. 
AS –low risk 75 or 
younger STS 
Score <4%
TAVR, 
Retrograde 
transfemoral 
transcatheter 
aortic valve 
replacement 
with any CE 
mark approved 
aortic 
bioprosthesis 
with or without 
concomitant 
percutaneous 
coronary 
intervention
SAVR 2020
4. NCT02675114The Safety and 
Effectiveness of the SAPIEN 3 
Transcatheter Heart Valve in Low Risk 
Patients with Aortic Stenosis. 
Severe Calc. AS, 
STS <4
Edwards 
Sapien3
SAVR Any 
commerci
ally 
available 
2018/2027
5. NCT02701283 Medtronic Transcatheter 
Aortic Valve Replacement in Low Risk 
Patients. 2018. 
Severe AS, 
symptomatic or 
asymptomatic, 
Risk of mortality 
<3% at 30-day 
follow-up
Medtronic 
TAVR Systems
SAVR 
(any 
commerci
ally 
available)
2018
6. NCT03011346 Safety and Efficacy of the 
Symetis ACURATE Neo/TF Compared 
to the Edwards SAPIEN 3 Bioprosthesis.
AS symptomatic, 
Increased risk 
(STS>10%) or 
other reasons 
considered by 
heart team not 
covered by risk 
score, frailty and 
life expectancy
Symetis 
ACURATE 
neo/TF 
transfemoral 
TAVI
Edwards 
SAPIEN 3
2017
Table A4. Excluded due to P being High risk or risk not specified
P: AS High risk or risk not specified
I: TAVI any system/model
C: SAVR; TAVI another system/model; 
O: Not extracted 
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Trial (Number and name) P (study inclusion 
criteria)
I C Estimated 
Completion
1. NCT03192813 Safety and Efficacy 
Comparison of Two TAVI Systems in a 
Prospective Randomized Evaluation II. 
AS – 
Symptomatic high 
risk
Symetis 
ACURATE 
neo™ 
transfemoral 
TAVI system
Medtronic 
CoreValve 
Evolut R 
TAVI 
System
2019
2. NCT02668484 Repositionable Versus 
Balloon-expandable Prosthesis for 
Trans-catheter Aortic Valve Implantation. 
AS symptomatic, 
trans-femoral 
TAVI is 
appropriate
Lotus, 
repositionable 
valve
Balloon 
expandabl
e, 
Edwards 
SAPIEN
2017/2019
3. NCT02163850 SALUS trial, 
Transcatheter Aortic Valve Replacement 
System Pivotal Trial. 2017. 
AS symptomatic, 
Extreme or High 
risk
Direct Flow 
Medical TAVR
Commerci
ally 
available 
TAVR
2017/2021
4. NCT02000115 Portico Re-sheathable 
Transcatheter Aortic Valve System US 
IDE Trial: 
Severe AS, 
Extreme risk or 
High risk 
Portico 
transcatheter 
aortic valve
Commerci
ally 
Available 
Valve 
2018/2021
5. NCT02668484 Repositionable Versus 
Balloon-expandable Prosthesis for 
Trans-catheter Aortic Valve Implantation. 
AS symptomatic, 
trans-femoral 
TAVI is 
appropriate
Lotus, 
repositionable 
valve
Balloon 
expandabl
e, 
Edwards 
SAPIEN
2017/2019
Table A5. Excluded due to either the population (P) not being aortic stenosis per se, or the intervention 
(I) not being TAVI alone or per se and/ or comparator (C) not being SAVR or another TAVI system/model 
Trial (Number and name) Reason 
for 
exclusio
n 
1. NCT03163329 The Safety and Effectiveness of Transcatheter Aortic Valve Replacement in 
Intermediate Risk Patients with Bicuspid Aortic Stenosis. P (AS- 
bicuspid
)
2. NCT03058627 Revascularization in Patients Undergoing Transcatheter Aortic Valve 
Implantation. 2021/2025
C
3. NCT03315832 Efficacy of Angiotensin Receptor Blocker Following Aortic Valve Intervention 
for Aortic Stenosis: a Randomized multicentric Double-blind Phase II Study. I+C
4. NCT03360591 Functional Assessment In TAVI: FATAVI. I+C
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Trial (Number and name) Reason 
for 
exclusio
n 
5. NCT02838199 Transcatheter or Surgical Aortic Valve Replacement in All-Comers with Severe 
Aortic Valve Stenosis. Withdra
wn
6. NCT03173534 WATCH-TAVR, WATCHMAN for Patients with Atrial Fibrillation Undergoing 
Transcatheter Aortic Valve Replacement. I + C
7. NCT02943785 Edoxaban Compared to Standard Care After Heart Valve Replacement Using 
a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF). P, I and 
C
8. NCT02735902 Anticoagulation Alone Versus Anticoagulation and Aspirin Following 
Transcatheter Aortic Valve Interventions (1:1). I+C
9. NCT03303612 Clinical Monitoring Strategy vs EP-guided Algorithmic in LBBB Patients Post-
TAVI. I +C
10. NCT03084978 Conscious Sedation vs General Anesthesia in TAVR Patients. I
11. NCT03201185 Renin-angiotensin System Blockade Benefits in Clinical Evolution and 
Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI). C
12. NCT02895737 Prospective Randomized Outcome Study in TAVI Patients Undergoing 
Periprocedural Embolic Cerebral Protection with the Claret Sentinel™ Device. 2019. I + C + O
13. NCT02664649 Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic 
Stenosis. 2019. I + C
14. NCT03107897 Prehabilitation for Patients Undergoing Transcatheter Aortic Valve 
Replacement. 2018. I + C 
15. NCT02247128 Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve 
Implantation. 2018. I+C
16. NCT03121053 Preventing Contrast Induced Nephropathy After Transcatheter Aortic Valve 
Replacement. 2018. I
17. NCT03291210 O2 Tension During TAVI. 2018. I+C 
18. NCT02974660 Protamine Sulfate During Transcatheter Aortic Valve Implantation. 2018. I + C
19. NCT02541877 Sizing-Strategy of Bicuspid Aortic Valve Stenosis with Transcatheter Self-
expandable Valve. 2018. I
20. NCT03347032 Remote Ischemic Preconditioning for Renal Protection in TAVI. 2018. C
21. NCT02768064 Temporary Pacemaker in Transcatheter Aortic Valve Implantation Patients. 
2018. I + C
22. NCT02781896 Direct Left Ventricular Rapid Pacing Via the Valve Delivery Guide-wire in TAVI. 
2018. I+C
23. NCT03284827Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet 
Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement. 2018. C
24. NCT03001960 Dual Antiplatelet Therapies for Prevention of Periinterventional Embolic Events 
in TAVI. 2018. I+C
25. NCT03383445 Transcatheter Aortic Valve Replacement versus Surgical Aortic Valve 
Replacement for Treating Elderly Patients with Severe Aortic Stenosis and Small Aortic Annuli: 
A Prospective Randomized Study The VIVA Trial. 2018. 
P (small 
aortic 
annuli)
26. nct02661451 Transcatheter Aortic Valve Replacement to Unload the Left Ventricle in Patients 
with Advanced Heart Failure (TAVR UNLOAD). 2018. P 
27. NCT02805309 Home-Based Exercise Program for Recovery After Transcatheter Aortic Valve 
Replacement. 2018. I + C
28.  NCT02556203 Global Study Comparing a Rivaroxaban-based Antithrombotic Strategy to an 
Antiplatelet-based Strategy After Transcatheter Aortic Valve Replacement to Optimize Clinical 
Outcomes 2018.
I + C
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Trial (Number and name) Reason 
for 
exclusio
n 
29. NCT01982032 Edwards SAPIEN Periprosthetic Leakage Evaluation Versus Medtronic 
CoreValve in Transfemoral Aortic Valve Implantation (the ELECT Trial). 2017. Terminat
ed 
30. NCT02448927 The Predilatation in Transcatheter Aortic Valve Implantation Trial. 2017. I+C
31. NCT02080299 117 Protection by Remote Ischemic Preconditioning During Transcatheter 
Aortic Valve Implantation. 2017. C
32. NCT02696226 Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement 
and Transcatheter Aortic Valve Replacement. 2017. Terminat
ed
33. NCT02855099 Can Rehabilitation after TAVI Precipitate Recovery and Improve Prognosis. 
2017. Withdra
wn
34. NCT01866800 The Effect of the Forced Diuresis with Matched Hydration in Reducing Acute 
Kidney Injury During TAVI. 2017. I + C
35. NCT02766075 A STEP for Patients Prior to Undergoing TAVR: A Pilot Study. 2017. I + C
36. NCT02921880 Does Cardiac Rehabilitation Improve Functional, Independence, Frailty and 
Emotional Outcomes Following Trans Catheter Aortic Valve Replacement? 2017. I + C
37. NCT02597985 Functional and Clinical Outcomes in Patients with Aortic Stenosis. 
NCT02597985 2017. I
38. NCT02536196 The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions 
After Transcatheter Aortic Valve Implantation. 2017. C
39. NCT02468219 Assessment and Cardiovascular Rehabilitation in Patients with Severe Aortic 
Stenosis. 2017. I+ C
40. NCT02640794Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following 
TAVI. 2017. I+C
41. NCT02833948 Comparison of a Rivaroxaban-based Strategy with an Antiplatelet-based 
Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced 
Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography 
(4DCT). 2017.
I + C
42. NCT02224066 Platelet Reactivity After TAVI: A Multicenter Pilot Study. 2017. I+C
43. NCT01642134 Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to 
Prevent Cerebral Embolism After TAVI. 2017. I+C
44. NCT02721758 Understanding and Promoting Health Behaviour Change Amid Transition to 
Cardiac Rehabilitation. 2016. I+C
45. NCT02283398 Cardioprotective Effect of RIPC in Patients Undergoing TAVI. 2016. I+C
46. NCT02214277 Cerebral Protection in Transcatheter Aortic Valve Replacement. 2016. I+C
Risk of bias tables
Table A6. Risk of bias study level (RCTs) summary: review authors' judgements about each risk of bias 
item for each included study according to type of outcome and time follow-up.
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(a) Objective outcomes at 30-day follow-up
(b) Objective outcomes at 2-year follow-up
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Subjective outcomes (30-day follow-up)
Subjective outcomes (2-year follow-up)
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For the purpose of transparency, a separate document with comments on the 2nd draft 
assessment from external experts and the MAH/manufacturer(s) (fact check), as well as 
responses from authors, is available on the EUnetHTA website.
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APPENDIX 2. SYSTEMATIC REVIEWS CROSS-MATCHED WITH THE TRIALS
Author year
Co
reV
alv
e
NOTIO
N
PART
NER A
PARTN
ER 2
SAPIE
N 3
STACC
ATO
SURT
AVI Notes
AK 2017 [71] Not found
Amato 2016 [72] x x x
Ando 2017 [73] x x x
Ando 2017 [74] x x x x
Arora 2016 [75] x
Arora 2017 [76] x
Athappan 2013 
[77]
x x
Biondi-Zoccai 
2014 [78]
x x x
Boothroyd 2013 
[79]
x
Burrage 2017 
[80]
x x x x x
Cadth. 2013 [81] x
Cao 2013 [82] x x x
Cao 2016 [83] x x x
Cao 2015 [84] Excluded: Abstract
Cardoso 2015 
[85]
x x x
Enezate 2017 
[86]
x x x
Ferrari 2016 [87] x
Garg 2017 [88] x x x x
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APPENDIX 4. RISK OF RADIATION-INDUCED CANCER IN TAVI
Input to assessment of TAVI - A radiation protection view
Anders Widmark, senior adviser, Norwegian Radiation Protection Authority
TAVI is a catheter-based administration of an aortic valve and replaces open surgery, primarily for 
patients with high operational risk or patients who cannot undergo open surgery (method introduced 
in 2008). The method is now being evaluated for patients with intermediate surgical risk. There are 
several manufacturers of cardiac valves and equipment. TAVI is potentially associated with high 
radiation doses for both patient and personnel.
Radiation doses for patients and personnel depend on several factors such as equipment (technical 
possibilities, mono- or bi-plane), working techniques, experience and competence of personnel, use 
of protective equipment and shielding of X-ray room, complexity of the procedure, route of 
administration and equipment (type of catheters). In addition, presurgery investigation and 
postsurgery follow-up with assumed coronary angiography will contribute, but their frequency is not 
known at this stage.
The Radiation Protection Regulation have requirements for all medical use of radiation, and it is a 
prerequisite for implementing the method that the requirements of the Radiation Protection 
Regulations are respected.
Contraindication in patients with renal failure and / or anaphylaxis must also be included in the 
overall risk assessment for all identified risks associated with TAVI and contrast media 
administration. 
Stochastic risk for patients
Dose statistics have been collected for all nine cardiological interventional departments that offer 
coronary angiography from the Norwegian Registry for Invasive Cardiology (NORIC) for 2016. 
There are also statistics for TAVI for Haukeland University Hospital, Rikshospitalet and partly the 
Feiring clinic for 2016 (Table A7). Haukeland and Rikshospitalet are reported to undertake 
approximately 50% of all TAVI procedures in Norway. The remaining hospitals are expected to 
report dose data for their TAVI procedures to the NORIC registry within 2017.
Table A7. Statistical data for coronary angiography and TAVI obtained from NORIC. Angiography data 
contains some children, but this only affects the minimum value due to the high number of procedures. 
* Conversion factors between dose area product (DAP), effective dose and skin dose respectively are 
obtained from Karambatsakidou et al. (163).
No. Average DAP [Gycm2] Median DAP [Gycm2] Effective dose [mSv] * Skin dose [mGy]
Coronary angio 13 601 16.5 (0.1-241) 11.9 4.0 (0.1-57.8) 160 (1-2336)
TAVI 245 56.9 (0.4-385) 40.7 13.7 (0.1-92.3) 552 (3.7-3732)
The statistics do not contain age-related data for the patients, so a risk calculation presented in 
table 2 includes risk of morbidity and mortality for different age groups and dose levels (Table A8).
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Table A8. General natural risk of morbidity and mortality in cancer for Norwegian population, compared 
to additional risk from TAVI for different age groups. 
Female Male Female Male
Risk coefficient 
[% per Sievert]
Average increased 
fatal risk [%]
Worst case [%] 
(max value tab. 1)
Population 9.6 12.1 27.2 33.6 5 0.0685 0.462
50-59 9.6 12.1 27.2 33.6 4 0.0548 0.369
60-69 9.6 12.1 27.2 33.6 3.1 0.0425 0.286
70-79 9.6 12.1 27.2 33.6 1.6 0.0219 0.148
80+ 0.75 0.0103 0.069
General fatal cancer 
before 75 yrs age (%) **
General incidence of cancer 
before 75 yrs age (%) **
Increased risk of fatal cancer after TAVI.                           
Comes in addition to the general risk. 
Risk coefficients obtained from NRPB** (164). General risk of cancer incidence and fatal cancer 
before 75 years of age for 2010 and 2011, respectively, are taken from NORDCAN (165).
In general, the additional risk of radiation induced cancer following a TAVI procedure will be small, 
in relation to the natural risk of morbidity and mortality in cancer. Typically, an increase in the first 
or second decimal. However, the age of patients will be important. Patients with intermediate risk 
are expected to be younger, with a slightly increased risk of stochastic effects as a result. Women 
in general have also a higher risk of radiation induced cancer. Probably since the breast glandules 
are quite radio-sensitive. There will also be a dose contribution from the presurgery investigation 
and postsurgery follow-up. If e.g. a preoperative coronary angiography and three postoperative 
angiographs are being performed, the fatal risk are assumed to be doubled. 
Epidemiological and experimental studies have also shown a risk of damage to cardiovascular 
systems, etc. Preston et al. (166), finds that 0.8% of mortality in the Hiroshima and Nagasaki 
population are due to radiation-induced non-cancer, such as heart disease, stroke and respiratory 
disease. However, no effects were found below 500 mSv, but more research has to be done in this 
area. It is also uncertain whether the radiation-induced non-cancer effects are of stochastic or 
deterministic nature, i.e. are the risk increasing with increasing dose or has the dose to be over a 
certain threshold to develop the certain effect?
The risk of genetic damage is negligible and does not have to be estimated. 
Deterministic effects of the patient
Deterministic effects will primarily include tissue reactions such as erythema, hair loss and more 
serious skin lesions. Typical for deterministic effects are that the dose must exceed a certain 
threshold value for a certain effect (Table A9). The indicated effects in table 3 occur with 1% 
incidence for the given dose level, and there will be large variations in tissue sensitivity between 
different persons and possibly also between different ethnicities. The average skin dose for 
coronary angiography and TAVI give no general cause for concern. However, in difficult procedures 
with coronary angiography, followed by a difficult TAVI procedure, doses may exceed values where 
acute deterministic effects can be seen (see max values in Table A7).
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Table A9. Acute skin effects at different dose levels with latency to develop the certain effect. The table 
is modified from Wagner et al. (167). 
Effect
Typical threshold 
dose [Gy]
Time to onset 
of effect
Transient erythema 2 Hours
Temporary epilation 3 3 wk
Permanent erythema 6 10 d
Permanent epilation 7 3 wk
Dry desquamation 10 4 wk
Dermal atrophy 11
Teleangiectasia 12 >14 wk
Late erythema 15 >52 wk
Dermal necrosis 18 >10 wk
Secondary ulceration 20 >6 wk
Radiation risk personnel
Personnel closest to the patient will be exposed to the highest radiation doses, and cardiologists 
are the occupational group receiving the highest radiation doses in Norway. Radiated tissue will be 
fingers (especially in transapical administration) and eye lenses (usually is the left lens most 
exposed). Periodic monitoring of finger and eye lens doses should be performed. A personal dose 
meter attached to the left shoulder will give a good indication of the eye lens dose if no safety 
goggles are used. The induction of postcapsular opacities and cataracts seems to have a stochastic 
nature, that is, a small dose means a small risk, and an increasing dose an increasing risk. The 
EURALOC project (www.euraloc.eu) conducted a dose-response analysis of 318 interventional 
cardiologists, compared to 235 non-exposed persons in a control group (168). It was found that 
radiation had a significant effect on the induction of postcapsular opacities, with a relative risk for 
interventional cardiologists with an odds ratio of 2.62 (95% confidence interval 1.35-5.08). 
The thyroid gland has low radio-sensitivity for men over 45 years and women over 50 years. It is 
important that adequate shielding equipment is used and that the personnel have competence to 
use it properly. Lead aprons should be adapted to the current work situation and be personal. 
Careful selection of lead aprons should be made for thickness and design. Use of safety goggles 
will significantly reduce the risk of induction of postcapsular opacities and cataracts, if the goggles 
are ergonomically shaped and suitable for the cardiologist concerned. Lead curtains should be used 
on the side of the x-ray board, and ceiling mounted screens should be optimally positioned.
Personnel must also comply with regulatory dose limits, as proposed by The International 
Commission on Radiological Protection (ICRP) (169), (170).
 Skin / hands: 500 mSv (equivalent dose).
 Eye lens: 20 mSv (equivalent dose).
 Whole body dose: 20 mSv (effective dose).
Some publications recommend that the TAVI procedures should be performed by several different 
(many) cardiologists, in order to reduce the radiation dose to the individual. It is doubtful whether 
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this is a good solution, since TAVI is a highly specialized procedure and cardiologists need many 
procedures for maintaining and building expertise. 
Definitions
Effective dose - A radiation dose taking into account all radiation-sensitive organs that have 
received a radiation dose. Effective dose gives an estimate of cancer risk but should not be used 
on individuals. Used primarily to compare different irradiation situations. Specified in the unit 
milliSievert (mSv) or decadian prefixes.
Skin dose - The radiation dose to a skin area. Says something about the likelihood of developing 
an acute (deterministic) injury. Specified in the unit milliGray (mGy) or decadian prefixes.
Dose area product - A measure of the total amount of radiation (energy) that hits the patient. 
Indicated in unit Gycm2 (dose x area).
Stochastic effect - A random effect (injury, here cancer), where the likelihood of injury, but not the 
severity of the effect, increases with increasing radiation dose. Biological cause is damage to DNA.
Deterministic effect (also called tissue reactions) - An effect that occurs when a given threshold is 
exceeded for a certain effect. Increasing the dose also increases the effect. Biological cause is 
massive cell death.
Conversion Factor - A numerical factor used to calculate (here) effective dose or skin dose based 
on dose-area product.
Postcapsular opacity or cataract - An injury to the eye lens that is typical for radiation. Can also be 
found to some degree in the population
